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ABSTRACT 
This research investigated the mechanism of action in bacteria of 3,4-
methylenedioxy-β−nitropropene (BDM-I), a very broad spectrum antimicrobial lead 
compound in development as an anti-infective drug.  The thesis proposes that BDM-I 
inhibits bacterial protein tyrosine phosphatases, a novel mechanism of action for an 
antimicrobial agent and a new target in microorganisms. 
This very open investigation was directed by considerable biological 
information on the effects of BDM-I in microorganisms and animals which provided 
insights into possible and improbable cellular targets.  The biological effects of BDM-I 
were investigated using biochemical and cell-based assays, transmission electron 
microscopy and whole genome DNA microarray analysis.  The specific experiments 
and order of execution were largely dependent on information gained as the project 
progressed. 
BDM-I was shown not to target the metabolic pathways of the major classes 
of antibacterial drugs, which supports a novel mechanism of action.  Investigation of 
several species-specific effects suggested that cell signalling pathways were a possible 
target.  Based on the structure of BDM-I and review of the scientific literature on cell 
signalling in bacteria, the hypothesis that BDM-I acted by inhibition of protein tyrosine 
phosphatases (PTP) was supported by demonstrating inhibition of human and bacterial 
PTP’s in an enzyme assay.  This mechanism was consistent with other demonstrated 
effects: inhibition of the intracellular pathogen, Chlamydia trachomatis; inhibition of 
swarming in Proteus spp. and inhibition of pigment production in Serratia marcescens; 
and with kill kinetics in bacteria and yeast. 
A pilot global genome analysis of BDM-I treated Bacillus subtilis did not 
detect differential expression of PTP genes but has provided many avenues for further 
investigation. 
This research further supports the development of BDM-I as a broad 
spectrum anti-infective drug. 
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CHAPTER 1 GENERAL INTRODUCTION 
1.1 AIM OF THIS RESEARCH 
The aim of the project was to identify the mechanism(s) of action of a novel 
small molecule synthetic antimicrobial compound, BDM-I (3,4-methylenedioxy-β-
nitropropene), in bacteria.  Given its broad activity against bacteria, fungi and protozoa, 
a very general major mechanism against a target highly conserved across microbial 
types was hypothesised.  This was thought more likely than multiple mechanisms of 
action against the different susceptible microbial types.  It was further hypothesised that 
BDM-I would be unlikely to act on the metabolic targets of the common antibacterial 
and antifungal agents which are more specific to microbial types.  The hope was to 
discover a novel bacterial target which was also common to eukaryotic unicellular 
organisms.  A more modest hope was to discover additional mechanisms specific to 
certain bacterial types which would explain idiosyncratic responses by certain species to 
BDM-I. 
The biological profile of BDM-I described below (Section 1.2), supported 
the belief that BDM-I might target a novel pathway.  The very broad spectrum activity 
against phenoytypes resistant to common antimicrobials and the lack of development of 
phenotypes resistant to BDM-I in vitro all suggest a new but widely used and important 
metabolic target common to unicellular prokaryotic and eukaryotic organisms. 
1.1.1 Significance of the project 
The rapid development and spread of resistance and the emergence of multi-drug 
resistant pathogens has created a pressing need for new classes of antimicrobial agents 
attacking novel microbial targets that will not be affected by existing resistance 
mechanisms.  This need has coincided with a decline in the development of anti-
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infective agents by pharmaceutical companies in favour of drugs treating chronic 
conditions such as diabetes, heart disease, neurodegenerative and inflammatory 
diseases.  As a result the number of new anti-infective drugs brought to market in the 
last 20 years has been very low and there are currently relatively few in clinical 
development (Gringauz, 1997).  Targeted discovery of anti-infective drugs requires 
identification of sufficiently selective microbial targets.  Identification of new targets in 
microorganisms, particularly bacteria, is thus of great significance for the design or 
selection of compounds for clinical development (Section 1.3.2). 
Many drugs have been successfully used therapeutically without knowledge 
of their mechanism of action (MOA) (Denisenko et al., 27 Dec. 2002  International 
patent).  However, an understanding of mechanism(s) of action is highly desirable in 
understanding the interaction of the pathogen with both the chemical and the host and 
assisting in the design of improved antimicrobials, determining effective combinations 
of drugs and understanding microbial resistance. 
The mechanisms of action of developmental compounds that have not 
originated from target-based discovery should be explored as early as possible because 
such knowledge can aid in the modification of the drug scaffold for improved selectivity 
of action and an improved pharmaceutical profile.  BDM-I is in commercial 
development as an antimicrobial agent (Section 1.2). 
1.1.2 Plan of investigation for mechanism studies 
Mechanism studies for a new agent are necessarily very open and involve 
many different types of investigation from enzymic assays to genetic analysis and 
observation of ultrastructure.  The starting points and sequences of investigation vary 
greatly according to the existing biological information, the characteristics of the 
compound and the nature of the target organisms.  Findings from early investigations 
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therefore direct future investigations.  Many experiments presented here were conducted 
concurrently and others were constrained by availability of laboratory resources. 
One problem facing investigators of antimicrobial mechanisms is to 
distinguish a primary activity from secondary and follow-on effects.  Failure to 
distinguish these may erroneously suggest multiple mechanisms.  Another is that many 
observations remain unexplained in the absence of detailed knowledge about microbial 
metabolic networks. 
The plan of investigation for this characteristically open project was guided by: 
i) review of the biological data available for BDM-I (Section 1.2) and related 
compounds (Section 1.2.1) for insights into likely (and unlikely) target 
pathways; 
ii) further characterisation of the metabolic effects of BDM-I on selected 
microbial species as suggested by these results; 
iii) investigate the metabolic targets of the main classes of antibacterial 
compounds (because most new compounds have attacked various aspects 
of existing, well-known target pathways); and 
iv) investigate biochemical, physiological and structural species-specific 
effects (for secondary targets). 
It was the latter investigations in the later stages of the project that were 
most fruitful because attempts to explain these specific effects led to a review of cell 
signalling in bacteria and the formation of the hypothesis that BDM-I interferes with 
cell signalling by inhibition of bacterial tyrosine phosphatases, a mechanism that could 
explain both broad and specific effects. 
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1.1.3 Summary of chapter contents 
Results are presented by grouping similar topics rather than in a logical 
order of investigation.  The chapters should not be viewed as the sequential order of 
investigation although some results presented in Chapters 5 and those in Chapter 6 were 
begun in the last year of the project.  Not all results are presented here but none omitted 
contradict these findings. 
Chapter 2 reports on the effect of thiol-containing compounds on BDM-I 
activity in vitro, investigations of the kill kinetics of BDM-I, its interactions with major 
antibiotics with known mechanisms of action and the action of BDM-I on the obligate 
intracellular bacterial pathogen, Chlamydia trachomatis. 
Chapter 3 reports the effect of BDM-I on the bacterial cell wall/envelope 
and the cytoplasmic membrane and on the ultrastructure of bacteria and yeast. 
In Chapter 4, effects of BDM-I on several cell functions are reported: 
production of exopolysaccharides and pigments, induction of variant colonial 
morphology and inhibition of swarming motility.  Attempts to relate some of these latter 
observations directed attention to cell signalling in bacteria as a possible target. 
Chapter 5 investigates the effect of BDM-I on ATP production, cell-free 
protein synthesis and on human and bacterial protein tyrosine phosphatases (PTP’s).  
BDM-I is shown by an enzymic assay to be an inhibitor of a human and a bacterial PTP.  
Inhibition of bacterial PTP functions is therefore proposed as a major MOA of BDM-I 
in bacteria (and by extension, eukaryotic microorganisms).  All earlier observations 
were reviewed for their consistency with this hypothesis. 
A pilot DNA microarray analysis to investigate the effect of BDM–I on 
whole genome transcription in Bacillus subtilis is presented in Chapter 6. 
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1.2 BDM-I 
BDM-I (3,4-methylenedioxy-β-nitropropene) belongs to the class of benzyl 
nitroalkenes (Figure 1-1).  It is a yellow crystalline solid (MW 207.2), insoluble in 
water and soluble in organic solvents such as dimethylsulfoxide, ethanol and acetone, 
forming a solution of neutral pH.  It has an octanol-water partition coefficient (KD) of 
345, a melting point range of 96-98°C, is stable to heat and labile to UV light on 
continued exposure.  It binds strongly and reversibly to human serum albumin. 
 
Figure 1-1.  Molecular structure of BDM-I. 
 
BDM-I has been shown to be effective in vitro against a wide range of 
Gram-positive and Gram-negative bacteria, filamentous fungi and yeasts (Table 1-1).  
BDM-I also has very similar activity against species within a genus where multiple 
species have been tested (Staphylococcus, Enterococcus, Clostridium, Bacillus, 
Campylobacter, Proteus, Neisseria, Candida, Aspergillus and Rhizopus) with minimum 
inhibitory concentrations (MIC’s) rarely differing more than four-fold.  BDM-I is 
equally active against clinical bacterial strains of major pathogens showing resistance to 
antibiotics, including methicillin resistant Staphylococcus aureus (MRSA) and 
vancomycin resistant enterococci (VRE), indicating an absence of resistance 
mechanisms to BDM-I (Denisenko et al., 27 Dec. 2002 International patent,  Nicoletti et 
al., unpublished). 
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Table 1-1.  Minimum Inhibitory Concentration (MIC) of BDM-I (µg/mL) against 
representative bacteria and fungi. 
Bacteria 
   
Gram-negative  
 
Gram-positive 
 
Haemophilus influenzae  RMIT 140/1-1 0.3 Streptococcus pyogenes  RMIT 345/1 2 
Pasteurella multocida  RMIT 284/1-2 2 Clostridium perfringens  NCTC 8237 2 
Neisseria gonorrhoeae  RMIT 240/2 5 Staphylococcus aureus  ATCC 29213 6 
Moraxella catarrhalis  RMIT 211/2 16 Corynebacterium xerosis  RMIT 53/5  8 
Bacteroides fragilis  RMIT 31/1 20 Enterococcus faecalis  ATCC 29212 1b 
Brucella abortus  RMIT 33/1 64 Lactobacillus casei  RMIT 190/3 64 
Proteus vulgaris  ATCC 13395 8 Fungi  
Yersinia enterocolitica  RMIT 430/1 16 Trichophyton rubrum  RMIT 235 1 
Proteus mirabilis  RMIT 281/1 128 Pseudoallescheria boydii  RMIT 141 2 
Acinetobacter calcoaceticus  RMIT 3131  128 Fusarium graminearum  RMIT 790/1 2  
Salmonella Typhimurium  ATCC 14028 304 Aspergillus fumigatus  RMIT 702/1-1 4 
Escherichia coli  ATCC 25922 406 Rhizopus stolonifer  RMIT 905/2-1 4 
Klebsiella pneumoniae  ATCC 13833 512 Rhodotorula rubra  RMIT 655 8 
Pseudomonas aeruginosa  ATCC 27853 >512 Candida albicans  ATCC 10231 8  
Assays performed using standard methods outlined by the NCCLS. 
(Denisenko et al., 27 Dec. 2002 International patent,  Nicoletti et al., unpublished) 
BDM-I has also demonstrated anti-protozoal activity.  It is rapidly 
microbicidal to Trichomonas vaginalis at 2 µg/mL.  BDM-I is also active against the 
intracellular sporozoan pathogens, Plasmodium and Eimeria which are discussed in 
Chapter 2. 
BDM-I shows very low potential to produce resistant phenotypes.  On long 
term exposure for 12-16 weeks BDM-I did not induce resistance in vitro in Candida 
albicans, fungi (R. rubra, A. fumigatus, R. stolonifer, F. graminearum) or Gram-
positive and Gram-negative pathogens known to develop multi-drug resistance (S. 
aureus MRSA, E. faecalis, VRE, C. perfringens, K. oxytoca, P. vulgaris) (Brian et al., 
1946; Dominguez et al., 1953; Milhazes et al., 2006; Schales & Graefe, 1952; Worthen 
& Bond, 1970; Zatula, 1974).  The failure to readily develop resistant phenotypes is 
advantageous for BDM-I as a putative anti-infective drug.  However, lack of resistant 
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strains precluded the study of such phenotypes to identify metabolic or genetic changes 
associated with the mechanisms of action of BDM-I. 
The development of other compounds in the same structural series as BDM-
I will be facilitated by knowledge of its MOA, allowing more directed lead optimisation 
to generate more clinically useful compounds.  Over 31 compounds based on the 
structure of BDM-I have been synthesized, chemically characterized and assayed 
against a panel of bacteria and fungi by whole cell assay (Nicoletti et al., unpublished).  
Analogues were also compared for toxicity to zebrafish and with respect to octanol-
water partition coefficients (KD).  BDM-I was found to be, overall, the most broadly 
active agent, although some analogues also showed broad and high activity against 
particular groups, including the enteric and related Gram-negative bacteria.  Toxicity to 
zebrafish eggs generally correlated with toxicity to microorganisms.  No gross effects 
on embryonic development of zebrafish were observed for BDM-I and selected 
analogues. 
BDM-I is well tolerated in rodents and chicks on oral dosing (Nicoletti et 
al., unpublished).  In studies conducted in rats under good laboratory practice (GLP) 
conditions, the maximum tolerated single dose was 2000 mg/kg and a 7 day repeat dose 
of 300 mg/kg gave a no-observed adverse effect level (NOAEL) and a lowest lethal 
dose of <1150 mg/kg.  BDM-I is poorly absorbed with 1-2% of the ingested dose 
reaching the blood.  In non-GLP studies, a 7 day repeat oral dose of 200 mg/kg in 
canola oil was well tolerated by mice.  A 28 day repeat oral dose study in broiler chicks 
gave a NOAEL of 125 mg/kg with some toxicity evident at 150 mg/kg.  Intra-peritoneal 
doses of 10, 25 and 40 mg/kg BDM-I daily for 17 days were well tolerated in mice.  
Intravenous doses from 10 to 25 mg/kg given twice weekly for 3 weeks to nude mice 
were well tolerated with no adverse symptoms. 
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This relative lack of toxicity for such a broadly active antimicrobial 
compound suggests that the metabolic target of BDM-I in prokaryotic and eukaryotic 
microorganisms is sufficiently selective to allow for differential toxicity between 
microbial and mammalian cells. 
1.2.1 Benzyl nitroalkenes 
Substituted benzyl nitroalkene compounds have been studied previously for 
a number of interesting properties, including as broad spectrum antimicrobial agents.  
The antimicrobial properties of several benzyl nitroethenes have been demonstrated in 
bacteria (1952).  Arylnitroalkene compounds prepared by Schales & Graefe (Cavier et 
al., 1978; Worthen & Bond, 1970; Zatula, 1974) were found to be more effective 
against Gram-positive than Gram-negative bacteria and to have low oral toxicity to 
mice.  With an increasing number of discoveries of conventional antibiotics, interest in 
this class of synthetic compounds subsided until the 1970’s when several derivatives 
were shown to have broad anti-bacterial, anti-fungal and anti-protozoal activity 
(Milhazes et al., 2006).  Most recently, a structure-property-activity relationship study 
investigated the antibacterial activity of a number of benzyl nitroalkenes (Carter et al., 
2002; Dore & Viel, 1975; Kaap et al., 2003; Kim et al., 2003; Leite et al., 2004; Micale 
et al., 2003; Milhazes et al., 2006; Ramos et al., 1997).  There has been recent interest 
in substituted benzyl nitroalkenes for their chemotherapeutic potential as anti-tumour 
agents (Leite et al., 2004).  Benzodioxoles, such as safrole and myristicin, which occur 
in a variety of plants, have been shown to have similar biological activities (Leite et al., 
2004).  The benzodioxole derivatives reported have not included substitution with 
nitroalkenes (as for BDM-I).  A series of benzodioxole-peptide derivatives did not 
exhibit antibacterial activity but showed anti-tumour activity for mouse sarcoma 
(Micale et al., 2002; Micale et al., 2003; Yokota et al., 2000).  Other benzodioxole 
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derivatives have been shown to have activity against a range of human tumours, in vitro 
and in vivo (Batra et al., 1985; Jurd et al., 1987) and to bind tubulin and to be anti-
mitotic (Schwarz & Kehrenberg, 2006). 
1.3 THE NEED FOR NEW ANTIMICROBIAL AGENTS 
Antimicrobial compounds have provided an important means of defence 
against pathogenic microorganisms.  The introduction of modern antibiotics into clinical 
practice was a significant medical advance, enabling successful treatment of feared and 
lethal bacterial diseases.  Their widespread use has led to the rapid development and 
spread of resistant phenotypes and the emergence of multi-drug resistant pathogens 
which have become a major cause of therapy failure in infectious diseases.  Without 
new antibiotics, rather than places of safe refuge for the sick, hospitals become 
dangerous reservoirs of resistant microorganisms making surgical procedures and 
clinical therapy precarious. 
Protection from microbial pathogens relies on our ability to effectively 
manage current antimicrobial agents and continue to develop new classes of 
compounds.  Modified versions of existing drug structures have proved cost-effective 
but quickly lose efficacy as bacteria acquire resistance with increasing rapidity (Projan, 
2007).  Opportunistic infections in immunocompromised patients, especially fungal 
infections due to Candida spp. and Aspergillus spp., have few successful treatments 
available and infection relapses are common.  The problem extends to protozoal 
infections such as malaria (Plasmodium spp.) that also face a lack of chemotherapeutic 
options and the development of resistant strains.  Microbial resistance is thus eroding 
the efficacy of current therapies and increasing the demand for new classes of anti-
infective drugs attacking novel microbial targets. 
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Resistance has now developed to every major class of anti-infective drug in 
current use.  Antibiotics vary in their ability to promote the development of resistant 
strains which may be related to their molecular structure and/or MOA (Nordmann et al., 
2007).  The propensity to induce low levels of resistant phenotypes is a very desirable 
characteristic in new drugs. 
The potential of an organism to develop resistance is influenced by the 
MOA of the drug, the metabolic capability of the organism, bacterial efficiency in 
exchanging genetic information and the availability of a pool of resistance genes.  
Multi-drug resistance has emerged in a number of significant and highly adaptive 
pathogens including Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus 
spp. and the enteric and related Gram-negative bacteria (El'Garch et al., 2007).  
Transporter efflux pumps that render bacteria  resistant to multiple unrelated drugs are 
widespread (Livermore & Woodford, 2006; Queenan & Bush, 2007).  Production of 
extended-spectrum β-lactamases and carbapenemases by multi-drug resistant enteric 
Gram-negative bacteria makes them a clinical threat as many β-lactam antibiotics 
become ineffective (Blower & Supervie, 2007; Lambert, 2002; Musser, 1995; Smith, 
2007).  Many strains of Mycobacterium tuberculosis have become resistant to current 
therapies (Russell, 1998). 
1.3.1 Therapeutic anti-infective agents 
There are many therapeutic antimicrobial agents available today, mostly 
secondary metabolites of bacteria or fungi or semi-synthetic derivatives of these natural 
products.  The major classes of anti-bacterial therapeutic agents are the naturally 
derived β-lactams, aminoglycosides, tetracyclines, macrolides, lincosamides and 
glycopeptides and the synthetic sulfonamides and fluoroquinolones(Denyer & Hugo, 
1991; Denyer & Stewart, 1998). 
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These classes have provided a chemical platform for the successful 
synthesis of generations of drugs with improved stability, pharmacokinetics and 
spectrum of activity.  The main sites of action for antibacterial drug classes are cell wall 
biosynthesis, protein synthesis, DNA replication and folate metabolism.  The majority 
of antibiotics also have metabolic targets additional to the major targets. 
Antiseptics 
Antiseptics are synthetic compounds (eg. cationic compounds, phenolics 
and dyes) which generally have a much broader range of activity and display less 
selective toxicity than therapeutic antimicrobials and more than disinfectants and 
industrial biocides (Heath et al., 1999).  They generally target several structures or 
functions essential for viability and common to many microbial types and are rapidly 
microbicidal.  Antiseptics are used at high concentrations where they exert non-specific 
effects and development of resistance by microorganisms is not a problem.  Many target 
the cytoplasmic membrane and general cytoplasmic proteins while some have more 
specific effects, observable at low concentrations.  Triclosan, a bisphenol is a broad 
spectrum biocide which inhibits FabI, an enzyme involved in chain elongation in 
bacterial fatty acid biosynthesis (Ioannou et al., 2007; Kuyyakanond & Quesnel, 1992; 
Schweizer, 2001).  Fatty acid biosynthesis is a recently identified novel target for 
development of anti-infective agents.  Cationic agents such as chlorhexidine and 
quaternary ammonium compounds disrupt cell membranes causing leakage of 
intracellular constituents (Chu et al., 1996). 
There are, however, synthetic compounds that fall between the classification 
of a therapeutic anti-infective and an antiseptic because they display antimicrobial 
activity against a broad range of organisms and, while generally being relatively more 
toxic than commonly used therapeutic drugs, are less toxic than antiseptics and have 
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attributes that would allow selected therapeutic uses.  BDM-I and the related benzyl 
nitropropenes are such a class of compounds. 
1.3.2 Development of anti-infective drugs 
The successful use of anti-infective drugs unfortunately seems to lead to an 
inevitable increase in resistant microorganisms and a loss of clinical efficacy which, in 
turn, drives the need to develop new anti-infective drugs.  Unlike successful therapeutic 
drugs used in other areas, a continuing supply of novel antimicrobial agents is therefore 
needed to maintain effective therapy of infectious disease.  Very few major new classes 
of therapeutic antimicrobial agents have been introduced since the azoles and 
fluoroquinolones, first approved in the 1960’s.  Semisynthetic derivatives optimised for 
the common targets and with special properties, including the circumventing of 
resistance mechanisms, continue to be the main source of new drugs. 
Approaches to developing new antimicrobial agents include the classical 
screening of natural or synthetic compounds, structural changes to existing agents based 
on structure-activity relationships and rational design or searching the genome for novel 
targets against which compounds may be effectively designed or compound libraries 
screened (McDevitt & Rosenberg, 2001; Root et al., 2003).  Lead compounds may then 
be optimised for activity and pharmaceutical properties to obtain the most suitable 
derivative.  In the last 15 years genomically-based targeted discovery of therapeutic 
drugs by high throughput screening of synthetic and natural chemical libraries using 
specific enzyme and cell-based assays has been used to identify compounds affecting an 
identified target(Chopra et al., 2002).  This approach however, has not yet been 
successful with anti-infective drugs as there has been a lack of sufficiently selective, 
new microbial targets.  Exploitation of the well-understood microbial pathways affected 
by the major classes of antibiotics can identify further targets and new agents (Table 
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1-2) (Projan, 2007).  However, new metabolic targets for which there are no resistance 
phenotypes are an urgent need. 
The most successful approach for anti-infective drugs continues to be the 
traditional approach of assaying natural or synthetic compounds for inhibition using 
whole cell systems, characterizing the activity and then identifying cellular mechanisms 
responsible for the antimicrobial activity. 
New approved drugs 
The newer approved drugs tend to have a narrow spectrum of activity with a 
focus on targeting antibiotic resistant Gram-positive cocci.  Very few new agents are 
directed at the multi-drug resistant Gram-negative bacteria.  In the past 8 years, only six 
new agents have been approved for clinical use in humans – Telithromycin, 
Gemifloxacin, Daptomycin, Tigecycline, Linezolid and quinupristin/dalfopristin (Table 
1-2).  Of these, only Tigecycline is active against Gram-negative bacteria , highlighting 
the need for a greater focus on this group (Hancock, 2005; Nordmann et al., 2007).  
Five of the six new drugs attack two existing bacterial targets, protein synthesis or DNA 
replication, with an inherent likelihood of eventual obsolescence with the emergence of 
resistance (Alborn et al., 1991; Canepari et al., 1990). 
Only two, linezolid and daptomycin, belong to new structural classes.  Only one of 
these has a truly novel target.  Daptomycin, a narrow spectrum semi-synthetic cyclic 
lipopeptide, causes calcium-dependent depolarisation of the cell membrane, disrupting 
its energisation and interfering with multiple membrane functions, resulting in many 
secondary effects (Seedat et al., 2006; Skiest, 2006).  It is, as expected, rapidly 
bactericidal and to date no microbial mechanism of resistance has been identified.  
Linezolid, an oxazolidinone, is the only synthetic compound.  It inhibits protein 
synthesis in a novel way by binding to the 50S sub unit and blocking assembly of the  
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Table 1-2.  Recently approved anti-bacterial drugs. 
Antimicrobial 
class 
Antimicrobial 
compound 
(Trade name) 
Approval 
date 
Site of antimicrobial action / 
target 
Spectrum References 
Streptogramin 
Cyclic peptides 
quinupristin& 
dalfopristin 
combination 
(Synercid) 
1999 50s Ribosome unit 
Blocks peptidyl transferase 
and promotes premature 
release of peptidyl chain  
Gram-positive 
bacteria 
Legionella 
Chlamydia 
(Berisio et al., 2003; 
Farrell et al., 2004) 
Macrolide 
(ketolide) 
Telithromycin 
(Ketek)  
 
2001 
 
Ribosome 
Blocks exit of peptide from 
50S sub-unit 
Gram-positive 
bacteria (MDR) 
Some Gram-
negative bacteria 
(Saravolatz & Leggett, 
2003) 
Fluoroquinolone Gemifloxacin 
(Factive) 
2003 DNA replication 
Bind to topoisomerases  
I & II 
Gram-positive 
bacteria 
Anaerobes 
Some Gram-
negative bacteria 
(Alborn et al., 1991; 
Canepari et al., 1990) 
Cyclic lipopeptide Daptomycin 
(Cubicin) 
 
2003 Cell membrane depolarisation Gram-positive 
bacteria 
(Olson et al., 2006; 
Sum & Petersen, 
1999) 
Tetracycline 
(Glycylcycline) 
Tigecycline 
(Tygacil) 
 
2005 Ribosome 
Binds to 30S rRNA blocking 
binding of tRNA 
Gram-positive 
and Gram-
negative bacteria 
(Jones et al., 1996; 
Lin et al., 1997; 
Swaney et al., 1998; 
Zurenko et al., 1996) 
Oxazolidinone Linezolid 
(Linezolid) 
2007 Ribosome 
Interferes with tRNA binding to 
23S rRNA preventing 
formation of 70S initiation 
complex 
Gram-positive 
cocci. Clostridia 
and some Gram-
negative  
(Hunter et al., 2004; 
Kennelly, 2002; 
Pawson & Scott, 
2005; Tonks, 2006). 
 
70S initiation complex, preventing translation of mRNA.  Both compounds have a low 
spontaneous resistance rate but some anecdotal resistance has been reported in 
staphylococcal and enterococcal infections (Allen & Nicas, 2003; Appelbaum & Jacobs, 
2005). 
Drugs in development are predominantly modifications of existing scaffolds 
acting on existing targets and directed against Gram-positive bacteria.  For example, 
dalbavancin and oritavancin are cyclic glycopeptides inhibiting cell wall biosynthesis 
and targeting the resistant Gram-positive cocci (Walker et al., 2005).  Ramoplanin, a 
lipoglycodepsipeptide antibiotic, also inhibits peptidoglycan biosynthesis and is very 
active against resistant Gram-positive bacteria (Fass, 1991). 
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1.3.3 Novel cellular targets for drugs 
Protein kinases and recently phosphatases, are new targets in the 
development of therapeutic drugs for a range of chronic diseases in humans.  They have 
not, to date, been proposed as suitably selective drug targets in microorganisms, 
eukaryotic or prokaryotic. 
Protein phosphatases 
Post-translational modification of proteins by the covalent addition and 
removal of phosphoryl groups is a major mechanism controlling intracellular signalling.  
Coordinated and complementary phosphorylation by protein kinases (PK’s) and 
dephosphorylation by protein phosphatases (PP’s), directly regulate molecular processes 
in response to extracellular and intracellular signals (Tonks, 2006; Zhang, 2002).  PK’s 
catalyse the formation in proteins of serine, threonine or tyrosine monoesters which are 
readily hydrolysed to the amino acid residue and free phosphate by cognate PP’s. 
There are two major classes of protein phosphatases in eukaryotes, those 
dephosphorylating serine and threonine (PSTP) and those dephosphorylating tyrosine 
(PTP).  Most phosphorylation in eukaryotic cells occurs on serine and threonine 
residues.  Tyrosine phosphorylation, although minor in signalling pathways in 
eukaryotes, controls normal cellular growth, progression through the cell cycle, cell 
differentiation, cell-to-cell communication, cell migration, gene transcription, apoptosis 
decisions and the immune response (2006). 
Protein tyrosine phosphatases form a large family with a highly conserved 
catalytic site which is defined by its amino acid sequence (PTP signature motif) and in 
which cysteine and arginine are key to activity.  The PTP family includes the tyrosine 
specific and dual specific phosphatases (DSP).  The latter are less well conserved and 
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have little sequence similarity beyond the signature motif.  DSP’s are able to hydrolyse 
phosphate residues on tyrosine and either a serine or threonine on the same protein.  
Tonks (Grangeasse et al., 2007; Kennelly, 2002; Ponting et al., 1999; Shi et al., 1998; 
Vincent et al., 1999) reviews the structure, functions and regulation of PTP’s and their 
role in signal transduction and as an underlying cause of human disease. 
Bacterial phosphatases 
Protein phosphorylation on tyrosine, serine and threonine was long 
considered a post-translational modification specific to eukaryotes.  In prokaryotes the 
presence of protein tyrosine kinase and phosphatase activity was discovered much later.  
Homology searches across many bacterial species show a general distribution of 
orthologs for PK’s and PP’s (Grangeasse et al., 2007).  Tyrosine residues are less 
abundant than serine and threonine and more stable than histidine/aspartate residues.  
Tyrosine  phosphorylation seems to regulate particular functions in bacteria different 
from those in eukaryotes (Grangeasse et al., 2007; Kennelly, 2002).  Bacterial 
phosphorylation is a rapidly expanding field of investigation and tyrosine 
phosphorylated proteins have been reported in a variety of bacteria (Kennelly, 2002).  
Bacteria encode a smaller number of PTP’s compared to eukaryotic cells (Grangeasse et 
al., 2007; Kennelly, 2002; Mijakovic et al., 2003; Mijakovic et al., 2005b; Morona et 
al., 2002; Musumeci et al., 2005; Vincent et al., 1999; Vincent et al., 2000).  For many 
PTP genes the endogenous substrates have not yet been identified and their biological 
functions are unknown. 
While bacterial PTP’s have sequence and structure similarity to eukaryotic 
counterparts, those so far investigated are not as specialized as eukaryotic PTP’s, 
showing functional overlap, greater catalytic versatility and a heterogeneous 
distribution.  Most PTP’s identified in bacteria are dual specific phosphatases, which are 
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more common in bacteria than in eukaryotes, or homologues of eukaryotic low 
molecular weight PTP’s (LMWPTP’s) (Grangeasse et al., 1997; Grangeasse et al., 
1998; Musumeci et al., 2005).  LMW PTP’s are the most ancient and highly conserved 
family of PTP’s and show a high degree of identity with human homologs (Grangeasse 
et al., 2007). 
Tyrosine phosphorylation influences gene regulation and enzyme activity in 
bacteria and seems to be related to the virulence mechanisms of many pathogens 
(Musumeci et al., 2005) and response to stresses which enable survival in hostile 
environment (Denisenko et al., 27 Dec. 2002  International patent).  To date there is no 
report of the development of antimicrobial agents targeting bacterial phosphatases. 
 19 
CHAPTER 2 ANTIBACTERIAL ACTIVITY OF BDM-I 
2.1 INTRODUCTION 
BDM-I has been assayed for bacteriostatic and bacteriocidal activity by 
standard whole cell growth inhibition assays against a wide range of bacteria and fungi 
selected to represent broad taxonomic and metabolic types and to include clinically 
significant pathogens, particularly those exhibiting considerable development of 
resistance to current antimicrobial drugs (Denisenko et al., 27 Dec. 2002  International 
patent).  Representative species assayed previously are shown in Table 1-1. 
Bacterial groups were differentiated on the basis of cell wall structure, 
which influences susceptibility to antimicrobial agents.  These groups were Gram-
positive bacteria, non-enteric Gram-negative bacteria, and enteric and related Gram-
negative bacteria.  Gram-positive bacteria included strictly aerobic, facultatively 
anaerobic, aerotolerant fermentative and anaerobic fermentative species of clinical 
significance.  Non-enteric Gram-negative bacteria included nutritionally and 
environmentally fastidious and parasitic bacteria (aerobic, facultative and anaerobic) 
that are relatively susceptible to antibiotic drugs.  Enteric Gram-negative bacteria and 
related genera are those characterised by a greater resistance to drugs and the ready 
development of multi-drug resistant phenotypes. 
BDM-I is broadly but variably antibacterial, with greatest activity overall 
against Gram-positive bacteria and least against enteric and related Gram-negative rods.  
It is highly active against fastidious and parasitic Gram-negative rods and cocci, with 
Neisseria and Haemophilus being among the most susceptible bacteria tested 
(Denisenko et al., 27 Dec. 2002  International patent).  BDM-I also shows very 
consistent whole cell growth inhibition against different species within a genus.  
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Multiple species within Staphylococcus, Enterococcus, Clostridium, Bacillus, 
Campylobacter, Proteus, Neisseria, Candida, Aspergillus and Rhizopus have MIC 
values rarely differing more than four-fold.  BDM-I is slowly bactericidal to the 
majority of genera tested, with the Minimum Microbicidal Concentration (MMC) 
usually the same or two-fold higher than the MIC.  BDM-I is also highly and uniformly 
active against a broad range of unicellular and filamentous fungi from different 
taxonomic phyla and is fungicidal to all species assayed (NCCLS, 2002; NCCLS, 
2003). 
Obligate parasites have reduced structural, physiological and metabolic 
activities, using host metabolism to fulfil some essential metabolic functions.  BDM-I 
has been shown to inhibit the replication of Plasmodium falciparum, a sporozoan 
parasite causing malaria.  BDM-I inhibited trophozoite growth and replication in red 
blood cells in a concentration-dependent manner at blood levels achievable and 
tolerable in mice (Nicoletti et al., unpublished).  Activity against four species of 
Eimeria commonly causing coccidiodosis in poultry was shown in a chick model of 
infection (Nicoletti et al., unpublished).  Oral treatment with BDM-I reduced levels of 
infection in chicks challenged with virulent Eimeria spp. and reduced oocyst counts in 
infected chicks in a dose-dependent manner.  Activity against such pathogens indicates 
intracellular activity and restricts the possible targets to those in pathogen or host cells 
that are essential for pathogen infectivity and replication. 
The generally uniform activity of BDM-I against microorganisms using 
oxidative, fermentative and facultative energy metabolism and under aerobic and 
anaerobic atmospheric conditions, suggests that antimicrobial activity is not targeted to 
cellular energy pathways.  The activity of BDM-I across prokaryotic and eukaryotic 
genera suggests that it is acting on one or more highly conserved cellular target(s).  
Such target(s) appear to be heterogeneously distributed across bacterial species.  The 
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more uniform inhibition across fungal genera suggests that the target(s) in fungi are 
more highly conserved, functionally similar and more evenly distributed across 
taxonomic types.  The unusually broad spectrum of activity is more characteristic of a 
disinfectant or antiseptic than a therapeutic antimicrobial agent.  However, BDM-I is 
not uniformly rapidly microbicidal as are biocides, suggesting the toxic mechanisms are 
more selective. 
2.2 ACTIVITY SPECTRUM FOR BDM-I:  MINIMUM INHIBITORY 
AND MINIMUM MICROBICIDAL CONCENTRATIONS 
2.2.1 Background 
An important consideration in investigations of mechanisms of action is the 
selection of appropriate bacterial species, agent concentration ranges and assay 
conditions to reveal a metabolic effect.  Failure to optimise an assay may result in a 
failure to demonstrate an effect.  As an extension of the activity spectrum of BDM-I, a 
variety of bacteria were investigated based on their susceptibility to BDM-I and 
suitability for assays designed to investigate the MOA of BDM-I.  The yeast, Candida 
albicans was also included in assays to provide a comparison of bacteria with a 
unicellular eukaryote.  The MIC and MMC of BDM-I was determined in relevant media 
to provide a basis for selection of concentrations and time frames for further 
investigations. 
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2.2.2 Materials and Methods 
Microbial stocks, media and test compounds 
Strains are as follows: Bacillus cereus RMIT 30/7, Bacillus subtilis ATCC 
6633, Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 29213, 
Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 13883, Moraxella 
catarrhalis RMIT 211/2, Proteus mirabilis RMIT 281/1-4, Proteus vulgaris ATCC 
13315, Pseudomonas aeruginosa ATCC 27853, Serratia marcescens RMIT 342/1-32 
and Candida albicans ATCC 10231. 
Stocks of all microorganisms were kept in -80°C in MHB (Oxoid, 
Cambridge, UK) with 20% v/v glycerol (BDH chemicals, Poole, UK).  All strains were 
subcultured onto Nutrient agar (NA, Oxoid) and subcultures between three and nine 
used to prepare inocula.  Inoculum densities were prepared by adjusting a suspension to 
match McF 0.5 turbidity standard (equal to ~1.5 × 108 bacterial cells/mL or ~1.5 × 106 
yeast cells/mL) and subsequent dilution to the required density. 
Antibiotics, erythromycin and tetracycline (Sigma-Aldrich, St-Louis, MO, 
USA) and ciprofloxacin and vancomycin (ICN Biomedicals; now MP Biomedicals, 
Irvine, CA, USA) were received as dry powders, weighed, dissolved in diluent and 
stored as per manufacturer’s instructions.  BDM-I was dissolved at 100 mg/mL 
concentrated stock solution in dimethyl sulfoxide (DMSO, #103234, AnalaR, BDH 
Chemicals) and stored at -20°C.  Aliquots and dilutions of BDM-I were stored in the 
dark at room temperature for up to 1 month and retained inhibitory potency when 
assayed by measurement of the MIC in bacterial species.  The highest concentration 
assayed was 512 µg/mL for species able to grow well in 1% v/v DMSO. 
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Minimum Inhibitory Concentrations 
Broth microdilution testing was based on the National Committee for 
Clinical Laboratory Standards standard methods (NCCLS, 2002; NCCLS, 2003) in 
MHB (Oxoid) or Sabouraud Liquid Medium (SLM, Oxoid) for C. albicans.  Microplate 
assays were performed in clear, round-bottomed, 96-well plates (Sarstedt Australia, SA, 
AUS) with a total volume of 200 µL per well.  Inoculum densities were estimated by 
suspension turbidity using McF0.5 standard.  Standard inoculum densities were 
approximately 1 × 105 Colony Forming Units per mL (CFU/mL) for bacteria and 1 × 
104 CFU/mL for C. albicans. 
The MIC of BDM-I against bacterial strains used in assays was determined in 
relevant media to provide a basis for selection of suitable assay concentrations.  
Inoculum densities higher than the standard were required for some assays, therefore 
MIC’s were determined for different inoculum densities and reported as MIC (MIC 
using the standard inoculum density) and MICH (MIC using a 10-fold higher inoculum). 
Inoculum densities were confirmed by serial dilution plating onto NA and 
incubation aerobically at 37°C for 24 h.  BDM-I was added to plates at 2× test 
concentrations in 100 µL media.  Ciprofloxacin was used as an internal positive control.  
Microplates were incubated 18-24 h at 37°C aerobically before reading wells visually 
for turbidity.  All assays included duplicated wells and were replicated at least twice.  
The geomean MIC (µg/mL) for each strain was adjusted to the nearest log2 dilution 
tested.  MIC results were reported as MIC and MICH for standard and 10-fold higher 
inoculum densities respectively. 
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Minimum Microbicidal Concentrations 
The minimum microbicidal concentration (MMC) for BDM-I was 
determined following the MIC assay.  Wells without visible growth of the test organism 
were sampled (10 µL), plated onto NA and incubated 48 h at 37°C aerobically.  Viable 
organisms were calculated as colony forming units per mL (CFU/mL).  The MMC for 
each strain was defined as the minimum concentration sufficient to decrease the number 
of viable cells from the initial inoculum by 99.9% (equivalent to a 3-log10 reduction in 
CFU/mL on subculture to NA). 
2.2.3 Results 
The geometric mean MIC values (µg/mL) for the test strains of bacteria and 
Candida albicans, in MHB with standard or high inoculum densities are shown in Table 
2-1.  There was no significant increase in the MIC with a 10-fold higher inoculum 
(MICH).  These values were used as the basis for choosing treatment concentrations in 
further investigations. 
2.2.4 Discussion 
The activity of BDM-I presented here, as measured by MIC and MMC, 
reflects that found in more extensive studies (Nicoletti, et al., unpublished).  BDM-I is 
clearly acting in a selective manner with a range of MIC and MMC values obtained for 
even a small representative sample of bacteria and fungi.  The differential effect on 
genera of a group, especially among Gram-Negative bacteria, has not yet been 
explained.  It is possible that the activity of BDM-I could be affected by intracellular 
access and therefore connected to the composition or structure of bacterial membranes. 
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Table 2-1.  Inhibitory and microbicidal activity of BDM-I against Gram-positive 
and Gram-negative bacteria and Candida albicans strains used in this study. 
 
MIC & MMC (µg/mL)a 
 MIC MICHb MMCc 
Gram-positive bacteria 
Bacillus cereus RMIT 30/7 8 8 16 
Bacillus subtilis ATCC6633 8 8 16 
Enterococcus faecalis ATCC 29212 16 16 512 
Staphylococcus aureus ATCC 29213d 8 16 >512 
Gram-negative bacteria 
Escherichia coli ATCC 25922 512 >512 >512 
Klebsiella pneumoniae ATCC 13883 256 >512 >512 
Moraxella catarrhalis RMIT 211/2 8 8 8 
Proteus mirabilis RMIT 281/1-4e 128 - >512 
Proteus vulgaris ATCC 13315 8 8 32 
Pseudomonas aeruginosa ATCC 27853 >512 >512 >512 
Serratia marcescens RMIT 342/1-32 >512 - - 
Yeast 
Candida albicans ATCC 10231 4 8 8 
MIC assays performed using standard methods outlined by the NCCLS (Snyder & MacIntosh, 
2000) 
aThe geometric mean MIC, MICH and MMC (µg/mL) for each strain was adjusted to the 
nearest log2 dilution tested. 
bThe MICH was determined using a 10-fold higher inoculum than for the MIC. 
cThe inoculum level used for the MMC was that used for the standard MIC.  The MMC is the 
lowest concentration showing a 3 log10 reduction in CFU/mL from the initial inoculum density. 
dThe MIC for ciprofloxacin against S. aureus (geomean 0.3 µg/mL) was used as a positive 
control and was within the NCCLS guidelines acceptable range on all occasions. 
eDue to the swarming by P. mirabilis plate counts to determine MMC were not performed. 
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2.3 ACTIVITY AGAINST AN LOS-DEFICIENT MUTANT 
2.3.1 Background 
Among MIC results, the low susceptibility of some enteric Gram-negative 
bacteria to BDM-I was of particular interest.  Gram-negative bacteria are characterised 
by a phospholipid outer membrane (or envelope) which contains variable levels and 
types of hydrophilic liposaccharides in the outer leaflet.  While the lipid A and core 
structures of these liposaccharides in the outer membrane (OM) remain similar between 
all Gram-negative bacteria, the repeat sugar units can be unique to a species or strain 
and together have antigenic properties.  Enteric bacteria generally possess high density 
lipopolysaccharides (LPS) and a greater resistance to lipophilic drugs while non-enteric 
bacteria generally possess a lower density of lipo-oligosaccharide (LOS) with a shorter, 
non-repeating chain (O-antigen).  These structures have antigenic properties and are 
virulence factors that provide an effective barrier to hydrophobic molecules, detergents 
and host proteins (Heinrichs et al., 1998; Kanipes et al., 2004).  Mutants that lack LPS 
or LOS structures have been found to lose their inherent resistance to antibiotics due to 
major alterations in the OM and are described as having a deep rough phenotype (Perera 
et al., 2007).  BDM-I is a highly lipophilic molecule and its relative inactivity against 
many Gram-negative bacteria was hypothesised to be partly due to its exclusion by the 
OM. 
To investigate whether the hydrophilic OM of Gram-negative bacteria was 
partly responsible for the low activity of BDM-I a Campylobacter jejuni mutant 
possessing the smallest possible LOS component (WaaF) was compared to the wild 
type strain (C. jejuni HB93-13) (Friedman et al., 2000). 
Campylobacter are fastidious microaerophilic animal pathogens which 
invade intestinal epithelial cells and are among the most common cause of bacterial 
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diarrhoeal disease worldwide (2006).  BDM-I shows relatively low activity against 
Campylobacter spp. with MIC’s from 64 to 256 µg/mL (Nicoletti et al., unpublished).  
The mutant C. jejuni strain and the similarity of structure of the Gram-negative 
envelope allows extrapolation of the findings to other Gram-negative bacteria. 
2.3.2 Materials and Methods 
Campylobacter jejuni HB93-13 and the WaaF mutant lacking lipo-
oligosaccharides (LOS) were obtained from Dr Viraj Perera (RMIT) and stored in 
Brucella broth (BB, BD Biosciences, San Jose, CA USA) with 20% v/v glycerol at  
-80°C.  C. jejuni HB93-13 and the mutant were grown for 48 h on Horse blood agar 
(HBA, Oxoid) with Campylobacter Growth Supplement (Skirrow’s, Oxoid) at 42°C 
under microaerophilic conditions - 5% oxygen, 10% carbon dioxide and 85% nitrogen 
(CampyGen sachet, Oxoid).  The test inoculum was prepared from an 18 h culture 
incubated at 42°C in BB with Campylobacter growth supplement.  Inoculum densities 
were confirmed by viable plate counts on HBA for 48 h at 42°C under microaerophilic 
conditions.  Assays were performed in sterile Wassermann vials in total volumes of 2 
mL.  Doubling dilutions of BB alone or with 2× BDM-I in 1 mL were prepared in each 
tube, inoculated with 1 mL volumes of C. jejuni suspension and incubated for 48 h at 
42ºC under microaerophilic conditions.  Tubes showing no turbid growth were plated 
onto HBA and incubated for 48 h at 42ºC under microaerophilic conditions to determine 
the minimum microbicidal concentration. 
2.3.3 Results 
The mean MIC’s for BDM-I against the C. jejuni parent (HB9313) and LOS 
mutant (WaaF–) were each 256 µg/mL and the geometric mean MMC for both was 362 
µg/mL.  Possession of a severely truncated LOS structure in the WaaF mutant of C. 
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jejuni HB9313 did not result in a greater susceptibility to BDM-I indicating that the 
presence of intact LOS in the outer leaflet of the OM was not a barrier to entry of BDM-
I in Campylobacter.  
2.3.4 Discussion 
The amount of LOS on the envelope of C. jejuni was shown not to be a 
factor in the low activity of BDM-I against Campylobacter.  The similarity in structure 
and function of LOS and LPS side chains in the outer leaflet of the envelope in Gram-
negative bacteria, supports the extrapolation of the absence of a barrier effect to LPS-
containing enteric and related bacteria.  BDM-I shows a considerable range in activity 
against enteric Gram-negatives with MIC values varying from 8 µg/mL for Proteus 
vulgaris to >512 µg/mL for Pseudomonas aeruginosa.  A barrier effect is unlikely to 
explain this variability since the more susceptible enteric species have lower MIC 
values than bacteria which have a lower LPS content including Brucella, 
Campylobacter and Bacteroides (Table 1-1).  It seems unlikely that the lipophilicity of 
BDM-I contributes significantly to its lack of activity against high LPS bacteria.  
Milhazes et al. (Denisenko et al., 27 Dec. 2002  International patent) showed that the 
antibacterial activity of a series of benzyl nitroalkene derivatives against Gram-positive 
cocci was not correlated with lipophilicity but did not report testing of Gram-negative 
bacterial species. 
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2.4 EFFECT OF THIOL-CONTAINING COMPOUNDS ON 
INHIBITORY ACTIVITY 
2.4.1 Background 
Evaluation of how inhibitory activity of an agent is affected (positively or 
negatively) by growth conditions, stresses of the external environment or cellular 
metabolites, can provide clues to antimicrobial mechanism(s) of action. 
External factors affecting the activity of an agent in vitro include 
temperature, pH, oxidation-reduction potential, ultra-violet light and the presence of 
interfering compounds.  The antimicrobial activity of BDM-I has been found to be 
unaffected by a 4 log10 change in medium pH, by incubation in aerobic and anaerobic 
atmospheres, by changes in incubation temperature and to be minimally affected by the 
presence of 10% whole blood or plasma or DNA (0.05% w/v), the MIC generally 
differing no more than two-fold (Eyer, 1994).  BDM-I binds strongly and reversibly to 
serum albumin.  It is slowly degraded by exposure to UV light, losing 4-fold activity 
after exposure to natural light for 6 weeks (Nicoletti et al, unpublished). 
This investigation extends these investigations and reports on the effects of 
the presence of thiol-containing reducing compounds, cysteine and dithiothreitol, on the 
antibacterial action of BDM-I.  Thiol-containing compounds activate nitroheterocyclic 
antimicrobial agents such as the nitrofurans and nitroimidazoles by conversion to toxic 
nitrosamines by intracellular nitroreductases (Markowitz & Williams, 1985; Nakken et 
al., 1960).  Thiol compounds have been reported to interfere with the activity of 
penicillins and cephalosporins by opening of the β-lactam ring (2004). 
Cysteine is a low-molecular weight thiol compound present in many 
structural and enzymic proteins.  The thiol group is nucleophilic, usually in the thiolate 
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form (S−) and readily oxidised to the disulfide cystine.  It is for example a component of 
the cellular anti-oxidant, glutathione.  Cysteine is of particular interest as the signature 
amino acid residue at the catalytic site of protein tyrosine phosphatases (Section 1.3.3 & 
Chapter 5).  Dithiothreitol (1,4-bis-sulfanylbutane-2,3-diol) is used in biochemical 
reactions to reduce disulphide bonds to dithiols and to protect thiol groups. 
2.4.2 Materials and Methods 
Stock solutions (5 M) of cysteine (#C7880, Sigma-Aldrich) and 
dithiothreitol (DTT, Bio-Rad Laboratories, CA, USA) were prepared in sterile distilled 
water and diluted to 3× working stock solutions in MHB.  Test concentrations were of 
cysteine and DTT were 0.1 and 1 mM.  BDM-I test concentrations were 2-fold from 0.5 
to 256 µg/mL.  Strains used were S. aureus ATCC 29213, E. faecalis ATCC 29212, B. 
cereus RMIT 30/7 and P. vulgaris ATCC 13315.  Assays were performed in 96-well 
microplates (Sarstedt Australia), which were prepared with 50 µL each of 3× BDM-I, 
3× cysteine or 3× DTT and inoculated with 50 µL of bacterial inoculum.  Microplates 
were incubated for 24 h at 37°C aerobically and MIC values recorded based on visual 
turbidity as for standard MIC assays (Section 2.2.2). Assays were performed at least 
twice and the geometric mean calculated. 
2.4.3 Results 
Molar excesses of 2-4 DTT and cysteine had no effect on the MIC for 
BDM-I against any of the species tested.  Greater molar excesses of DTT and cysteine 
also failed to have a significant impact on the MIC for BDM-I against S. aureus and P. 
vulgaris.  There was a significant change in the MIC for E. faecalis in the presence of a 
90-fold excess of cysteine and 6-fold excess of DTT, and for B. cereus in the presence 
of a 10-fold excess of DTT. 
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Table 2-2  Effect of cysteine and dithiothreitol on the MIC for BDM-I. 
 
GeoMean MIC for BDM-I (µg/mL)a in presence of: 
Bacterium MHB 0.1 mM Cysteine 
1 mM  
Cysteine 
10 mM 
Cysteine 
0.1 mM 
DTTb 
1 mM  
DTTb 
10 mM 
DTT 
Staphylococcus aureus 
ATCC 29213c 4 (0.02) 6 (0.03) 4 (0.02) 6 (0.03) 8 (0.04) 11 (0.05) 304 (1.47) 
Enterococcus faecalis 
ATCC 29212 10 (0.05) 10 (0.05) 10 (0.05) 23 (0.11) 8 (0.04) 32 (0.15) 362 (1.75) 
Bacillus cereus RMIT 
30/7 5 (0.02) 5 (0.02) 7 (0.03) 10 (0.05) 6 (0.03) 21 (0.10) 362 (1.75) 
Proteus vulgaris ATCC 
13315 6 (0.03) 6 (0.03) 8 (0.04) 11 (0.05) 8 (0.04) 8 (0.04) 215 (1.04) 
aBDM-I molar concentrations equivalent to the MIC shown in table in brackets. 
bDTT – dithiothreitol. 
cThe MIC for ciprofloxacin was used as an internal control and acceptable according to NCCLS 
guidelines (0.25 µg/mL). 
2.4.4 Discussion 
Cysteine and DTT inhibited the action of BDM-I in a whole cell MIC assay 
against two of the four species tested.  Against E. faecalis, according the the increase in 
MIC, DTT was twice as inhibitory as cysteine.  This inhibition is likely to be due to 
thiol reduction of BDM-I to an inactive benzyl nitroalkane. 
Park & Pei (Milhazes et al., 2006) showed that some benzyl nitroalkenes 
(0.02 mM) reacted readily and reversibly with mercaptoethanol (1 mM), resulting in 
saturation of the double bond and a ~200-fold inactivation of their ability to inhibit 
some PTP’s in an enzyme assay.  They further proposed that the interaction with 
mercaptoethanol was different from the reaction occurring directly between benzyl 
nitroalkenes and cysteine residues at the PTP catalytic site that is responsible for 
inhibition of enzyme activity.  The explanation that cysteine and DTT similarly interfere 
with the activity of BDM-I by reduction of the propene side chain is plausible if BDM-I 
acts by inhibition of tyrosine phosphatases.  Inhibition of two PTP’s in an enzymic 
assay is demonstrated in Chapter 5. 
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The ability of thiols to inhibit BDM-I by reduction suggests that the nitro 
group and/or the double bond is required for activity.  The double bond has been shown 
recently to be essential to the antimicrobial activity of benzyl nitroalkenes (Tocher, 
1997).  The likelihood that cysteine and DTT are acting here as reducing agents is 
suggested by the two-fold greater inhibition of BDM-I against E. faecalis by DTT 
which has two thiol groups compared to one for cysteine.  The lack of enhanced activity 
of BDM-I in the presence of thiol-containing compounds suggests BDM-I does not act 
in a similar manner to nitroheterocyclic antimicrobial agents where activity depends on 
the formation of an active amine by bacterial nitroreductases (Nikaido & Saier, 1992). 
Cysteine and DTT may interact with BDM-I in the medium or inside the 
cell.  As the peptidoglycan layer of the cell wall of Gram-positive bacteria is relatively 
porous, cysteine and DTT would pass through readily.  This is evidenced here by the 
greater inhibitory effect of thiols in Gram-positive species.  The lesser effect on the 
inhibitory action of BDM-I on P. vulgaris could be due to the presence of the envelope 
providing an additional membrane barrier to the entry of these small hydrophilic 
molecules.  These results suggest that interaction between BDM-I and thiols is 
occurring intracellularly and not just in the medium. 
Both the envelope and plasma membrane of Gram-negative bacteria contain 
transport proteins that mediate the passive and active transport of polar solutes (Gilson 
et al., 1988).  The Gram-negative envelope has some barrier activity and contains porins 
that allow the diffusion of small nutrients.  Gram-negative bacteria transport sugars and 
amino acids by binding these substrates to periplasmic binding proteins.  Similar 
binding proteins anchored in the plasma membrane have been described in Gram-
positive bacteria (Higgins, 2001).  Sugars and amino acids are transported across the 
cytoplasmic membrane of bacteria by a range of ABC (ATP-binding cassette) 
transporters specific to different nutrients (2004).  Cysteine and DTT, which are 
 33 
assumed to be transported similarly to sugars, will compete for transport binding 
proteins which will limit their intracellular concentration despite the molar excesses 
supplied in the medium.  BDM-I is a small lipophilic molecule and should readily 
diffuse across microbial membranes.  There was a low level of inhibition (2-4-fold) 
shown by a 6-90-fold molar excess of cysteine and DTT in the whole cell assay reported 
here, compared to a 200-fold inhibition by a 50-fold molar excess of mercaptoethanol in 
the enzyme assay reported by Park & Pei (Clifton et al., 2004).  This could be explained 
by the interaction of cysteine and DTT with complex medium constituents, their 
restricted transport into the cell and their interaction with cytoplasmic components. 
2.5 IN VITRO ACTIVITY AGAINST CHLAMYDIA TRACHOMATIS  
2.5.1 Background 
Chlamydia are among the most simple prokaryotic cells, lacking several 
specialised metabolic functions and relying mainly on host epithelial cells to supply 
energy and metabolites for replication.  Chlamydia have a unique biphasic development 
cycle, existing as two distinct functional and morphological forms over the life cycle of 
48-72h.  Elementary bodies (EB’s) are small, metabolically inactive, stable and adapted 
for extracellular survival.  They are capable of infecting a variety of cell types but 
primarily enter and differentiate within epithelial cells.  EB’s bind to host cells and 
induce endocytosis  forming intracellular vacuoles (inclusion bodies) (AbdelRahman & 
Belland, 2005).  Chlamydia actively modify the inclusion membrane to incorporate host 
components to prevent fusion with endosomes or lysosomes and insert chlamydial 
proteins (AbdelRahman & Belland, 2005). Following endocytosis, within the inclusion 
body, EB’s differentiate into larger reticulate bodies (RB’s) within 6-8 h.  RB’s have an 
inner and OM like other Gram-negative bacteria and use aerobic respiration.  The 
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metabolically active RB’s replicate by repeated cycles of binary fission before 
redifferentiation into EB’s which are released by cell lysis to continue the infection 
cycle (Stephens et al., 1998). 
Chlamydiae have a small genome and are phylogenetically distant from 
other eubacteria.  Most of the 28% predicted proteins that are unique to chlamydiae 
have unidentified functions (Gupta & Griffiths, 2006; Stephens et al., 1998).  Many 
encoded proteins show only a low level of homology with known bacterial proteins.  
Those with identified or suggested functions are related mainly to the vacuole 
membrane, transport of nutrients and DNA repair, replication and translation (Stephens 
et al., 1998). 
Chlamydia are energy parasites and import ATP using chlamydial 
ADP/ATP translocases similar to those in Rickettsia spp.  Genetic analysis, however, 
shows they possess genes for restricted oxidative and substrate level production of ATP 
and use glutamate as the primary carbon source, supplemented by glucose and glutarate. 
(2003).  Chlamydia also import host amino acids, purines and pyrimidines despite 
possessing some genes capable of limited synthesis.  Therefore Chlamydia, as obligate 
intracellular parasites with a clear development cycle and restricted metabolic 
capabilities, are an attractive organism in which to study possible mechanisms of action. 
This study investigates the activity of BDM-I against Chlamydia 
trachomatis, which infects epithelial cells and is a prevalent cause of sexually 
transmitted disease and eye infections in humans.  The effect of BDM-I on the infection 
of epithelial cells by EB’s and the replication of RB’s was assessed in a cell culture 
assay in McCoy cells infected with a clinical isolate of C. trachomatis. 
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2.5.2 Materials and Methods 
McCoy cells and a clinical isolate of Chlamydia trachomatis were supplied 
and maintained by Dr. Robert Alexander (Virology Laboratory, Royal Children’s 
Hospital, Melbourne, Victoria, Australia).  Methods were based on general methods for 
Chlamydia cell assays and those used by Suchland et al. (Suchland et al., 2003) and are 
described below.  BDM-I was assayed for inhibition of binding and endocytosis of the 
elementary body and inhibition of reticulate body replication in infected cells. 
Briefly, epithelial cell monolayers (McCoy) were infected and the 
chlamydial bodies detected by immunofluorescent staining.  The level of infection of 
the monolayer was recorded manually under a fluorescent microscope (IX71, Olympus 
Australia, Vic, AUS).  BDM-I was assayed to determine whether it had an inhibitory 
effect on infection of McCoy cells by EB’s and whether it inhibited replication of RB’s 
in inclusion vacuoles. 
Monolayer preparation 
McCoy cells (ATCC, CRL-1696), a mouse fibroblast line, were grown and 
maintained in growth media (Minimum Essential Medium with Earle’s Salts, 7.5% w/v 
sodium bicarbonate, 200 mM glutamine, non-essential amino acids, 100 mM sodium 
pyruvate and  10% v/v foetal calf serum, Thermotrace, Vic., AUS).  Cells were grown 
to confluent monolayer in a 175 cm2 culture flask (Greiner Bio-One, Frickenhausen, 
Germany).  Cells were washed with phosphate buffered saline, harvested with 
trypsin/EDTA at 37°C (2-5 min), resuspended in growth media and 200 µL used to seed 
each well of a 96-well tissue culture treated microplate (#9102, Corning, NY, USA) 
with ~3 × 105 cells /mL).  Plates were grown to confluent growth for approximately 72 
h before infection with a clinical strain of C. trachomatis. 
 36 
Chlamydia titration 
Before assaying BDM-I for activity the Chlamydia trachomatis stock 
suspension was titrated to estimate the number of infectious units.  A stock vial of C. 
trachomatis (clinical isolate) was recovered from liquid nitrogen storage and the 
contents diluted 10-fold to 10-8 in Maintenance Medium (MM) (growth medium with 
0.5 µg/mL cycloheximide and 4.5 g/L glucose).  The medium was aspirated from the 
96-well microplate containing confluent McCoy cells and 100 µL of each dilution of C. 
tracomatis was added to triplicate wells.  The plate was centrifuged for 50 min at 35°C 
at 340 ×g (Hettich Rotanta 96R, Andreas Hettich & Co., Tuttlingen, Germany).  The 
medium was aspirated, replaced with 200 µL MM and incubated 48 h, 37°C, 5% CO2 
before fixing cells and staining as described below. 
Assay for inhibition of cell infection 
A dilution of C. trachomatis in MM determined from the titration to give a 
suitable level of infection was used as the inoculum.  Medium was aspirated from the 
plate of McCoy cells and 100 µL each of Chlamydia and BDM-I or tetracycline 
(positive control) added to appropriate wells.  The plates were centrifuged at 35°C for 
50 min at 340 ×g (Hettich Rotanta 96R, Andreas Hettich & Co.) to adsorb the 
Chlamydia into the McCoy cells.  The aspirated medium was replaced with 200 µL MM 
containing 1× BDM-I, or tetracycline (#T7660, Sigma-Aldrich) as a positive control 
and 100 µL MM to maintain test concentrations.  A titration series was also included on 
each assay plate to verify the number of infectious units of Chlamydia.  Plates were 
incubated at 37°C in 5% CO2 for 48 h. 
Fixation and staining 
All cells were fixed and stained with fluorescein-conjugated monoclonal 
antibodies to C. trachomatis (Bio-Rad Laboratories) in situ at 48 h post-infection.  The 
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medium was aspirated and the wells left to air-dry for 2 minutes.  Cells were fixed at  
-20°C for 15 min in acetone:methanol (1:2) (BDH Chemicals).  The fixative was 
aspirated and the cells left to air-dry for 3 min at room temperature.  One drop of C. 
trachomatis monoclonal antibody (Bio-Rad Laboratories) was added to each well, the 
plate covered with parafilm to increase the humidity and incubated at 37°C in 5% CO2 
for 1 h.  All wells were washed several times in immunofluorescence washing buffer 
(Appendix A), once in distilled water and left to dry for 2 min at room temperature.  
Mounting medium (Appendix A) was added to each well and a fluorescent microscope 
(IX71, Olympus Australia) used to view fluorescent antibody bound to the major outer 
membrane protein of elementary and reticulate bodies.  The assay was completed once 
and photos were taken with a digital camera (A525, Canon Australia, NSW, AUS) 
using a microscope eyepiece attachment. 
Assay for inhibition of Chlamydia post-infection 
Drugs were tested against a chlamydial infection, established for 24 h using 
the method described above except that the addition of drugs was delayed until 24 h 
after infection.  This assay was repeated twice and phots taken as above. 
2.5.3 Results 
BDM-I, when added at the time of inoculation of the monolayer with EB’s, 
reduced the number of RB’s in McCoy cells at 48 h compared to the untreated control.  
Photographs of the fluorescent chlamydial bodies in infected McCoy cells are shown in 
Figure 2-1.  BDM-I at a concentration of 5 µg/mL gave a similar level of reduction of 
RB’s to that of tetracycline at 0.06 µg/mL, indicative of an approximately 80× lower 
activity by concentration.  Results for tetracycline were comparable to those reported in 
previous studies where, in the absence of standardised methodology, the MIC (0.25 
µg/mL) was conservatively defined as 2-fold above the concentration resulting in  
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Figure 2-1.  Reduction in fluorescent Chlamydial bodies in vitro after exposure to BDM-I. 
Chlamydia 48 h after infection of McCoy cells (a) and when exposed to BDM-I at 2.5 µg/mL (b), 
5 µg/mL (d), or 0.06 µg/mL tetracycline (c).  Assay performed as described in Section 2.5.2. 
alterations to 90% of inclusions (Stephens et al., 1998).  By this measure a reduction 
would have been seen at 0.06 µg/mL 
BDM-I (5 µg/mL), did not inhibit reticulate body replication when 
administered 24 h post infection (results not shown).  Tetracycline inhibited replication 
when administered at both time points.  This suggests that BDM-I is interfering with 
binding and/or entry stages within the first few hours of infection but was not able to 
inhibit subsequent replication of chlamydial cells in inclusion membranes at the 
maximum concentration used in this assay.  However, toxicity of BDM-I to McCoy 
cells precluded testing higher concentrations. 
 39 
2.5.4 Discussion 
Activity against this obligate bacterial pathogen in addition to the protozoal 
intracellular pathogens, Plasmodium and Eimeria, confirms that BDM-I acts 
intracellularly on a fundamental metabolic process common to prokaryotic and 
eukaryotic pathogens and/or their host cells. 
The inhibition of early stage infection of McCoy cells but not reticulate body 
replication suggests that BDM-I is affecting one or more of the metabolic functions 
necessary for binding or endocytosis which could be an effect on a host cell mechanism 
coopted for entry or a target unique to Chlamydia spp.  BDM-I was not shown to affect 
replication of EB’s, which suggests that there is no direct interference with unique 
chlamydial or commandeered host cell metabolic functions involved in cell replication.  
However this is qualified by the observation that the level of BDM-I achievable in 
McCoy cells may be too low to inhibit these functions.  Future work will be needed to 
replicate these results as replication was not possible in the given time-frame due to 
experimental complications.  BDM-I, however, is effective against other intracellular 
Gram-negative pathogens such as Neisseria and Haemophilus at 1-5 µg/mL (Table 1-1), 
within the concentration level used in the C. trachomatis assay. 
There is evidence that Chlamydia exploit host signalling and trafficking 
pathways for their development.  Two open reading frames (ORF’s) showing homology 
with serine threonine protein kinases and one ORF showing homology to a serine 
threonine protein phosphatase, PP-2C, have been identified (1997).  No tyrosine 
phosphatases in Chlamydia have been identified.  Fawaz et al. (2004) showed that 
chlamydial infection of epithelial cells with C. trachomatis resulted in tyrosine 
phosphorylation of several host proteins, including proteins involved in signal 
transduction and associated with the cytoskeleton, including cortactin.  Active cortactin 
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is a tyrosine phosphorylated protein which is associated with the chlamydial vacuole 
early in pathogenic invasion.  They showed that orthovanadate, a PTP inhibitor, 
inhibited infection of cells by C. trachomatis. 
Tyrosine phosphorylation events occur very early in infection, consistent 
with a role in the entry step.  Clifton et al. (Dautry-Varsat et al., 2005) have identified a 
chlamydial actin-recruiting tyrosine phosphoprotein (TARP) which is expressed in EB’s 
(unphosphorylated) and translocated into the host cell by the chlamydial TTSS.  It is 
then rapidly phosphorylated and is associated with signalling events for actin 
recruitment and cytoskeletal reorganisation (Gupta & Griffiths, 2006; Stephens et al., 
1998). 
Chlamydia possess a type III secretion system (TTSS), as do many 
intracellular pathogens. The TTSS is a protein export apparatus allowing proteins to be 
secreted across the cytoplasmic membrane.  TTSS translocates microbial proteins into 
the cytosol of eukaryotic cells to facilitate bacterial pathogenesis.  TTSS in Chlamydia 
is probably used to modify host cell processes involved in cell invasion, to modify the 
inclusion membrane and host cell regulatory pathways (Stephens et al., 1998).  
Chlamydial phosphorylated proteins in the inclusion membrane, such as IncA may be 
phosphorylated by host kinases (Tuomanen et al., 1986). 
The significance of signalling events, particularly through phosphorylation 
by host kinases, of both host and chlamydial proteins, in binding, entry and formation of 
inclusion bodies suggests that the mechanism of BDM-I against Chlamydia trachomatis 
may be inhibition of host tyrosine phosphatases involved in entry of EB’s into the host 
cell and formation of inclusion bodies.  In Chapter 5 BDM-I is shown to inhibit tyrosine 
phosphatases in an enzymic assay.  Since no ORF’s for likely tyrosine phosphatases 
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have been identified in the chlamydial genome, any inhibition by BDM-I of PTP’s is 
likely to be of host PTP’s. 
2.6 KILL RATES 
2.6.1 Background 
Rate of Kill 
The Minimum Microbicidal Concentration (MMC) is defined as the lowest 
concentration producing a 3 log10 reduction in inoculum density within 24 h in the 
standard MIC assay.  This also describes the microbicidal or microbistatic status of an 
agent, a microbicidal drug having an MMC ≤4× the MIC.  This index does not provide 
information on kill kinetics at various concentrations at and above the MIC.  Different 
rates of kill of susceptible microbial species can indicate differences in the metabolic 
significance of the target(s) of BDM-I.  Rapid killing may indicate that the target is 
particularly important in survival of that species or that there is an additive effect 
between primary and secondary targets. 
Time-kill assays for BDM-I were performed to investigate differences in the 
rate of kill of different microbial species and also provide a basis for treatment times 
and concentrations for later assays. 
Effect of BDM-I on S. aureus at different population growth rates 
In vitro assays for antimicrobial activity are usually performed in cells 
growing in optimal conditions.  This measures the microbicidal ability on fast growing, 
rapidly metabolising cells which are more susceptible to inactivation of a pathway.  The 
effects of a compound on slowly growing or dormant cells can be different.  β-lactam 
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antibiotics, for example, have more pronounced effects on rapidly growing cells 
actively synthesising peptidoglycan (Craig, 1998). 
Microbicidal drugs are characterised by fast killing of microbial cells in 
vitro.  If this activity is time-dependent, concentrations above the MIC will make little 
difference to the rate of kill and a dose-response may not be evident (e.g. β-lactams, 
macrolides, oxazolidinones).  This is in contrast to concentration-dependent killing 
where the bacterial load can be reduced faster by using increasing concentrations above 
the MIC (e.g. aminoglycosides, fluoroquinolones) (Eng et al., 1991). 
Time kill studies are usually determined for a fixed concentration of 
inhibitor against cells under optimal conditions and in the log or exponential phase of 
growth and therefore growing rapidly.  However, this may not be indicative of 
microbicidal activity against organisms when conditions are not optimal and the growth 
rate is slow or cells are dormant, conditions characteristic for pathogens infecting hosts 
(Eng et al., 1991). 
Here, time-kill rates were determined in media supporting optimal, 
suboptimal growth rates or not supporting growth, to determine if BDM-I was more 
active against actively replicating cells and therefore affecting a metabolic activity 
essential to microbial replication or structural integrity.  Often when the maintenance of 
cellular structural integrity or vital metabolism is targeted by an agent, the effects will 
be more pronounced in rapidly multiplying cells that have a greater metabolic demand. 
2.6.2 Materials and Methods 
Rate of Kill 
Strains used were B. cereus RMIT 30/7, B. subtilis ATCC 6633, S. aureus 
ATCC 29213, E. faecalis ATCC 29212, P. vulgaris ATCC 13315, M. catarrhalis RMIT 
211/2, E. coli ATCC 25922 and C. albicans ATCC 10231.  Overnight cultures were 
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diluted 1/100 in MHB (SLM for C. albicans) and incubated at 37ºC on a platform 
shaker at 160 rpm (Ratek, Vic, AUS).  Log-phase cultures were diluted in medium to 
approximately 1 × 106 CFU/mL. Sterile McCartney bottles were prepared with 5 mL 
medium with or without BDM-I at various multiples of the MICH and pre-warmed to 
37ºC.  Each was inoculated with 50 µL of the bacterial suspension.  All test systems 
contained a final 1% v/v DMSO (BDH chemicals), including controls without BDM-I.  
All bottles were incubated at 37ºC, at 160 rpm on a platform shaker between sampling 
times.  At time points 10 µL aliquots of 10-fold serial dilutions in saline were plated 
onto NA and plates incubated for 24 h at 37ºC aerobically to determine the number of 
viable cells per mL.  Cultures were sampled at 0, 4, 8 and 24 h except for M. catarrhalis 
and E. coli (0, 3, 6, 24 h) and E. faecalis (0, 6, 8, 24 h).  Each assay was completed 
twice and average viable counts reported. 
Effect of BDM-I on S. aureus at different population growth rates 
Based on the method of (Denisenko et al., 27 Dec. 2002  International 
patent), time-kill curves were performed in medium formulations designed to support 
optimal, suboptimal and no population increase of Staphylococcus aureus, to identify 
the effect of a difference in growth rate on to BDM-I activity.  MHB (Oxoid) was used 
as the control medium for comparison.  Yeast Nitrogen Broth (YNB, Difco, BD 
Biosciences), without a carbon source or amino acids, leaving a sole nitrogen source (5 
g/L, ammonium sulfate), was used for the ‘no population growth’ state.  The ‘optimal 
growth’ formulation consisted of YNB with 0.5% w/v glucose (Sigma-Aldrich) and 
1.7% w/v Casamino acids (Difco, BD Biosciences, CA, USA).  The ‘suboptimal 
growth’ formulation consisted of YNB with 0.05% w/v glucose and 0.0017% w/v 
Casamino acids (Difco, BD Biosciences). 
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Four McCartney bottles were each prepared with 5 mL of a formulation.  
BDM-I in DMSO was added at a concentration 100× that of the final test concentration 
(16 µg/mL) and the solution warmed to 37ºC overnight.  The controls also contained a 
final concentration of 1% v/v DMSO.  An overnight broth culture of S. aureus was 
diluted and each bottle inoculated with approximately 1 × 106 CFU/mL log phase 
bacteria.  Ten-fold dilutions were plated onto NA and incubated at 37°C for 24 h to 
obtain viable counts.  Cell numbers (log10 CFU/mL) were plotted over time and growth 
rates of cultures treated with BDM-I compared to rates of the control cultures. 
2.6.3 Results 
Rate of Kill 
Time kill curves for BDM-I against selected bacteria and C. albicans are 
shown in Figure 2-2.  The MICH was used as a reference value for reporting effective 
concentrations because this inoculum density was used for rate of kill studies.  BDM-I 
reduced population growth in bacteria slowly and in a weakly dose-dependent manner 
in general.  BDM-I concentrations above the lowest concentration, that were first to 
show bactericidal activity, usually resulted in little or no increase in the kill rate.  There 
was no common pattern based on cell wall structure (Gram-reaction) for the bacterial 
species tested and there was considerable variability in killing rate for strains similarly 
susceptible when compared by MIC values. 
BDM-I was most rapidly bactericidal against B. subtilis and B. cereus, with 
concentrations 4× MICH producing a 5.5 log10 and 3 log10 reduction in viable cells over 
24 h respectively.  A less rapid kill over 24 h for concentrations ≥2× MICH was 
observed for M. catarrhalis and P. vulgaris, BDM-I reducing cell numbers by 3-4 log10 
and showing no dose response.  BDM-I was much less bactericidal to the Gram-positive 
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cocci, failing to reduce cell numbers of staphylococci at 16× the MICH and reducing cell 
number of enterococci by 1 log10  at 8× MICH. 
The yeast, C. albicans was killed more rapidly than the bacterial strains 
tested with a 5 log10 reduction in 8 h at 2× the MICH.  Only C. albicans showed a clear 
increase in kill rate with concentration.  The fungicidal action on C. albicans confirms 
the low minimal fungicidal concentrations for fungi which were generally the same as, 
or 2-fold higher than the MIC (Table 1-1). 
Effect of BDM-I on S. aureus at different population growth rates 
The growth rates of S. aureus in the broth formulations permitting optimal 
and suboptimal growth can be seen in Figure 2-3a.  There was a 1 log10 reduction in cell 
numbers in suboptimal growth conditions between 6 h and 24 h.  BDM-I at 16 µg/mL 
(2× MICH) to YNB (which has no carbon source) did not kill non-replicating cells 
(Figure 2-3b).  BDM-I, at 16 µg/mL, was equally bactericidal under both suboptimal 
and optimal growth conditions, producing a similar 1 log10 reduction in cell numbers 
between 6 h and 24 h.  This suggests BDM-I only kills metabolising cells but is 
attacking a target not immediately essential to cell replication such as cell wall, protein 
and DNA synthesis.  The lack of kill of dormant cells confirms that BDM-I is not 
directly degrading cell wall or membranes.  It is also consistent with the lack of a dose 
response in the kill rate for bacteria. 
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Figure 2-2.  Time-kill curves for BDM-I against bacteria and Candida albicans. 
Bacterial time-kills were performed in MHB and C. albicans in SLM as described in Section 
2.6.2.  Each line represents BDM-I concentrations in µg/mL.  Controls contained media (1% v/v 
DMSO) without BDM-I.  Error bars represent standard deviation. 
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Figure 2-3.  Effect of BDM-I on S. aureus at different population growth rates. 
The rate of growth in MHB in broth formulations without BDM-I is shown in a).  The effects of 16 
µg/mL BDM-I on S. aureus in MHB and in media supporting no growth, suboptimal growth and 
optimal growth are shown in b).  Broth formulations were as follows: no growth, YNB without 
additives; suboptimal growth, YNB with 0.01% w/v glucose and 0.0017% w/v Casmino acids; 
optimal growth, YNB with 0.5% w/v glucose and 1.7% w/v Casmino acids.  Broth formulations 
and assay method are described in Section 2.6.2. 
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2.6.4 Discussion 
Rate of Kill 
BDM-I is not uniformly bactericidal to susceptible species, the MMC being 
much more variable across genera than the MIC.  For example, BDM-I is bacteriostatic 
against Staphylococcus and Enterococcus spp. and bactericidal to Streptococcus spp. 
with a similar or lower MIC (Denisenko et al., 27 Dec. 2002  International patent).  
Bactericidal activity in the Gram-negative bacteria is variable, BDM-I being 
bactericidal to the fastidious species but not to several enteric and related species.  This 
differentiates BDM-I from broad spectrum biocides which kill cells directly and 
uniformly. 
The bactericidal action of BDM-I is minimal or slow and is little affected by 
increases in the concentration.  This suggests a target or targets not immediately 
significant to cell viability or cell replication, but that over time is/are important to cell 
survival.  The differential in kill rates between species suggest that the target varies in 
significance for cell survival between species or that different or additional targets are 
attacked across species. 
Since the site of action of BDM-I is intracellular and not on the cell wall or 
cell membrane of bacteria, as established from other studies (Chapters 2 and 3), entry 
rate into the cell and accessibility to the target could be a factor in the slow kill rate.  
However, variation in kill rate between species with a similar wall structure (Gram-
positive) or envelope structure (Gram-negative) and all with very similar cytoplasmic 
membranes, suggests compound entry rate into the cell is not a factor. 
C. albicans, in contrast, was rapidly killed within 4 hours and showed a 
clear dose response (Figure 2-2).  This suggests the targets are more directly related to 
cell replication in eukaryotic microorganisms than in prokaryotes.  BDM-I is more 
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uniformly active across fungal species (Table 1-1) and is fungicidal to all species tested 
at concentrations at or 2-fold above the MIC (Eng et al., 1991).  The difference in 
microbicidal activity between fungi and bacteria could be explained by a difference in 
target or in the significance of the target to growth and replication, between eukaryotic 
and prokaryotic cells.  The broad antimicrobial spectrum of BDM-I favours a common 
major MOA.  A proposal that this major target is cellular protein tyrosine phosphatases 
is made in Chapter 5, where the occurrence and significance of PTP’s in eukaryotic and 
prokaryotic cells is discussed.  Protein tyrosine phosphatases have been shown to be 
involved in cell growth, cell differentiation and the cell cycle in eukaryotic cells.  The 
important role of PTP’s in eukaryotic cell growth could explain the more rapid 
microbicidal activity observed in C. albicans. 
Effect of BDM-I on S. aureus at different poopulation growth 
rates 
In common with many bactericidal antibiotics, BDM-I does not kill dormant 
cells.  This differentiates it from broad spectrum biocides which kill microbial cells 
directly.  The β-lactams, fluoroquinolones and aminoglycosides exert a maximum effect 
on rapidly growing cells and kill rates are considerably reduced with suboptimal growth 
conditions (Pankey & Sabath, 2004).  BDM-I, although slowly bactericidal, has the 
advantage of being equally effective in killing slowly replicating cells, an advantage for 
an anti-infective drug because growth rates are usually initially slow and infected 
tissues contain a dense population of non-growing bacteria (Denyer & Hugo, 1991).  
Failure to kill infecting cells can lead to latent or chronic infections if cells are 
inaccessible to host defence mechanisms.  Slow bactericidal activity is not always a 
disadvantage in an anti-infective drug.  Other than in severe and sudden infections, 
 50 
adequate and continuing control of replication can be sufficient to tip the advantage in 
favour of host defence mechanisms. 
2.7 INTERACTIONS WITH ANTIBIOTICS 
2.7.1 Background 
Interactions between antibiotics can be investigated for antagonistic or 
synergistic effects on target bacteria.  The interaction between two compounds may 
indicate a relationship between their mechanisms of action (Odds, 2003).  In 
combination, drugs with synergistic effects are required in less concentrated amounts 
than either drug alone.  Synergism can arise when the mechanisms of the two 
compounds are directly complementary (affecting the same metabolic function) or 
indirectly complementary (affecting a necessary related function).  Antagonistic 
reactions are observed where the addition of one drug increases the concentration 
required of the second drug.  This may be due to interference of the second drug’s 
mechanism by the mechanism of the first.  For example, most antibiotics are 
bacteriostatic against enterococci, however a synergistic effect between a cell-wall 
active β-lactam agent and an aminoglycoside, targeting the ribosome can produce a 
bactericidal effect through increased penetration of the aminoglycoside. 
The checkerboard titration is an efficient technique for demonstrating 
synergism (greater effect in combination) or antagonism (lesser effect in combination) 
between two compounds (Sweeney & Zurenko, 2003).  Interactions between BDM-I 
and representatives from the major classes of antibiotics were investigated for 
antagonistic or synergistic effects on selected bacteria by chequerboard titration and 
calculation of Fractional Inhibitory Concentration Indices (FICI).  Interactions were 
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further investigated by determining time-kill kinetics for drug combinations shown to 
interact in checkerboard titrations. 
2.7.2 Materials and Methods 
Synergism or Antagonism of BDM-I with antibiotics 
BDM-I was investigated for interaction with a protein synthesis 
translocation inhibitor (erythromycin), an aminoacyl-tRNA inhibitor (tetracycline), a 
glycopeptide inhibitor of cell wall synthesis (vancomycin) and a quinolone 
(ciprofloxacin) that interferes with DNA gyrase supercoiling. 
Strains used were S. aureus ATCC 29213, E. faecalis ATCC 29212 and E. 
coli ATCC 25922.  Each test strain was grown to log phase in MHB at 37°C and diluted 
to a final inoculum density of 1 × 105 – 1 × 106 CFU/mL in a total of 200 µL.  
Antibiotics and BDM-I were prepared as 2-fold dilutions at 4× test concentrations in 
MHB.  Microtitre plates (Sarstedt Australia) were prepared with 50 µL of increasing 
concentrations of the two compounds (i.e. BDM-I and one antibiotic) on adjacent axes.  
Inoculated plates were incubated at 37°C for 20 h and MIC’s for each compound alone 
and in combination were recorded.  The pattern of inhibition was indicative of the 
interaction between the two compounds and the method enables the calculation of a 
Fractional Inhibitory Concentration Index (FICI), a numerative interpretation of the type 
of interaction displayed. 
For wells containing the lowest inhibitory combinations of drugs, a 
Fractional Inhibitory Concentration (FIC) is derived for each well from the calculation: 
MIC of compound A with compound B + MIC of compound B with compound A 
The MIC of compound A alone   The MIC of compound B alone 
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The mean of all FIC values for each plate gives the FICI, a numerative 
interpretation of synergistic, antagonistic or indifferent interaction.  An FIC Index of 
≤0.5 was considered to indicate synergism, a value ≥4 to indicate antagonism and all 
values >0.05 to <4.0 indicated an indifferent interaction (Kadota, 1996; Pasquale & 
Tan, 2005; Williams, 2001).  All assays were performed on at least three different 
occassions. 
Time-kill interaction between an antibiotic and BDM-I  
Any interaction observed between an antibiotic and BDM-I against any 
strain was further investigated using a time-kill method in MHB at 37ºC as described in 
Section 2.6.2.  BDM-I was added from 100× working stock solutions in DMSO and 
equal concentration (µg/mL) of the antibiotic added.  Ratios of BDM-I and drug were 
mixed at 1:1 (µg/mL) with concentrations equal to ½, 1×, 2×, 4×, 8× and 16× the MICH.  
All tubes contained a final DMSO concentration of 1% v/v including the MHB control 
without BDM-I.  All tubes were incubated for at least 15 min at 37°C before addition of 
inoculum.  The test strain was grown overnight in MHB at 37ºC.  The overnight culture 
was then diluted in MHB, incubated to early log phase and used to inoculate 5 mL 
MHB to a density of approximately 5 × 106 CFU/mL.  All bottles were incubated at 
37ºC, at 160 rpm on a platform shaker (Ratek) between sampling times.  At 0, 8 and 24 
h, 10 µL aliquots of 10-fold serial dilutions in saline were plated onto NA and plates 
incubated for 24 h at 37ºC aerobically to determine the number of viable cells per mL.  
The assay was completed twice and average viable counts reported. 
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2.7.3 Results 
Synergism or Antagonism of BDM-I with antibiotics 
Checkerboard titration assays did not show synergistic or antagonistic 
interactions between BDM-I and erythromycin, ciprofloxacin or vancomycin.  
Borderline synergism was observed for concentrations of BDM-I and tetracycline with a 
mean FICI of 0.51.  This interaction was at the weaker end of the spectrum, being close 
to the maximum FICI value for a synergistic reaction 0.5.  It was further investigated by 
assessing the effect of combinations of tetracycline on the rate of kill of E. faecalis. 
Table 2-3.  Average FIC Indices resulting from chequerboard titrations between 
BDM-I and selected antibiotics. 
Antibiotic: Tetracycline Erythromycin Ciprofloxacin Vancomycin 
Bacteria 
Av. FICI 
(±SD) Interpretation 
Av. FICI 
(±SD) Interpretation 
Av. FICI 
(±SD) Interpretation 
Av. FICI 
(±SD) Interpretation 
E. faecalis 
0.51 
±0.12 
Weak 
Synergism 
/Indifferent 
0.75 
±0.22 Indifferent 
1.09 
±0.16 Indifferent 
1.03 
±0.29 Indifferent 
S. aureus 
0.92 
±0.25 Indifferent 1.4 ±0.4 Indifferent 
0.99 
±0.25 Indifferent 
1.15 
±0.3 Indifferent 
E. coli 
2.19 
±0.62 Indifferent — — 
2.46 
±0.24 Indifferent — — 
FIC Index Interpretations: ≤0.5, synergism; >4, antagonism; >0.5 to <4.0 indifferent interaction. 
SD, standard deviation. 
Time-kill interaction between an antibiotic and BDM-I  
The time-kill study on the interaction between BDM-I and tetracycline 
against E. faecalis showed antagonistic rather than the synergistic activity observed in 
the checkerboard titration).  BDM-I produced a reduction (~1 log10) in cell numbers at 
concentrations from 64 to 256 µg/mL, showing very little increase in kill rate at 
increasing concentrations from 4× to 32× above the MIC (16 µg/mL) which confirms 
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the observation in the time kill studies above (Section 2.6.3).  Tetracycline was much 
more rapidly bactericidal and showed a dose response from 16 to 256 µg/mL, with a 4 
log10 reduction in viable count at a concentration of 64 µg/mL, 4× the MIC (16 µg/mL) 
determined during checkerboard titrations.  At equal concentrations, the rate of 
inhibition was comparable for both compounds alone (Figure 2-4a & b) and together in 
combination (Figure 2-4c).  At equal concentrations (>32 µg/mL each), BDM-I had a 
small antagonistic effect on tetracycline resulting in lower kill rate than for tetracycline 
alone.  BDM-I at 2× MIC was also tested in the presence of tetracycline at 0.6×, 2.6× 
and 10× MIC and showed a similar antagonism (results not shown). 
2.7.4 Discussion 
The lack of any significant interaction of combinations of BDM-I with 
traditional antibiotics suggest that BDM-I is not affecting metabolic targets relating to 
the pathways targeted by these agents.  This supports a novel MOA for BDM-I.  The 
suggestion of possible weak synergism of tetracycline with BDM-I from the 
chequerboard titration is currently not explained.  BDM-I could be acting on a 
metabolic function which interferes with a target of tetracycline other than inhibition of 
ribosomal function. 
Antibiotics have many non-antimicrobial effects on eukaryotic cells and 
side effects in humans (Roberts, 2003).  Tetracycline is unusual among antibiotics in 
having a very broad antibacterial spectrum including the intracellular chlamydiae, 
mycoplasmae and rickettsiae and being active against some intracellular protozoal 
parasites while also being used to treat some non-infectious diseases (Madigan et al., 
2006).  This suggests that there may be unidentified effects in bacteria these two 
antibiotics which bind transiently that may explain the interactions reported here. 
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c) 
Figure 2-4.  Effect of BDM-I and tetracycline in combination on the rate of kill of 
Enterococcus faecalis. 
a) Effect of BDM-I (µg/mL) alone on E. faecalis;  b) Effect of tetracycline (µg/mL) alone on E. 
faecalis;  c) Effect of BDM-I & tetracycline (µg/mL) in equal proportions on E. faecalis. 
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CHAPTER 3 THE EFFECT OF BDM-I ON CELLULAR 
MEMBRANES 
3.1 INTRODUCTION 
Bacterial membranes 
Cell wall and membrane structures are a major defence against harmful 
agents.  The differences between prokaryotic and eukaryotic cell structure have made 
wall and membrane components attractive targets for selective agents. 
Gram-positive bacteria possess a cell wall composed of 90% peptidoglycan 
(Madigan et al., 2006).  This thick layer, external to the cytoplasmic membrane, 
provides a hydrophilic outer surface capable of resisting harsh environments whilst 
being porous to most molecules.  External to the cell wall there may also be a capsule or 
slime layer composed of high molecular weight polysaccharides or polypeptides, which 
are important virulence factors.  In Gram-negative bacteria there is a much thinner 
peptidoglycan layer (10 %) surrounded by a lipid bilayer constituting an outer 
membrane (or envelope) and enclosing the periplasmic space (Nakae & Nakae, 1982; 
Thanassi et al., 1995; Toro et al., 1990).  The OM is impermeable to large molecules, 
selectively permeable to hydrophilic molecules and highly selective and slowly 
permeable to lipophilic molecules.  The outer leaflet of the OM is composed of 
lipopolysaccharides and proteins, while the inner leaflet is a complex of lipoproteins 
and phospholipids, similar to the cytoplasmic membrane.  The outer leaflet lacks 
phospholipids that allow diffusion of lipophilic molecules.  It contains porins for 
passage of low molecular weight hydrophilic molecules such as sugars and amino acids.  
They may also allow passage of some small antibiotics, such as tetracyclines, 
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aminoglycosides and chloramphenicol (Nikaido, 1989).  Bacterial species vary with 
respect to the permeability due to porins, that of Pseudomonas spp. being very low 
(Madigan et al., 2006).  The structure and composition of the outer wall differ widely 
between species and are of major significance in susceptibility to antimicrobial agents. 
The cytoplasmic membrane is a semi-permeable phospholipid bilayer, 
embedded with integral proteins, which has complex biological functions.  It is 
responsible for transport of metabolites and solutes into and out of the cell and contains 
membrane-bound proteins and enzymes performing many functions in bacteria which 
are carried out in the cytoplasmic organelles of eukaryotic cells (Madigan et al., 2006).  
The cytoplasmic membrane is highly conserved across microbial species and is likely to 
be uniformly susceptible to membrane active agents which have access to it.  Access to 
the membrane will however vary depending on the chemical nature of the agent and the 
cell wall or OM structure of microorganism as described above. 
Fungi have cell walls that are structurally similar to plant cell walls though 
their composition differs.  They are typically ≥80% polysaccharide, with the main 
constituent being chitin and also contain proteins, lipids, polyphosphates and inorganic 
ions (Madigan et al., 2006).  The cytoplasmic membrane in fungi differs from that of 
bacteria in that ergosterol, rather than substances such as hopanoids in bacteria, regulate 
membrane fluidity and stability (Maillard, 2002). 
Agents disrupting the cell wall or membrane  
Damage to the cell wall and cytoplasmic membrane is a key action of some 
therapeutic agents and many disinfectants.  Microbicidal activity by membrane-active 
agents may involve physical disruption, dissipation of the proton motive force or 
inhibition of membrane-associated enzymes (Maillard, 2002).  Disinfectants, such as 
phenolics, biguanides, quaternary ammonium compounds, alcohols and cationic 
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surfactants act primarily on the cytoplasmic membrane causing leakage and/or 
coagulation of the cytoplasm.  At low concentrations, well below their concentration of 
use, many disinfectants have been shown to have more specific actions, such as 
interference with membrane enzymes and biosynthetic capabilities (Odds et al., 2003). 
Anti-infective agents are much more selective in their action on membranes 
than biocides.  Gram-positive bacteria are susceptible to penicillins, cephalosporins and 
glycopeptides which inhibit the synthesis of cell wall peptidoglycan.  Wall disruption 
results in secondary damage to the cell wall and ultimately cell lysis.  Polymyxin B, a 
cationic cyclic lipopeptide, binds to the lipid A portion of lipopolysaccharide in the 
Gram-negative envelope, disrupting and damaging the OM.  Daptomycin inserts into 
the cytoplasmic membrane, disrupting membrane potential, resulting in cell leakage and 
multiple downstream effects.  Anti-fungal agents such as the imidazoles (ketoconazole), 
the triazoles (fluconazole) and the polyenes (nystatin and amphotericin B) inhibit 
biosynthesis of ergosterol weakening membrane stability (Oliva et al., 2003). 
3.2 CYTOPLASMIC MEMBRANE INTEGRITY 
3.2.1 Background 
Whole cell lysis 
Cell lysis can be a direct effect of degradation of the cytoplasmic membrane 
or a secondary autolysis resulting from disruption of the protective wall or envelope, for 
example by agents interfering with synthesis of peptidoglycan.  Depolarisation of the 
membrane leading to autolysis by daptomycin has been shown to be a new mechanism 
of membrane damage.  Lysis by wall-active agents may be slow while direct 
degradation of the membrane results in rapid lysis. 
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The effect of BDM-I on the integrity of the cytoplasmic membrane of B. 
cereus and C. albicans was assessed using a whole cell lysis assay.  The species were 
selected because they are rapidly killed by BDM-I (section 2.3.3).  The inclusion of C. 
albicans enables comparison of activity on both bacterial and fungal cells.  In 
suspensions of bacterial and yeast cells, turbidity correlates directly with whole cell 
density and measures both living and dead cells.  Lytic activity can be shown by a 
decrease in viable cells accompanied by a decrease in turbidity and is most easily 
demonstrated at high concentrations where there is little or no increase in turbidity. 
Lysis of spheroplasts 
Direct lysis of the cytoplasmic membrane can be investigated using 
bacterial spheroplasts.  Spheroplasts are Gram-negative bacteria in which nearly all of 
the OM has been removed.  Lysozyme destroys peptide bonds in peptidoglycan and 
weakens the wall.  Protoplasts of Gram-positive bacteria can then be produced by 
adding sucrose to balance solute concentrations inside and outside the cell allowing 
lysozyme to digest peptidoglycan without cell lysis.  In treating Gram-negative bacteria, 
EDTA (Ethylenediaminetetraacetic acid) is needed to disrupt the OM and allow access 
of lysozyme to the peptidoglycan layer.  Spheroplasts have increased sensitivity to 
membrane damage, making them a useful indicator of agents directly active against the 
cytoplasmic membrane.  A decrease in the optical density of a protoplast or spheroplast 
suspension in the presence of a compound allows direct measurement of cell lysis due 
to disruption of the cytoplasmic membrane (1999).   
The ability of BDM-I to lyse spheroplasts of E. coli and M. catarrhalis was 
investigated.  E. coli has low susceptibility to BDM-I and M. catarrhalis is very 
susceptible.  They have differing levels and types of LPS in the outer envelope which 
could affect access of an agent to the cell membrane. 
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3.2.2 Materials and Methods 
Whole cell lysis assay  
C. albicans and B. cereus colonies were inoculated into 5 mL of SLM and 
MHB respectively and incubated at 37°C aerobically for 2 h with agitation.  A 96-well 
flat bottomed microtitre plate (Greiner Bio-One) was prepared with BDM-I in media at 
4× the test concentrations of 32, 64 and 128 µg/mL in 4% v/v DMSO.  Each culture 
(100 µL) was added to microtitre wells and the plate incubated aerobically at 37°C for 
up to 8 h.  Blank wells received no bacteria.  Optical density at 600 nm (OD600nm) was 
read at room temperature at the time of inoculation, 15, 30, 45 min and 1, 2, 4, 8 h after 
inoculation on a spectromphotometer (Cary 50 UV-Vis Spectrophotometer, Varian, Vic, 
AUS).  The plate was kept at 37°C between readings.  Microbicidal activity was 
measured by plating dilutions of the wells (10-fold) onto NA at 0, 2, 4 and 8 h and 
incubating plates aerobically at 37°C for 24 h for viable counts.  Microbicidal lysis is 
indicated by a loss of turbidity and a fall in viable count.  Decrease in viability with no 
loss in turbidity of the culture indicates a non-lytic attack on cells. 
Lysis of Gram-negative spheroplasts 
E. coli (MIC 512 µg/mL) and M. catarrhalis (MIC 2 µg/mL) were grown in 
10 mL of MHB, incubated aerobically overnight at 37°C on a shaker at 160 rpm 
(Ratek).  Each culture (100 µL) was used to inoculate 20 mL fresh medium and 
incubated at 37°C on a shaker (Ratek) at 160 rpm for 2 h.  Log cultures were 
centrifuged at 2000 ×g for 5 min at 4°C (3K15, Sigma Laborzentrifugen) and washed 
twice in cold 50 mM Tris, pH 8 (C4H11NO3, Amresco, Solon, Ohio, USA) with 20% 
w/v sucrose (AnalaR, BDH Chemicals).  Washed cells were resuspended in 5 mL of 
50 mM Tris, pH 8, with 20% w/v sucrose and each divided into 2× 2.5 mL for 
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preparation of whole cells or spheroplasts.  Spheroplasts were prepared according to the 
method of Ganzle et al. (Helander & Mattila-Sandholm, 2000) by incubation with 0.6 
mg/mL lysozyme (500 µL, 5 mg/mL in 50 mM Tris, pH 8; Sigma-Aldrich) with 20% 
w/v sucrose and 0.06 M EDTA (1 mL, 0.25 M, Amresco, Solon, Ohio, USA) for 30 
minutes at 37°C.  Cells were checked for spherical appearance indicating absence of 
cell envelope with a phase contrast microscope.  Spheroplasts were collected by 
centrifugation at 500 ×g for 5 min and resuspended in 3 mL 50 mM Tris (pH 8) with 
20% w/v sucrose and 10 mm CaCl2 (BDH Chemicals).  Whole cell suspensions 
received 1.5 mL 50 mM Tris (pH 8) with 20% w/v sucrose (instead of lysozyme and 
EDTA) solutions and were incubated for 30 minutes at 37°C. 
Resuspended spheroplasts and whole cells were adjusted to an OD570nm of 
0.2 and 100 µL of each added to a clear, flat-bottomed microtitre plate (Greiner Bio-
One) in duplicate wells.  BDM-I, 10 µL in 50% DMSO/PBS (Appendix A) was added 
to test wells for both preparations at 10× the desired final concentration.  To the control, 
10 µL of 50% DMSO in PBS (pH 7.4) was added in place of BDM-I.  The final 
concentration of DMSO in all wells was 5% v/v.  Turbidity was monitored 
spectrophotometrically at 570 nm every 10 minutes for 1 h (Cary 50 UV-Vis 
Spectrophotometer, Varian). 
The percentage of intact spheroplasts or whole cells was calculated as: 
(sample OD at time X / sample OD at time 0)*100 
The experiment was repeated four times and calculations made based on 
average percentages of intact spheroplasts or whole cells.  Decrease in the OD of the 
suspension after addition of a membrane-active agent indicates lysis of spheroplasts. 
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3.2.3 Results 
Whole cell lysis assay 
Lytic activity can be shown by a decrease in viable cells accompanied by a 
decrease in turbidity (usually rapid) and is most easily demonstrated at high 
concentrations where there is little or no increase in turbidity.  BDM-I at 128 µg/mL 
(16× the MICH) reduced the viable count of both B. cereus and C. albicans without loss 
of turbidity, indicating non-lytic microbicidal activity (Figure 3-1).  The OD of cell 
suspensions exposed to BDM-I (8 - 128 µg/mL) gradually increased over 8 h in a dose-
dependent manner.  For both species tested, at 4× and 8× the MIC for BDM-I, OD600nm 
continued to increase despite no increases in viability.  During the assay, at 8 h, 
concentrations of 16× the MICH for BDM-I resulted in a decrease in viable cells of B. 
cereus and C. albicans of 3 log10 and 4 log10 respectively (data not shown). 
Lysis of Gram-negative spheroplasts 
Lysis of spheroplasts shows a direct action on the cell membrane which is 
not secondary to breakdown of the cell wall.  Lysis of spheroplasts compared to lysis of 
whole cells indicates whether the OM is a barrier to penetration of an agent. 
E. coli formed ≥80% spheroplasts after treatment with lysozyme and M. 
catarrhalis (~70%).  There was no difference in the OD of suspensions of intact 
spheroplasts compared to whole cells of E. coli or M. catarrhalis in the presence of 
BDM-I (Figure 3-2).  BDM-I caused no disruption of the cytoplasmic membrane of 
Gram-negative spheroplasts, confirming the observed lack of lytic action for whole cells 
of a Gram-positive bacterium and a yeast. 
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Figure 3-1.  Optical density of Bacillus cereus and Candida albicans cultures 
continuously exposed to BDM-I.  
B. cereus (a) was assayed in MHB, C. albicans (b) in SLM.  BDM-I concentrations (µg/mL) in 
the media are shown as individual lines on the graphs.  OD600nm measurements carried out as 
described in Section 3.2.2.  MICH for B. cereus 8 µg/mL, MICH for C. albicans 8 µg/mL. 
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Figure 3-2.  Percentage of Escherichia coli and Moraxella catarrhalis 
spheroplasts and whole cells remaining intact during exposure to BDM-I. 
E. coli (a) and M. catarrhalis (b) spheroplasts (S) and whole cells (W) remaining intact in the 
presence of BDM-I (µg/mL).  Assays were performed in Tris buffer with 20% w/v sucrose by 
OD570nm as described in Section 3.2.2. 
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3.2.4 Discussion 
Whole cell and spheroplast lysis 
BDM-I is a small, highly lipophilic, neutral molecule which should readily 
diffuse through the lipid bilayers of microbial cells.  It appears to do so readily and 
without disrupting the cytoplasmic membrane of E. coli.  Cell lysis can be due to 
disruption of the cytoplasmic membrane or secondary to disruption of the cell wall.  
Spheroplasts, lacking the protection of the cell OM, are highly sensitive to disruption 
and degradation.  The plasma membranes of bacteria and yeast are very similar and the 
results for E. coli spheroplasts are highly likely to apply to bacterial and yeast 
protoplasts.  BDM-I does not lyse or crenellate red blood cells or affect the membranes 
of mammalian cells at concentrations which kill invading parasites (Nicoletti et al., 
unpublished).  This supports its lack of effect on bacterial spheroplasts.  These assays 
suggest that BDM-I does not degrade the cell wall or cytoplasmic membrane of B. 
cereus and C. albicans, either directly or as a secondary effect of its microbicidal 
activity. 
3.3 PERMEATION OF THE GRAM-NEGATIVE CELL ENVELOPE 
BY NPN  
3.3.1 Background 
The OM of Gram-negative bacteria is a significant permeability barrier 
protecting the cytoplasmic membrane.  Its composition and significance to resistance to 
lipophilic agents is discussed above and in Section 2.3.1.  Several anti-infective agents 
are able to permeate the OM and can be used to treat Gram-negative bacterial 
infections.  BDM-I has shown variable activity against Gram-negative pathogens which 
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may partly reflect a barrier effect by the OM.  Several substances, such as polycationic 
macromolecules, chelating agents and cationic peptides, can bind to polyanionic LPS 
displacing cross-bridging divalent cations, disorganising the structure of the outer 
leaflet.  This increases permeability of the OM and allows access of lipophilic 
antimicrobial agents to the phospholipid bilayers. (Vaara 1992). 
NPN (1-N-phenyl naphthylamine) is a hydrophobic probe that fluoresces 
weakly in aqueous environments and strongly when it enters a hydrophobic 
environment, such as a phospholipid bilayer, allowing detection of changes in 
permeability (Denyer & Maillard, 2002).  It is normally excluded from the hydrophobic 
core of the OM of Gram-negative bacteria by the closely packed hydrophilic LPS 
component of the outer leaflet (2000).  The chelating agent EDTA destabilises LPS by 
removal of Ca2+ and Mg2+, causing release of LPS and exposure of the inner leaflet of 
the OM.  Polymyxin, a cationic lipopeptide that binds to LPS, similarly destabilises the 
structure of the outer leaflet and disrupts the cytoplasmic membrane causing lysis and 
death.  When bacteria are treated with EDTA or polymyxin, NPN is able to penetrate 
the outer leaflet and in the hydrophobic core its fluorescence increases. 
Uptake of NPN was used to investigate whether BDM-I is able to rapidly 
permeabilise and/or directly degrade the OM of E. coli.  EDTA and polymyxin were 
used as positive controls. 
3.3.2 Materials and Methods 
The method was based on that of Helander & Mattila-Sandholm (Anderson 
et al., 2004; Bellamy et al., 1993; Didenko et al., 2005; Thomas et al., 1999).  Mid-log 
phase E. coli, grown in 5 mL MHB at 37°C for 2 h was centrifuged at 3000 ×g 10 min 
(3K15, Sigma Laborzentrifuge), washed and resuspended in 5 mM HEPES buffer, pH 
7.2 (Thermotrace, Vic. AUS) at an OD600nm of 0.5 U.  Ten-fold serial dilutions were 
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plated onto nutrient agar for viable cell counts.  The final inoculum for NPN assays was 
approximately 5 × 106 CFU/well. 
The stock solution of BDM-I (100 mg/mL in DMSO) was diluted in 5 mM 
HEPES buffer to 4× the test concentration of 250 µg/mL and 50 µL added to six wells 
each of a 96-well flat bottomed microtitre plate (Greiner Bio-One).  EDTA (Amresco) 
and polymyxin B (Sigma-Aldrich) in 5 mM HEPES buffer, pH 7.2 (Thermotrace), were 
used as a positive controls and added at 4× test concentrations of 250 mM and 250 µM 
respectively to six well each.  A negative uptake control was also included (in triplicate) 
containing 50 µL HEPES buffer in place of a treatment compound.  A stock solution of 
50 mM NPN in acetone (BDH chemicals) was diluted in 5 mM HEPES to 40 µM and 
50 µL added to half of each group of wells containing test compounds (in triplicate).  
The remaining group of triplicate wells received 50 µL HEPES buffer.  The bacterial 
suspension 100 µL was added to all test wells excluding the buffer/vehicle control 
immediately before beginning fluorescence readings.  Fluorescence was measured at 
excitation 350 nm and emission 450 nm within 5 min of addition of bacteria on a 
multilabel counter (Wallac 1420 Victor3, Perkin Elmer, Vic, AUS). 
The experiment was repeated twice and the results represented as relative 
fluorescence values (corrected for background fluorescence in absence of NPN) and 
NPN uptake values (relative fluorescence values as a ratio of those for the buffer 
control). 
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The ‘NPN uptake factor’ was calculated from the Fluorescence units 
according to the formula: 
NPN uptake factor = (T - C) / (N - B) where: 
T = fluorescence of test well containing test compound and NPN, 
C = fluorescence of test well containing test compound without NPN 
N = fluorescence of well containing buffer and NPN 
B = fluorescence of well containing buffer alone. 
An increase in fluorescence values is indicative of OM permeability as the 
hydrophobic compound moves into the hydrophobic core of the OM. 
3.3.3 Results 
When the OM is disrupted, NPN, which is usually excluded by Gram-
negative bacteria, can partition into the hydrophobic core of the OM where it fluoresces 
strongly.  Damage to the OM by an antimicrobial agent will result in enhanced uptake 
of NPN manifested by fluorescence .  NPN uptake by E. coli treated with BDM-I,  
EDTA and polymyxin B is shown in Table 3-1.  EDTA and polymyxin B, known OM 
disrupters, resulted in NPN uptake values 1.5× and 3× that of the negative control 
containing untreated E. coli.  Exposure of E. coli to BDM-I at 250 µg/mL (≤0.5 × 
MICH) failed to increase fluorescence or NPN uptake values above that of the buffer 
control (Table 3-1).  BDM-I at the highest sub-inhibitory concentration tested did not 
increase the permeability of the OM of E. coli. 
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Table 3-1.  Fluorescence values obtained in an NPN uptake assay using 
Escherichia coli exposed to BDM-I for 5 min. 
 
Average Relative  
fluorescence ±SD 
Average NPN*  
Uptake values ±SD 
Buffer 2175 ± 371 1.0 ± 0.0 
Bacterial suspension 3177 ± 1046 1.5 ± 0.7 
+ BDMI 250 µg/mL 2091 ± 665 1.0 ± 0.5 
+ EDTA 250 µM 4703 ± 974 2.4 ± 0.2 
+ PolyB 0.25 µg/mL  10018 ± 627 4.7 ± 1.1 
*NPN uptake values were calculated as described in Section 3.3.2. 
3.3.4 Discussion 
BDM-I is poorly active against many Gram-negative bacterial species 
characterised by dense LPS in the OM.  Lipophilic antibacterial agents active against 
Gram-positive bacteria may be unable to cross the OM of Gram-negative bacilli despite 
a mode of action generally applicable to Gram-negative bacteria.  Antimicrobial agents 
capable of permeabilising the OM by interaction with the LPS component have access 
to the cytoplasmic membrane and cytoplasm and can allow access to agents otherwise 
excluded.  BDM-I, being uncharged, would not be expected to interact with the 
predominantly anionic components of LPS in the manner of EDTA and polymyxin.   In 
the short exposure time (5 min) of this experiment BDM-I did not enhance the ability of 
E. coli to take up NPN and therefore did not increase permeability of the outer 
membrane.  Its ability to enter other Gram-negative bacteria with a similar OM structure 
in effective concentrations suggests it is able to diffuse slowly through the outer leaflet 
of the cell envelope without damage. 
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3.4 TRANSMISSION ELECTRON MICROSCOPY OF BDM-I 
TREATED CELLS 
3.4.1 Background 
Transmission electron microscopy (TEM) provides useful cytological 
information about structural and cytoplasmic changes and has been widely used for 
investigating the effects of antimicrobial agents on microorganisms.  Ultrastructural 
studies can indicate likely targets from the changes produced by an agent to cell 
structure, flagella, endospores and cytoplasmic organelle organisation.  Structural 
changes can be used to confirm the results of biochemical and cell assays or direct 
further studies to determine if an effect is a direct or indirect consequence of exposure. 
B. cereus and C. albicans, strains against which BDM-I is both highly 
active and microbicidal, were exposed to sub-MIC concentrations of BDM-I and 
changes in ultramorphology investigated using TEM. 
3.4.2 Materials and Methods  
Cultures of Bacillus cereus and Candida albicans were grown overnight in 
MHB or SLM at 37°C.  Each was diluted to McF0.5 in fresh medium and BDM-I in 
DMSO added to test concentrations of 0.5, 1 and 2 µg/mL for B. cereus and 2, 4 and 8 
µg/mL for C. albicans.  Control cultures received the same volume of DMSO.  Ten-fold 
dilutions were prepared and 10 µL plated onto NA for viable counts.  Cultures were 
incubated 24 h at 37°C at 150 rpm.  Aliquots (1 mL) of treated culture were transferred 
to microcentrifuge tubes and pelleted at 4°C for 5 min at 1,180 ×g (3K15, Sigma 
Laborzentrifugen).  Glutaraldehyde (Pro Sci Tech, Qld, AUS), 2.5% (1 mL) in 0.1 M 
sodium cacodylate buffer (Pro Sci Tech) was run down the side of the tube and agitated 
for 10 min.  Pellets were stored in 2.5% v/v glutaraldehyde overnight where required.  
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Pellets were washed twice, 15 minutes each, with 1 mL 0.1 M sodium cacodylate 
buffer. Osmium tetroxide (Pro Sci Tech), 1% (250 µL) in 0.1 M sodium cacodylate 
buffer was added and left to fix bacteria for 15 minutes.  The osmium was removed and 
pellets washed twice, 15 minutes each, with 500 µL 0.1 M sodium cacodylate buffer.  
Samples were dehydrated stepwise with ethanol (BDH Chemicals) at 70%, 90% and 
100% for 10 minutes each.  Final dehydration was with 100% ethanol for 15 minutes.  
Samples were prepared for infiltration by washing in 1 mL propylene oxide (Pro Sci 
Tech), 15 min each.  Infiltration of the sample was performed on a rotator for 1 h with 
1:1 v/v mix of propylene oxide and Procure 812 resin prepared according to 
manufacturers instructions (Pro Sci Tech).  This was replaced with 1:2 v/v mix of 
propylene oxide and resin for 16 h.  Samples were incubated in 100% resin for 2 h 
before transferring to warmed embedding capsules (size 00, Pro Sci Tech) and replacing 
with final 100% resin for curing at 60°C for 48 h.  Blocks, at room temperature, were 
trimmed and sections cut using an ultramicrotome (Ultracut, Leica Microsystems, 
NSW, AUS, formerly Reichert-Jung) with a freshly prepared glass knife.  Sections were 
collected on 200 µm copper grids and stained with 2% uranyl acetate for 20 minutes, 
washed in CO2-free water and stained with lead citrate 10 minutes.  Sections were 
viewed at 80 kV on a transmission electron microscope (100 SX, JEOL, Tokyo, Japan).  
Three sections per specimen were examined by TEM on different magnifications in at 
least five fields of view and photographs taken on film and developed on site. 
3.4.3 Results 
Sections of BDM-I treated cultures of Bacillus cereus and Candida. 
albicans were examined by TEM for morphological changes and compared to untreated 
cultures.  Treated bacterial and yeast cells were comparable to untreated cells with 
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respect to the features of cell morphology that could be observed with the achieved 
magnification and resolution (Figure 3-3 and Figure 3-4). 
In Bacillus cereus there was no evidence of swollen cells, thickened, 
incomplete or defective walls, abnormal septation or detached or undulating 
cytoplasmic membranes in BDM-I-treated cells (Figure 3-3).  The resolution was not 
adequate for detection of changes in sub-cellular structures, however, cytoplasmic 
aggregates or uneven staining were not observed. The only notable effect was the lower 
incidence of endospores in treated samples compared to control samples.  C. albicans 
treated cells appeared morphologically similar to control cells and showed normal 
budding. 
3.4.4 Discussion 
The action of BDM-I at sub-lethal concentrations on bacterial and yeast 
cells does not result in morphological changes in the cell wall or cytoplasmic membrane 
or gross changes in the cytoplasmic contents.  Many reports in the literature show 
changes in ultramorphology in bacteria and yeasts as a result of exposure to agents 
acting on the cell-wall and cell-membrane (Errington, 2003).  The absence of 
morphological changes confirms the results of the cell assays reported in this chapter 
and indicates that BDM-I is not affecting the integrity of the cell wall or cell membrane 
of bacterial and yeast cells. 
Exposure to BDM-I appears to lower the incidence of endopsore formation 
in Bacillus cereus.  Sporulation is a very complex response to stresses such as starvation 
and high cell density and involves coordinated monitoring of many internal and external 
signals channelled through separate regulatory systems (Errington, 2003).  The 
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Figure 3-3.  Transmission electron micrograph of Bacillus cereus treated with BDM-I. 
B. cereus untreated control (top right, top left) and B. cereus treated with 2 µg/mL BDM-I for 24 
h (Bottom left, bottom right). 
1 µm 
1 µm 0.5 µm 
0.5 µm 
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Figure 3-4.  Transmission electron micrograph of Candida albicans treated with 
BDM-I. 
C. albicans untreated control (left) and treated with 4 µg/mL BDM-I for 24 h (right). 
formation of endospores has been extensively studied in B. subtilis and shown to 
involve complex regulatory systems.  The most prominent transcriptional regulator is 
Spo0A, whose synthesis is controlled transcriptionally and whose activity is regulated 
by phosphorylation (Iber et al., 2006).  Phosphorylated Spo0A is an essential positive 
regulator of sporulation, activating transcription of several sporulation-specific genes, 
spoIIAB, spoIIAA and spoIIE (Jiang et al., 2000).  Spo0A is phosphorylated on aspartate 
by a cognate histidine kinase, Spo0B, which is part of a phosphorelay signal 
transduction system transferring phosphates ultimately to Spo0A and controlling the 
initiation of sporulation.  Multiple kinases in this system provide signal inputs with 
ultimate transfer to Spo0A.  Negative regulation occurs through controlled 
dephosphorylation by aspartyl phosphate phosphatases, such as the RapA and RapB 
phosphatases which dephosphorylate Spo0A (Proctor et al., 1998).  To date, tyrosine-
phosphorylated proteins have not been shown to play a role in the initiation, or in the 
1 µm 0.5 µm 
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inhibition of initiation, of sporulation or in the various stages of cell differentiation 
leading to spore formation.  Many different signals are integrated in determining 
sporulation and very little is yet known about many aspects signal transduction in 
bacteria.  Sporulation can be inhibited at many stages of endospore formation, such as 
asymmetric cell division, chromosome segregation, engulfment of the pre-spore and 
spore morphogenesis.  Further work is required to determine whether BDM-I does 
inhibit endospore formation in Bacillus spp. and, if so, which of the many complex 
components is affected. 
The results of the microarray analysis of gene transcription in BDM-I 
treated cells of B. subtilis reported in Chapter 6 have shown a change in genes involved 
in the sporulation process which supports the observation that BDM-I has inhibited 
sporulation in the closely related B. cereus.  The implications of this for the 
mechanism(s) of action of BDM-I remains to be explored. 
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CHAPTER 4 EFFECT OF BDM-I ON COLONIAL 
MORPHOLOGY AND CELL PHYSIOLOGY 
4.1 INTRODUCTION 
In search of clues to BDM-I targets in bacteria, physiological changes in 
response to BDM-I in individual species were examined.  Species-specific physiological 
effects (in colony size, pigment, motility) that had been observed in response to 
exposure to BDM-I were investigated.  These changes had been observed during MIC 
and MMC assays and included the formation of small colony variants by S. aureus, 
inhibition of pigment formation by Serratia marcescens and inhibition of swarming 
motility in Proteus spp.  These were examined more closely along with capsule 
formation by Klebsiella pneumoniae as this is an important virulence factor for many 
bacteria. 
4.2 INDUCTION OF SMALL COLONY VARIANTS OF S. AUREUS  
4.2.1 Background 
Small-colony variants (SCV’s) of Staphylococcus aureus are a slow-
growing heterogeneous sub-population of colonies, generally ten times smaller than the 
‘normal’ phenotype that cause major problems in persistent and recurring infections 
(Proctor et al., 1995).  They may be a naturally occurring part of a population and can 
be induced following exposure to aminoglycosides, β-lactams or sulphonamide-
trimethoprim (Baumert et al., 2002; Proctor et al., 1994).  These colony variants are 
non-pigmented and non-haemolytic with reduced metabolic capabilities.  This leads to a 
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number of physiological changes, including reduced production of virulence factors 
such as coagulase and α toxin and increased resistance to antibiotics, such as 
aminoglycosides and penicillins (Proctor et al., 1995).  There are possibly several 
mutations leading to the small colony variant phenotype that have not been well 
characterised, since colony stability varies considerably and revertants to normal 
morphology are common (Baumert et al., 2002). 
Many SCV’s are respiratory deficient and have been shown to be 
auxotrophic for menadione, thiamine  and haemin, important precursors for, 
respectively, menaquinone and the cytochromes, electron acceptors in the electron 
transport chain required for oxidative phosphorylation (Baumert et al., 2002).  Reduced 
electron transport, and consequential lack of ATP, results in many phenotypic changes 
such as the small colony size, reduction in biosynthesis of carotenoids and reduced 
secretion of macromolecules.  A reduced membrane potential in small colony variants is 
also responsible for an increased resistance to antibiotics that require a high 
electrochemical gradient for efficient uptake such as the aminoglycosides (Dierstein et 
al., 1989). 
The production of variable sized colonies was noted in MMC assays for S. 
aureus.  The production and stability of small colony variants on exposure to BDM-I 
was investigated in S. aureus since their development could indicate induction of 
mutations or selection of existing stable small colony phenotypes with genetic or 
biochemical lesions useful for studies of MOA. 
4.2.2 Materials and Methods 
MHB (5 mL) containing 0, 32 or 128 µg/mL BDM-I with a final DMSO 
concentration of 1% v/v, was inoculated with 100 µL log phase culture of S. aureus in 5 
mL MHB, visually standardised to 105-106 CFU/mL by McFarland opacity standards 
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and the cultures incubated at 30°C, aerobically to improve pigment production 
(Denisenko et al., 27 Dec. 2002 International patent,  Nicoletti et al., unpublished). 
Aliquots of 100 µL from test and control cultures were taken at 0, 24 and 48 
h after inoculation and serially diluted ten-fold and plated onto NA and incubated 
aerobically for up to 48 h at 37°C.  Dilution plates were observed for colony 
morphology and characteristics.  Selected colonies from dilution plates showing 
variations in size and pigment were confirmed by Gram-stain and catalase production 
(H2O2 slide test).  Typical variant colonies (3-5 per plate) from 24 and 48 h exposures 
were serially subcultured onto BDM-I-free nutrient agar to test for phenotypic stability.  
The assay was repeated twice and plates photographed with a digital camera (A520, 
Canon). 
4.2.3 Results 
BDM-I at 32 and 128 µg/mL is not microbicidal to S. aureus at 24 and 48 h 
and a sufficient number of colonies were produced on dilution plates of concentrations 
up to 512 µg/mL to be able to observe for colony heterogeneity.  Colonies of S. aureus 
grown in MHB and 1% DMSO had uniform colony diameters of 2 mm (Figure 4-1, 
right) when plated on NA.  Twenty four or 48 h exposure to BDM-I produced either 
uniform small colonies of ~1 mm diameter (Figure 4-1, left) or colonies of variable size 
from normal to small (data not shown).  Colonies showed loss of pigment but were 
otherwise of typical staphylococcal morphology.  Gram-reaction and cell morphology 
for variant colonies was the same as control cells and all were catalase positive.  On 
subculture to NA, small colonies from both concentrations and both times gave rise to 
heterogeneous colonies (normal to small) at either the first or second subculture.  No 
stable variant phenotypes resulted from exposure to concentrations of BDM-I for up to 
48 h at concentrations up to 128× the MIC.  After subculture in drug-free medium 
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variant colonies had the same MIC as the parent.  No further characterisation  of 
atypical colonies was performed.  BDM-I has not, in this experiment, produced any 
mutant colonies or the stable small colony variants noted with other antibiotics. 
 
Figure 4-1.  Small colonies of Staphylococcus aureus produced on agar after 
exposure to BDM-I in broth culture. 
S. aureus was exposed to 32 µg/mL BDM-I for 24 h in broth, plated out (left) and compared to a 
control culture (right). 
4.2.4 Discussion 
Exposure of S. aureus to BDM-I for up to 48 h did not induce or select any 
resistant mutant colonies, or the stable small colony variant phenotype in S. aureus 
which occur on exposure to antibiotics such as β-lactams and aminoglycosides.  BDM-I 
has been shown to be non-mutagenic by the Salmonella mutation reversion (Ames) test. 
(Nicoletti et al., unpublished).  No resistant mutants were observed during 12-16 week 
continuous exposure to BDM-I of S. aureus and several other bacterial species in 
resistance studies (Kennelly, 2002).  Very low incidence of stable resistant phenotypes 
is consistent with a single major target that cannot be readily circumvented by bacteria.  
 80 
Lack of development of resistant phenotypes on exposure to BDM-I is also consistent 
with a target such as inhibition of bacterial PTP’s.  PTP’s all share the same catalytic 
site but have many different functions which may vary between species (1975).  
Inhibiting bacterial phosphatases may be as effective as targeting multiple enzymes 
within a cell. 
On the evidence to date it is highly unlikely that BDM-I affects respiratory 
energy metabolism (Section 2.1).  The lack of an effect of BDM-I on ATP synthesis is 
supported by evidence in Chapter 5.  Stable phenotypes with genetic and/or metabolic 
lesions would have been useful for investigations of the biochemical effects of BDM-I.  
However, it is important to know that exposure to BDM-I does not induce slow growing 
stable and resistant variants that could survive treatment concentrations and cause 
persistent infections.  Small unstable colonies of E. faecalis and B. subtilis were also 
observed after exposure to BDM-I, however production of these variants was not as 
easily reproduced as for S. aureus (data not shown). 
4.3 PRODIGIOSIN PRODUCTION IN SERRATIA MARCESCENS 
4.3.1 Background 
Serratia marcescens is a plant and insect pathogen and an opportunistic 
human pathogen that is often multi-drug resistant and causes nosocomial respiratory and 
urinary tract infections.  It is one of three Serratia spp. that can produce an unusual, 
cell-associated intense red pigment termed ‘prodigiosin’ by Gerber (Boger & Patel, 
1988).  Prodigiosin (2-methyl-3-pentyl-6-methoxy prodigiosin) is one of a number of 
red pigments, based on the characteristic pyrrolylpyrromethene skeleton, referred to as 
prodigiosins or prodiginenes (Williamson et al., 2006).  Prodiginenes are also produced 
by Streptomyces spp. and various marine bacteria (Fineran et al., 2007; Montaner et al., 
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2000; Perez-Tomas et al., 2003; Thomson et al., 2000).  Serratia also produce an 
antibiotic, carbapenem and exo-enzymes such as pectinases, proteases and cellulases. 
Prodigiosin (PG) is a secondary metabolite with no known role in the 
physiology of producing strains but reported to have antimicrobial (antifungal, 
antibacterial and antiprotozoal), immunosuppressant and anti-cancer activity (Harris et 
al., 2004).  There is considerable heterogeneity among Serratia strains with some non-
prodigiosin producing species possessing ‘cryptic’ genes for PG production while 
others possess none (Carbonell et al., 2000).  PG production is characteristic of 
environmental strains of S. marcescens and clinical isolates are usually non-pigmented 
(Ang-Küçüker et al., 1999).  Non-pigmented variants, while proving more invasive in 
the conjunctival sacs of guinea pigs (Serenty test), have much lower LD50 values in 
mice than pigmented variants (Fineran et al., 2007).  A mutant strain of S. marcescens 
deficient in a protein (PigX) that represses transcription of the PG biosynthetic operon 
(pigA-pigO), exhibited increased production of PG and degradative exo-enzymes and 
increased plant virulence (Williamson et al., 2006).  Regulation of the swarming 
phenotype in Serratia was also shown to involve pigX.  PG, through its broad antibiotic 
action, may play a role in the competitive survival of Serratia. 
Synthesis of PG occurs as result of multiple cellular and environmental 
cues, a situation which is true for many secondary metabolites and necessitates complex 
genetic regulation of biosynthesis.  Investigations to date have shown regulatory 
variation between strains of the same genus and between genera (Fineran et al., 2007).  
The PG biosynthetic pathway in Serratia has been described  and the complex 
regulatory network for PG production elucidated (Williamson et al., 2006).  In Serratia, 
the pig operon containing genes pigA-pigO has been fully identified and specific Pig 
enzymes assigned to steps in biosynthesis (Fineran et al., 2007).  Regulator genes 
reverse the repression of transcription of pig biosynthetic genes in response to cell 
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signalling.  A master regulator, pigP, negatively regulates expression of the pig operon 
by modulating expression of other regulators, repressing both pigment and exoenzyme 
production (Whitehead et al., 2001). 
Bacteria regulate the induction and repression of genes in response to 
environmental cues, such as the density of the bacterial cell population, by extracellular 
signalling or quorum sensing (QS) systems.  Cell density-dependent gene regulation is 
mediated by the production of small signalling molecules, such as N-acyl homoserine 
lactones (AHL’s) in Gram-negative bacteria.  These small molecules accumulate and, 
above a threshold density, act as autoinducers of genes in the producer organisms. This 
process enables populations of bacteria to cooperate to achieve particular physiological 
outcomes which optimise growth or survival in their environment (Eberl et al., 1999; 
Morohoshi et al., 2007).  QS regulates the expression of virulence factors in many 
pathogens.  QS signalling in Serratia controls antibiotic and pigment production, 
biofilm formation and virulence factors such as the secretion of degradative 
exoenzymes and a surfactant (serrawettin) which facilitates swarming motility (2000).  
Thomson et al. (Blizzard & Peterson, 1963; Williams & Gott, 1964) showed that 
carbapenem, PG and degradative exoenzyme production was mediated by QS AHL’s 
which derepress transcription of the PG biosynthetic genes by modulating expression of 
regulator genes. 
Inhibition of PG production in Serratia spp. by antibiotics has been 
reported.  Streptomycin, tetracycline and chloramphenicol inhibit PG biosynthesis by 
interference with synthesis of pigment precursors (Tsang & Feng, 1983).  Polymyxin B 
inhibits PG production secondary to damage to the outer membrane (1999).  Ang-
Küçüker et al. (Dierstein et al., 1989) report inhibition of PG by subinhibitory 
concentrations of erythromycin, tobramycin, imipenam, co-trimoxazole, cefoxitin and 
nitrofurantoin.  The effect of BDM-I on prodigiosin synthesis and secretion in Serratia 
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marcescens was investigated following the observation of a loss of pigment in colonies 
in MMC assays for BDM-I. 
4.3.2 Materials and Methods 
Prodigiosin production in Serratia marcescens was evaluated by 
modification of methods used by (Williamson et al., 2006).  S. marcescens (RMIT 
342/1-32) was grown for 6 h in 30 mL peptone glycerol (PGB) broth aerobically at 
37°C and on a shaker (Ratek) at 160 rpm.  The culture was centrifuged 10 minutes at 
5000 ×g to concentrate cells (3K15, Sigma Laborzentrifugen).  Cells were resuspended 
in 5 mL sterile distilled water and stored overnight at room temperature as inoculum for 
tests. 
The stock cell suspension was diluted in PGB to an OD660nm 0.05 as the 
starting inoculum.  This culture was divided into four aliquots of 15 mL in 50 mL 
culture bottles.  BDM-I (15 µL) was added at 8, 32 and 128 µg/mL from 100× stock 
solutions in DMSO (BDH chemicals).  The control received an equal volume of DMSO.  
All cultures were incubated aerobically at 30°C, 160 rpm, for up to 48 h. At the time of 
BDM-I addition (0 h) and at 4, 8 and 12 h, 1.5 mL was removed from each culture and 
OD660nm used to to monitor cell density.  An aliquot of 100 µL was also removed at 
each time point and 10-fold dilutions (10 µL) plated onto NA for viable counts to 
monitor cell density.  Plates were incubated for 24 h at 37°C.  Pigment production in 
broth cultures was recorded at 0, 4, 8 and 12 h with a digital camera (A520, Canon). 
An aliquot of 300 µL was removed from all test and control samples into 
2.7 mL methanol with 4% 1 M HCl and left at room temperature for 1 h to extract the 
pigment.  The solution was then clarified by centrifugation at 5000 ×g for 15 min and 
the OD500nm used to detect the extracted pigment.  Percentage inhibition of pigment 
production was calculated for each treatment and time point by the formula:   
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((ODctrl-ODtest)/ODctrl) ×100.  Qualitative and quantitative assays were repeated three 
times on different days. 
4.3.3 Results 
Serratia marcescens was exposed to BDM-I in PGB and development of 
pigment formation recorded visually (Figure 4-2) and spectrophotometrically (Figure 
4-3).  Maximum inhibition of pigment production occurred at 8 h.  There was no 
marked dose-response, 8 µg/mL being almost as effective as 128 µg/mL at 8 h (Figure 
4-3).  Cell density, monitored by viable counts, showed that there was insignificant 
inhibition of S. marcescens at 128 µg/mL so the effect on pigment production was not a 
result of lower cell numbers.  BDM-I inhibits prodigiosin production at a concentration 
>64-fold less than its MIC for Serratia. 
4.3.4 Discussion 
Inhibition of pigment formation by Serratia marcescens was evident in the 
presence of BDM-I at concentrations well below the MIC.  Strains producing 
prodiginenes inhabit very diverse environments and belong to diverse bacterial genera.  
Secondary metabolites such as these show a great molecular diversity with specific 
functions of most not yet identified.  Genetic regulation of the production of 
prodiginenes which must integrate multiple cellular and environmental signals and 
therefore varies considerably between strains of the same genus and between genera 
(Williamson et al., 2006). 
Pigment production has been linked to protein phosphorylation in bacteria.  
Phosphorylation of PigQ, one of the pig response regulators, results in activation of 
prodigiosin biosynthesis by transcription of the pig operon (Matsumoto et al., 1994; 
Umeyama et al., 2002).  In Streptomycess coelicolor, phosphorylation on serine and 
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threonine residues of AfsR, a transcriptional factor in the regulation of secondary 
metabolism and morphological differentiation, is one factor controlling pigment 
production (1996).  Li & Strohl (Umeyama et al., 1996) isolated a gene, ptpA, from 
Streptomyces coelicolor coding for a low molecular weight tyrosine phosphatase 
(LMWPTP).  Cloned into Streptomyces lividans, ptpA resulted in production of 
undecylprodigiosin and a pigmented antibiotic actinorhodin (Li & Strohl, 1996).  PtpA 
belongs to a family of highly conserved small acidic PTP’s (SA-PTP) in bacteria, fungi 
and mammalian tissues.  Protein sequencing shows that PtpA is more closely related to 
mammalian and yeast SA-PTP’s than to bacterial SA-PTP’s (2004).  Bacterial SA-
PTP’s are clustered with different types of genes in different species.  The less closely 
related SA-PTP’s in Erwinia amylovora, Pseudomonas solanacearum and Klebsiella 
pneumoniae are associated with exopolysaccharide synthesis. 
Fürstner et al. (Harshey, 2003) have shown that nonylprodigiosin from 
Streptomyces, is an inhibitor of PTP’s and DSP’s.  Like BDM-I, prodigiosin was less 
inhibitory to DSPs.  PTP inhibition is a possible explanation of the antibiotic action of 
prodigiosin.  Inhibition of a PTP similar to PtpA of Streptomyces could be the cause of 
the inhibition of prodigiosin production in Serratia noted here for BDM-I.  It would be 
interesting to test the effect of combinations of BDM-I and PG for synergistic or 
antagonistic inhibition of bacteria, given that they may share a general mode of action. 
The proposed MOA of BDM-I is inhibition of bacterial tyrosine 
phosphatases (Chapter 5).  This action may explain the observed suppression of pigment 
production. 
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Figure 4-2.  Inhibition of pigment production in Serratia marcescens by BDM-I. 
BDM-I concentrations in broth (left to right): 0, 8, 32, 128 µg/mL.  Exposure times were 0 h (a), 4 
h (b), 8 h (c), 12 h (d). 
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Figure 4-3.  Inhibition of pigment production by Serratia marcescens exposed to 
BDM-I measured by absorbance of prodigiosin extracts. 
OD500nm measurements used to calculate inhibition of prodigiosin as described in Section 4.3.2.  
Dotted vertical bars represent standard deviation. 
a) 
b) 
c) 
d) 
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4.4 SWARMING MOTILITY IN PROTEUS SPP. 
4.4.1 Background 
Many bacteria are capable of self-propelled motion in certain circumstances 
and this motility can be achieved by a variety of mechanisms.  They may be driven by 
flagella or utilise a variety of flagella-independent surface translocation mechanisms 
such as gliding (Harshey, 2003).  The term swarming describes a unique type of 
flagella-dependent surface translocation involving the coordinated and rapid movement 
of bacteria across a semisolid surface and facilitating rapid colonisation, attachment to 
surfaces and biofilm formation.  Many bacterial species are motile but do not 
necessarily swarm.  Though both are dependent on flagella, swarming of a group of 
bacteria differs from the ‘swimming’ motility of individual bacterial cells through 
liquid.  Genera of flagellated bacteria known to be capable of swarming include 
Bacillus, Escherichia, Salmonella, Serratia, Pseudomonas, Vibrio, Yersinia and Proteus 
(Lai et al., 1998). 
Cells at the edge of a swarming colony differentiate into specialised 
elongated, multinucleated ‘swarmer’ cells, possessing up to 50 times as many flagella 
(Eberl et al., 1999).  Swarmer cells continue to move outwards as a coordinated group, 
while cells inside the colony continue to replicate (Allison & Hughes, 1991).  For 
Proteus, a characteristic periodic pattern of concentric circles is produced from the point 
of inoculation due to the repetitive alternation between growth of stationary cells 
(consolidation) and the production and subsequent migration of swarmer cells (Eberl et 
al., 1999). 
Swarming of cells is dependent on factors such as high nutrient availability, 
surface viscosity, wettability, lowered surface tension and cell density.  Secretion of 
exopolysaccharides and peptide surfactants facilitates swarming in Serratia (Gygi et al., 
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1995).  Proteus mirabilis does not secrete surfactant peptides but secretes a capsular 
polypeptide that reduces surface friction (Ariison et al., 1992; Davies et al., 1998; 
Iwalokun et al., 2004; Liaw et al., 2000; Young et al., 1999).  Swarming motility in 
Proteus spp. has been associated with colonisation, biofilm formation and the 
expression of virulence factors including protease, urease hemolysins and 
exopolysaccharides (Armitage, 1981).  Cells have also been found to have altered 
metabolic activity during swarming, including reduced rates of protein and nucleic acid 
synthesis and oxygen uptake (Eberl et al., 1999). 
Swarming is a coordinated, social behaviour where bacterial communication 
is essential and quorum sensing is an important regulatory mechanism.  The two 
coordinating pathways involved in the regulation of swarming motility are reviewed by  
(Liu & Matsumura, 1994).  Flagellar regulator genes control cell elongation and 
expression of flagella, and a QS signalling system based on AHL’s controls synthesis of 
extracellular molecules essential to cell-to-cell interactions.  In E. coli and S. 
typhimurium the flhDC flagellar operon encodes transcriptional regulators (FlhD and 
FlhC) that control the expression of genes related to flagellar structure, chemotaxis and 
cell division (Furness et al., 1997; Tolker-Nielsen et al., 2000).  Expression of flagellar 
operon, flhDC, mRNA in P. mirabilis is 30-fold higher in swarm cells than in 
vegetative cells (Williams & Schwarzhoff, 1978). 
A number of antibiotics have been shown to inhibit swarming including 
neomycin, sulfonamides and combinations of polymyxin with chloral hydrate or sodium 
azide (Hussain et al., 1998).  These antibiotics have different mechanisms of action and 
may affect different aspects of the complex pathways controlling swarming behaviour.  
The most well known and efficient specific inhibitor of swarming, ρ-
nitrophenylglycerol (PNPG), is not an antibiotic and prevents swarming by inhibition of 
differentiation into swarm cells (Logan et al., 1989). 
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Phosphorylated serine residues have been found in Campylobacter flagellin 
protein (Kelly-Wintenberg et al., 1993) and phosphorylated tyrosine residues in type a 
and b Pseudomonas flagellin proteins (Kelly-Wintenberg et al., 1993).  A membrane-
bound tyrosine kinase has also been reported (Liaw et al., 2000) and though their 
functions are not yet clear, it may be valuable structurally or related to flagellar 
assembly or transport. 
It was decided to investigate the effect of BDM-I on swarming in Proteus 
spp. since some inhibition of swarming by Proteus vulgaris had been noted during 
BDM-I time-kill studies while no inhibition of flagellar swimming motility was evident 
using a semisolid agar assay (Nicoletti et al., unpublished). 
4.4.2 Materials and Methods 
Exposure to BDM-I during surface growth 
Luria broth agar (LBA) plates were prepared based on the method of (Liaw 
et al., 2000; Liaw et al., 2001) containing 1% agar to facilitate swarming of P. mirabilis 
and P. vulgaris.  BDM-I in DMSO was added to the molten agar immediately before 
pouring to give two-fold concentrations of BDM-I between 4 and 64 µg/mL and a 
DMSO concentration of 1% v/v.  All plates were made the week of testing, stored at 
4°C and dried at 37°C for 30 minutes before inoculation. 
A colony from a fresh overnight plate of each species was used to inoculate 
5 mL MHB and incubated aerobically for 6 h at 37°C, on a shaker (Ratek) at 160 rpm.  
The culture, 5 µL, was used to centrally inoculate agar plates containing BDM-I at 4, 8, 
16, 3 and 64 µg/mL.  Plates were incubated aerobically at 37°C for 16 h. 
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Exposure to BDM-I prior to surface growth 
LBA plates were prepared as above without the addition of BDM-I.  A 
colony from a fresh overnight plate of each species was used to inoculate 5 mL MHB 
containing BDM-I at 8, 32 and 128 µg/mL and incubated aerobically for 6 or 24 h at 
37°C on a shaker (Ratek) at 160 rpm.  At each time point, LBA plates were inoculated 
centrally with 5 µL of the overnight culture and incubated aerobically at 37°C for 16 h. 
Both assay methods were completed twice.  For both exposure methods, 
confluency of growth at the inoculation point, indicating cell viability and patterns of 
growth from the centre point were recorded and plates photographed with a digital 
camera (A520, Canon). 
4.4.3 Results 
Exposure to BDM-I during surface growth 
P. mirabilis and P. vulgaris, grown in drug free MHB for 6 h, were centrally 
inoculated onto an LBA plate containing BDM-I to demonstrate a direct effect on 
characteristic swarming patterns during surface growth.  P. vulgaris and P. mirabilis 
grew as a confluent central button on LBA at 64 μg/mL, indicating the MIC in LBA by 
agar dilution was > 64 μg/mL, a concentration ≥6-fold higher for P. vulgaris than the 
mean MIC in MHB (11 μg/mL) (Figure 4-4a).  The higher MIC in LBA is not 
surprising since medium components affect the MIC.  BDM-I has previously been 
found to bind to agar and therefore the effective concentration may be less than the 
concentration added to the agar (Nicoletti et al., unpublished). 
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BDM-I caused dose dependent inhibition of swarming in both P. mirabilis 
and P. vulgaris at a concentration below that causing whole cell toxicity in the test 
medium (Figure 4-4).  There was complete inhibition of swarming of P .mirabilis by 64 
µg/mL and of P. vulgaris by 32 µg/mL BDM-I.  Inhibition of swarming in P. mirabilis 
occurred at a much lower concentration relative to its MIC in MHB than was the case 
with P. vulgaris.  The lesser inhibition of swarming in P. vulgaris seen for the 
concentration of 32 µg/mL when BDM-I is incorporated in LBA (Figure 4-4a) is 
explained by the interference of medium components and agar resulting in lower 
effective concentration of BDM-I. 
Exposure to BDM-I prior to surface growth 
Pre-exposure of P. vulgaris to 8, 32 and 128 µg/mL BDM-I in MHB for 6 h 
or 24 h before plating on LBA gave a dose dependent inhibition of swarming at both 
times, the inhibition being greater after 24 h exposure (Figure 4-5).  Swarming was 
almost completely inhibited by pre-exposure to 32 µg/mL for as little as 6 h.   
Pre-exposure to BDM-I for 6 h did not affect cell viability of P. mirabilis 
and all treated cultures swarmed on LBA plates to the same extent as the control (results 
not shown).  Growth of P. mirabilis after 24 h pre-exposure to 128 µg/mL BDM-I 
showed only a few colonies at the point of inoculation (See arrow in Figure 4-6).  
Swarming was completely inhibited in these few colonies surviving exposure to 128 
µg/mL.  The concentration range used failed to show a dose response for P. mirabilis. 
Exposure to BDM-I for 6 h has irreversibly affected the ability P. vulgaris  
to swarm on LBA, in a manner similar to when it is continuously present in LBA during 
growth.  A similar irreversible inhibition for P. mirabilis occurred only after exposure to 
128 mg/mL for 24 h. 
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a)   
b)   
Figure 4-4.  Swarming assays of Proteus vulgaris and Proteus mirabilis on agar 
containing BDM-I. 
P. vulgaris (a) and P. mirabilis (b) cultures (5 µL) were grown in MHB for 6 h and used to 
centrally inoculate LBA containing 0, 4, 8, 16, 32, 64 µg/mL BDM-I (clockwise from top left in 
each photograph). 
 
1 cm 
1 cm 
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a)   
b)   
Figure 4-5.  Surface swarming of Proteus vulgaris exposed to BDM-I in broth 
before plating onto BDM-I free LBA. 
Concentrations of BDM-I during broth exposure for 6 h (a) and 24 h (b).  BDM-I exposure 
concentrations clockwise from top left in each photograph: 0, 8, 32, 128 µg/mL.  Blue arrow in a) 
indicates inhibition of swarming without inhibition of growth at the inoculation point. 
1 cm 
1 cm 
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Figure 4-6.  Surface swarming of Proteus mirabilis exposed to BDM-I in broth 
prior to growth on BDM-I-free LBA. 
Concentrations of BDM-I, clockwise from top left, 0, 8, 32, 128 µg/mL.  Blue arrow indicates 
inhibition of growth at the inoculation point.  (Six hour exposure data not shown). 
4.4.4 Discussion 
BDM-I inhibited swarming in Proteus mirabilis at 64 µg/mL and in P. 
vulgaris, at 32 µg/mL when BDM-I was continuously present in the medium during 
surface growth.  Whole cell toxicity, as measured by standard MIC in MHB, is 128 
µg/mL and 11 µg/mL respectively.  Given this 10-fold difference in toxicity it would be 
expected that a much higher concentration would be needed in P. mirabilis relative to 
that of P. vulgaris to damage the pathways involved in swarming motility.  The 
metabolic target of BDM-I in these pathways may be more susceptible or more 
significant in P. vulgaris. 
Pre-exposure to BDM-I followed by surface growth on BDM-I-free medium 
showed that BDM-I could irreversibly damage some part of the pathways involved in 
1 cm 
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swarming motility for both species.  This permanent affect on a metabolic target is 
consistent with its bactericidal action on Proteus spp. (Chapter 2). 
A well-known swarming inhibitor, ρ-nitrophenylglycerol (PNPG, is 
structurally similar to diketopiperazines, natural QS signals that modulate swarming 
behaviour (Liaw et al., 2000; Liaw et al., 2001).  PNPG has been shown to inhibit the 
expression of virulence factors (urease, haemolysin and protease)  and the ability to 
invade uroepithelial cells but does not show whole cell toxicity (2001).  Super-
swarming P. mirabilis phenotypes, which were partially inhibited by PNPG, showed 
mutations in the rsbA gene encoding a histidine kinase of the two component signalling 
system.  Liaw et al. (Grangeasse et al., 2007; Kirstein & Turgay, 2005) hypothesised 
that RsbA may regulate swarming and virulence factor expression by repression and 
that PNPG may target RsbA or RsbA-regulated pathways. 
Surface swarming is regulated via the flagellar master and QS signalling 
(Section 4.3.1).  Since BDM-I does not affect flagellar motility (data not shown) but 
does inhibit swarming behaviour then it is probably acting on the signalling pathways 
involved in QS.  Phosphorylation (traditionally on histidine) is a key part of QS in 
bacteria and tyrosine phosphorylation has found to be involved in similar signalling 
events (Roberts, 1996).  A role for tyrosine phosphatases in QS in swarming motility 
has not been identified.  If PTP’s are involved, this would be consistent with the 
hypothesis that BDM-I may inhibit bacterial protein tyrosine phosphatases (Chapter 5). 
Swarming regulation in Proteus is associated with the regulation of 
expression of other virulence factors.  Direct effects of BDM-I on exoenzymes in 
Proteus spp. have not been investigated to date. 
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4.5 CAPSULAR POLYSACCHARIDE PRODUCTION IN KLEBSIELLA 
PNEUMONIAE 
4.5.1 Background 
Since cell surface polysaccharides are known to play a role in bacterial 
adherence, resistance to specific and non-specific host immunity and desiccation, all of 
which contribute to bacterial virulence (Vincent et al., 1999; Vincent et al., 2000; 
Wugeditsch et al., 2001), it was decided to investigate the effect of BDM-I on a capsule 
producing strain of Klebsiella pneumoniae. 
Low molecular weight protein tyrosine phosphatases and their associated 
protein tyrosine kinases have been shown to be involved in the synthesis and export of 
capsular polysaccharides in Gram-negative bacteria such as E. coli (Grangeasse et al., 
1998), Acinetobacter johnsonii (Preneta et al., 2002) and Klebsiella pneumoniae 
(Vincent et al., 2000).  Most of these genes, which show strong sequence similarity, are 
located in cps operons encoding capsular polysaccharides (CPS), such as K and M 
antigens and are a conserved feature of Gram-negative bacteria (Stevenson et al., 1996). 
CPS production can be regulated positively or negatively by 
phosphorylation of tyrosine residues.  For example, phosphorylation of the PTP Wzc of 
E. coli results in inhibition of the synthesis of colonic acid, a component of the slime 
polysaccharide or M antigen.  Dephosphorylation by the PTP Wzb thus positively 
regulates the production of colonic acid and inhibition of Wzb results in a decrease in 
capsule formation in E. coli (1991). This finding can be extended to the species which 
have cognate PTK/PTP enzyme pairs showing gene sequence similarity and which 
cross-react with E. coli Wzc//Wzb.  A range of enteric bacteria synthesize colonic acid 
but it has not been reported in Klebsiella.  McCallum & Whitfield (2002) have shown 
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that the K. pneumoniae rcsA gene, involved in expression of K antigen, when cloned 
into E. coli causes a mucoid phenotype resulting from the synthesis of colonic acid.  
Preneta et al. (Bender et al., 2003) reported that the PTK (Yco6) in Klebsiella 
pneumoniae and a PTP (Yor5) are involved in the regulation of CPS (K antigen) 
synthesis but how this regulation is achieved is not yet fully described. 
Tyrosine phosphorylation regulatory systems also play a role in 
exopolysaccharide production in Gram-positive bacteria.  In Streptococcus pneumoniae, 
a PTP (Cps2B) and a PTK (Cps2C/2D) regulate production of Type II CPS.  
Phosphorylation is essential for CPS production with Cps2C/2D being positive 
regulators of polysaccharide chain length and similar ‘polysaccharide co-polymerases’ 
occurring in Gram-negative bacteria (Domenico et al., 1985).  The PTP CpsB is 
manganese-dependent and does not have sequence similarity to E.coli Wzb and related 
PTP’s. 
Klebsiella pneumoniae is a significant opportunistic human pathogen 
causing pneumonia, urinary tract and systemic infections and strains are often multi-
drug resistant.  The characteristic polysaccharide layer, or capsule, of Klebsiella  
pneumoniae is an important virulence factor and capsule size has been related to 
pathogenicity (Kadurugamuwa et al., 1985).  CPS production is reduced in the presence 
of cephalosporins, cell wall synthesis inhibitors (2000). 
In subcultures from MMC assays, no inhibition of colony mucoidy was 
observed in K. pneumoniae treated with BDM-I in MHB.  The ability of BDM-I to 
interfere positively or negatively with capsule formation by individual cells on direct 
exposure to BDM-I was investigated by microscopic examination of stained cells. 
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4.5.2 Materials and Methods 
An overnight culture of K. pneumoniae in MHB (5 mL) was diluted 1:100 
in 50 mL MHB and incubated at 37°C, 160 rpm, 1-2 h until an opacity equivalent to 
McF 0.5 standard (~1.5 × 106 CFU/mL) was achieved.  The culture was divided into 
aliquots of 10 mL to which were added BDM-I in DMSO at 100× the test 
concentrations of 32, 128 and 512 µg/mL.  Cultures were treated with BDM-I for 8 h.  
The vehicle control culture contained 1% DMSO.  Viable counts were obtained from 
10-fold dilutions of cultures on NA incubated for 24 h at 37°C.  For examination of 
capsules, a 5 µL aliquot of cell culture was stained by mixing with 5 µl 5% Congo red 
on a microscope slide.  When the suspension was dry, Manevals’ background stain and 
fixative was applied for 1 min before rinsing in distilled water and examining under the 
light microscope.  The experiment was repeated twice and three slides prepared for each 
treatment on each occasion.  Photographs of stained cells were obtained using oil 
immersion at 1000× and recorded using a Motic digital camera (Motic China Group, 
Xiamen, China). 
4.5.3 Results 
No significant differences in capsule size were observed on microscopic 
examination of stained cells after exposure for 8 h to 32, 128 and 512 µg/mL BDM-I 
when compared to an untreated control (Figure 4-7).  An assay more directly measuring 
components of exopolysaccharide secretion might indicate an effect but this was not 
attempted here given the lack of any obvious effect on visual microscopic examination 
or examination of cultures. 
 99 
4.5.4 Discussion 
No reduction in capsule size was demonstrated after exposure of Klebsiella 
pneumoniae to BDM-I 512 µg/mL, the highest concentration testable because of 
insolubility of BDM-I.  The geometric mean MIC for Serratia marcescens is 800 
µg/mL, therefore 512 µg/mL may have been too low a concentration to inhibit 
exopolysaccharide production. 
K. pneumoniae possesses the Yco6 (PTK)/Yor5 (PTP) enzyme pair which is 
involved in CPS (K antigen) synthesis which have sequence homology with PTK/PTP 
enzymes involved in exopolysaccharide biosynthesis in E. coli (Wzb/Wzc) and A. 
johnsonii (Ptk/Ptp) (3.1.4).  A mechanism for PTP action has only been identified in E. 
coli to date.  Phosphorylation of the PTK (Wzc) of E. coli results in inhibition of the 
synthesis of colonic acid (M antigen).  Dephosphorylation by the PTP Wzb thus 
positively regulates the production of colonic acid and inhibition of the PTP results in a 
decrease in capsule formation in E.coli.  Production of colonic acid (M antigen) has not 
been demonstrated in Klebsiella and it is not known whether Yor5 regulates K antigen 
production positively or negatively. 
If BDM-I is functioning as a tyrosine phosphatase inhibitor, an affect, 
positive or negative on capsule production might be expected in Klebsiella.  If tyrosine 
phosphorylation is associated with increased CPS production, a PTP inhibitor would be 
expected to decrease prodigiosin production and vice versa.  In this preliminary 
investigation, BDM-I appears not to affect CPS production in K. pneumoniae.  Further 
investigation for any effect of BDM-I of the production of colonic acid in E. coli, is 
proposed. 
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Figure 4-7.  Klebsiella pneumoniae negatively stained capsules after exposure to 
BDM-I. 
BDM-I exposure was for 8 h.  Treatment clockwise from top left: DMSO control, 32 µg/mL, 128 
µg/mL, 512 µg/mL.  Cells stained with Congo Red and Maneval's Stain and photgraphed using 
an oil immersion lens at 1000× magnification. 
5 µM 
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Vincent et al. (Galperin & Koonin, 1999) suggest that protein tyrosine 
phosphorylation is part of a cascade of reactions determining bacterial pathogenicity.  
BDM-I has been shown to affect swarming motility in Proteus and the secondary 
metabolite prodigiosin but not capsular polysaccharide production in Klebsiella.  In 
bacteria, PTP’s are more phylogenetically distant and heterogeneous in both distribution 
and function than in eukaryotes, so differences in inhibitory effects and activities 
between inhibitors is not surprising. 
Inhibition of virulence factors, such as capsule production and swarming 
motility, in addition to inhibition of growth, is a positive attribute for anti-infective 
drugs.  Their inhibition can play a major role in the prevention of infections and 
virulence factors have recently been proposed as suitable selective targets for anti-
infective drug development (Lambert, 1998). 
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CHAPTER 5 THE EFFECT OF BDM-I ON CELL 
FUNCTIONS 
5.1 INTRODUCTION 
Investigations reported in Chapter 3 have shown that BDM-I does not affect 
the structural integrity of the bacterial or yeast cell wall and cytoplasmic membrane.  
BDM-I, as a small lipophilic uncharged molecule would diffuse through lipid 
membranes.  It has been shown to penetrate cells and to act on intracellular pathogens 
(Chapter 2).  Its broad spectrum of activity suggests a major target that is highly 
conserved across prokaryotic and eukaryotic microorganisms.  In Chapter 4, BDM-I 
was shown to inhibit metabolic pathways in bacteria involved in survival responses 
such as swarming motility and secretion of protective pigments.  This chapter presents 
investigations into the effect of BDM-I on three highly conserved metabolic functions: 
bacterial enzyme systems involved in ATP synthesis, RNA transcription and translation 
and intracellular signalling via protein tyrosine phosphatases. 
Respiration and protein synthesis are cellular functions which are universal 
and sufficiently diverse across cell types to provide selective targets for clinically 
effective anti-infective drugs (Shawver et al., 2002).  Protein kinases and phosphatases 
that coordinate the regulation of cellular responses to multiple environmental signals are 
also sufficiently diverse to provide selective targets (Section 1.3.3).  Drugs inhibiting 
the tyrosine kinase activity of epidermal growth factor receptor and vascular endothelial 
growth factor receptor are in clinical use or clinical development for the treatment of 
cancer (Lee & Wang, 2007).  Protein tyrosine phosphatases specifically, have emerged 
recently as promising drug targets with growing evidence of the importance of PTP1B 
in human conditions such as diabetes and obesity (Madigan et al., 2006).  No drugs 
targeting the kinases or phosphatases of microbial pathogens are reported to be in 
development to date. 
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5.2 ATP PRODUCTION BY ATP BIOLUMINESCENCE ASSAY 
5.2.1 Background 
The cell membrane of prokaryotes is more functionally active than that of 
eukaryotes.  Many enzyme systems that occur in organelles in eukaryotes are located in 
the cell membrane in bacteria, such as those for ATP synthesis and oxidative 
phosphorylation, where they are readily accessible to antimicrobial compounds.  
ATPase, or ATP synthase, is a multi-component enzyme which catalyses the synthesis 
of ATP using the electrochemical ion gradient (H+ or sometimes Na+) generated by 
oxidative phosphorylation (Deckers-Hebestreit & Altendorf, 1996).  ATP synthase is 
fully reversible and can hydrolyse ATP to generate a proton gradient.  It consists of the 
F0 component embedded in the membrane and attached by a stalk to the F1 component, 
which projects from the cytoplasmic face of the bacterial plasma membrane (Futai & 
Kanazawa, 1983).  ATP synthase enzymes are highly conserved but do show structural 
variations.  The bacterial F1F0ATPase (F type) is essentially the same in structure and 
function as the F1F0ATPases from mitochondria and chloroplasts of eukaryotic cells but 
differs from the ATPase’s in fungal, plant and animal cell membranes (Kuyyakanond & 
Quesnel, 1992). 
Interference with ATPase can be secondary to disruption of membrane 
integrity, depolarisation of the membrane or a direct result of action on the enzyme also 
causing depolarisation.  Most ATP synthesis inhibitors are biocides, such as phenolic 
compounds and chlorhexidine and inhibition is secondary to membrane disruption or 
depolarisation (Dinning et al., 1998).  Pyrithiones (1-hydroxy-2-pyridinethiol sodium 
salt and zinc chelate) depolarise cell membranes and  markedly reduce intracellular 
ATP levels in E. coli and Pseudomonas aeruginosa washed cells within 1 h of exposure 
to sub-inhibitory concentrations (Perlin et al., 1985).  Despite the similarity among the 
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F1F0ATP synthases, selective inhibitors have been reported.  Oligomycin only weakly 
inhibits bacterial ATP synthase but strongly inhibits mitochondrial ATP synthase while 
venturicidin strongly inhibits bacterial ATPase (Andries et al., 2005).  A diarylquinoline 
was identified from resistant mutant studies, as a probable inhibitor of atpE, whose 
product is the proton pump of the ATP synthase of mycobacteria (Denisenko et al., 27 
Dec. 2002  International patent).  This is a very selective target and the high bactericidal 
activity was shown to be highly specific to mycobacteria.  Diarylquinolines are in 
further development as drugs for the treatment of mycobacterial infections.  BDM-I has 
a high level of activity against Mycobacterium tuberculosis with an MIC of ~6 µg/mL 
(Deckers-Hebestreit & Altendorf, 1996; Rao et al., 2001). 
Although BDM-I does not disrupt the cell membrane, it could directly affect 
membrane-bound enzyme systems such as ATPases in bacterial cells and mitochondria 
or the enzymes involved in the electron transport chain.  Inhibition of ATP synthase 
leads to depletion of intracellular ATP and imbalance in pH homeostasis (Hattori et al., 
2003; Stanley, 1986). 
The effect of BDM-I on ATP production in Bacillus cereus and 
Staphylococcus aureus is investigated using a bioluminescent assay.  BDM-I is 
bactericidal to B. cereus and bacteriostatic to S. aureus.  Both use oxidative 
phosphorylation for synthesis of ATP when growing aerobically.  ATP production is an 
indicator of metabolically active cells as it is positively correlates with cell numbers in 
actively metabolising cells. 
5.2.2 Materials and Methods 
The Promega Bac-Titre™ Glo assay was used to determine whether 
inhibitory concentrations of BDM-I have a direct effect on ATP production in bacteria.  
Briefly, ATP was extracted at intervals from log phase cells growing aerobically and 
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ATP production measured by the luminescent signal generated by a luciferase detection 
system.  Beetle luciferin in the presence of ATP is oxidized to a luminescent 
oxyluciferin by a recombinant firefly luciferase and is detected spectrophotometrically.  
The assay has been validated for Bacillus cereus and Staphylococcus aureus. 
The Bactitre-Glo™ reagent, containing a cell ATP extraction system and a 
luciferase-based detection system, was prepared according to the manufacturers 
instructions (Technical Bulletin 337, revised 04/04, Promega, WI, USA) and stored at  
-80°C in 1 mL, single use aliquots.  Each aliquot was thawed, brought to room 
temperature and protected from degradation by light before use. 
For each assay, Bacillus cereus and Staphylococcus aureus were grown 
overnight in 5 mL MHB and diluted to ~1 × 106 in MHB.  BDM-I was added from 
100× stock solutions to give a final concentrations of 16 and 32 µg/mL for B. cereus 
and 8 and 32 µg/mL for S. aureus with 1% v/v DMSO.  Treated and untreated control 
cultures were incubated aerobically for 4 h at 37°C on a shaker (Ratek) at 160 rpm.  At 
0, 1, 2 and 4 h, 100 µL was removed from each culture for luminescence measurements 
and viable cell counts.  For luminescence, Bactitre-Glo™ reagent (100 µL) was added, 
the suspension vortexed and incubated for 5 min in the dark at room temperature.  
Luminescence in each tube (triplicate samples) was measured in a Luminometer (TD-
20/20, Turner Designs, Ca, USA) and recorded as Luminometer Units (LU).  For viable 
counts, the 100 µL aliquot was diluted to 10-2, plated onto NA and incubated aerobically 
at 37°C for 24 h.  Assays were completed at least twice on separate occasions.  Viable 
counts were reported as CFU/mL and plotted against time. 
An ATP standard curve was produced using adenosine 5-triphosphate 
standard disodium salt trihydrate (FLAAS, Sigma-Aldrich) at 10-fold concentrations 
(nM) in MHB instead of culture and proceeding as above.  Using the standard curve, 
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Luminescence Units were converted to units of ATP (1 nM = LU × 0.016 + 4.34) and 
plotted against time.  Correlation of ATP synthesis with cell numbers (viable count) was 
tested by regression analysis (Excel Data analysis, Microsoft, 2003). 
5.2.3 Results  
A standard curve with adenosine 5-triphosphate disodium salt trihydrate 
showed linearity over a range of 10-fold concentrations from 0.1 to 100 nM ATP 
(Figure 5-1). 
0.1
1
10
100
1000
10000
100000
0 0.01 0.1 1 10 100 1000
ATP concentration (nM)
Lu
m
in
e
sc
e
n
ce
 
u
n
its
 
Figure 5-1.  ATP Standard curve generated for the BacTitre-Glo™ ATP assay. 
Error bars represent standard deviation.  Linear trendline is shown dashed. 
Maximum measurable luminescence for B. cereus untreated control was 
reached at 4 h and for S. aureus at 2 h.  Production of ATP in B. cereus and S. aureus 
and exposed to BDM-I at inhibitory concentrations of 16 and 32 µg/mL compared to 
untreated cultures is shown in Figure 5-2.  Regression analysis of the curves is shown in 
Table 5-1.  ATP production shows good correlation of ATP production with increase in 
cell numbers in all treatments for B. cereus.  Correlation of ATP production with cell 
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numbers was not as good for S. aureus which grew faster than B. cereus under these 
experimental conditions.  BDM-I is bacteriostatic for S. aureus and at 32 µg/mL (8× the 
MIC) cell numbers increased ~5-fold over 4 h while ATP production increased ~3.3-
fold.  The poorer correlation for the untreated control may be due to reaching maximum 
measurable luminescence at 4 h.  The results suggest that BDM-I has not inhibited ATP 
production more than would be accounted for by a drop in the number of metabolising 
cells. 
Table 5-1.  Regression analysis of ATP production and CFU/mL for each 
treatment. 
 
B. cereus  S. aureus 
 Control 16 µg/mL 32 µg/mL  Control 8 µg/mL 32 µg/mL 
R2 0.94 0.75 0.91  0.79 0.74 0.67 
F statistic 30.18 6.05 21.37  7.33 5.68 4.13 
p value 0.03 0.13 0.04  0.11 0.14 0.18 
 
5.2.4 Discussion 
Measurement of ATP was used here to investigate the effects of BDM-I on 
total ATP production.  The assay detects intracellular and extracellular ATP.  However, 
cells in this experiment are growing exponentially in optimal conditions and nearly all 
cells would be viable and producing ATP by oxidative phosphorylation.  Therefore the 
ATP measured would be predominantly intracellular ATP generated by membrane-
bound ATP synthase.  Inhibition of ATPase can suggest disruption of membrane 
integrity or depolarisation of the membrane directly or by action on the enzyme.
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Figure 5-2.  Effect on total ATP production (nM) by B. cereus (a) and S. aureus (b) 
in MHB exposed to BDM-I (µg/mL). 
ATP (solid line) and viable cell numbers (dotted lines) were measured at each time point by 
luminescent assay and viable counts respectively as described in Section 5.2.2.  Ctrl, MHB with 
bacteria without BDM-I.  Each line represents a different concentration of BDM-I (µg/mL). 
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The results suggest that BDM-I does not directly inhibit ATP production 
and would indicate that it does not adversely affect the enzyme systems in the cell 
membrane involved in aerobic ATP production, either ATPase or the enzymes of the 
electron transport chain.  This is consistent with observation of an equal inhibitory 
effect by BDM-I on Bacillus, Staphylococcus and yeast spp. whether cells were grown 
in aerobic conditions or forced into fermentative energy production under anaerobic 
conditions (Nicoletti et al., unpublished). 
Cell types vary considerably in ATP content and intracellular concentrations 
are affected by a number of factors (Artsimovitch & Vassylyev, 2006).  S. aureus grew 
faster than B. cereus in this assay, reaching the maximum measurable luminescence 
(10,000 LU) at 2 h compared to 4 h for B. cereus.  It is also able to grow slowly in the 
presence of 512 µg/mL BDM-I (256× MIC).  Therefore the use of much higher 
concentrations where an inhibitory effect would be more obvious might demonstrate 
some direct interference with ATP production. 
5.3 TRANSCRIPTION/TRANSLATION ASSAY USING CELL-FREE 
E. COLI  SYSTEM 
5.3.1 Background 
Inhibition of RNA transcription and inhibition of translation result in 
inhibition of protein synthesis and are important targets for antimicrobial agents.  
Aminoglycosides, tetracyclines, macrolides, lincosamides and chloramphenicol are 
major antibiotic classes inhibiting the translation of mRNA.  Bacterial DNA-dependent 
RNA polymerase for transcription of mRNA is a less well exploited target.  The 
rifamycins (eg. rifampin) inhibit RNA polymerase (RNAP) and are the only class of 
inhibitors used clinically (2004). 
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Cell-free extracts which allow transcription and translation of mRNA are 
widely-used to investigate protein synthesis in vitro.  One of the most frequently used 
assay tools is a cell-free E. coli transcription/translation system which can be applied to 
the screening of compounds that may affect transcription or translation of a DNA 
template.  BDM-I was screened in such a cell-free assay system for inhibition of the 
transcription of the β-galactosidase gene and the synthesis of the enzyme. 
5.3.2 Materials and Methods 
The Promega ‘E. coli S30 Extract for Circular DNA’ contains all the 
macromolecular components required for transcription of an exogenous DNA template 
(generation of mRNA, tRNA and rRNA) and translation (synthesis of protein) and the 
necessary amino acids, energy sources, energy generating systems and cofactors for 
protein synthesis.  A control DNA template (pGEM® β-Gal) containing the coding 
sequence of β-galactosidase downstream of an E. coli wild type lacZ promoter, allows 
direct measurement of synthesised β-galactosidase from the conversion of ONPG (o-
nitrophenyl-β-D-galactosidase, colourless) to ONP (o-nitrophenyl, yellow).  ONP 
production, measured spectrophotometrically, is proportional to the amount of protein 
synthesised. 
The assay was performed based on the method of Ulvatne et al. (Ishihama, 2000).  
Doubling dilutions of BDM-I (8 – 128 µg/mL), were prepared in 60% DMSO so that 
the final percentage did not exceed the recommended maximum of 5%.  A 96-well 
white LIA microplate (Lumitrac® 200, Greiner Bio-one, Germany) was prepared with 
BDM-I (15 µL).  A vehicle control well received 15 µL of 60% DMSO vehicle.  The 
reaction control for maximum protein synthesis (no BDM-I) and negative control (no 
extract and no BDM-I) wells received nuclease free water.  Amino acids (2 µL) and S30 
premix (8 µL) (Promega, WI, USA) were thawed and added to all wells on the plate.  E. 
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coli S30 extract (5 µL) was added to all treatment wells and the reaction control.  The 
negative control received nuclease free water.  Nuclease-free water (20 µL, Promega) 
was added to wells to an assay volume of 50 µL and the plate incubated at 37°C for 30 
min.  DNA (1 µL of 0.25 mg/mL pGEM® β-Gal, Promega) was added to all wells and 
the plate re-incubated at 37°C for 30 min.  After incubation, 150 µL of 15 mM ONPG 
(Sigma-Aldrich) was added and OD420nm recorded every 10 min for 2 h to measure the 
amount of ONP produced.  An excess of ONPG is used to ensure that the rate limiting 
step in the conversion of ONPG to ONP is the amount of enzyme.  Some precipitation 
of BDM-I was noted at 128 µg/mL.  Since the amount of enzyme is directly 
proportional to ribosomal activity, the amount of ONP generated can be used as a 
measure of protein synthesis. 
Assays were replicated three times with measurements in triplicate.  The 
mean OD420nm was plotted against time.  Slopes of the curves (rate of production of 
ONP) were compared visually.  Relative rates of protein synthesis (corrected for the 
slope of the negative control) were calculated if necessary as slope of curve with BDM-
I/slope of positive reaction curve (no BDM-I). 
5.3.3 Results 
There was no change in the rate of protein synthesis (as measured by the 
rate of hydrolysis of ONPG to ONP in the presence of increasing concentrations of 
BDM-I up to 16× higher than the MIC (Figure 5-3).  Slopes were comparable on visual 
inspection and relative rates of protein synthesis were therefore not calculated.  BDM-I 
did not inhibit the transcription or translation of β-galactosidase.  BDM-I had no effect 
on ribosomal functions and/or on bacterial DNA-dependent RNA polymerase in vitro. 
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There was no interference with absorbance readings from BDM-I in the 
absence of pGEM-βgal DNA (data not shown) as these values were similar to the 
negative control which lacked the S30 extract template.  The higher absorbance values 
recorded for higher concentrations of BDM-I (64 and 128 µg/mL) are possibly due to 
the insolubility noted at 128 µg/mL and/or interference at the 420 nm wavelength since 
BDM-I has maximum absorbance at 370 nm. 
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Figure 5-3.  Effect of BDM-I (µg/mL) on synthesis of β-galactosidase by 
measurement of ONP (OD420nm). 
Cell-free protein synthesis assay using E. coli S30 extract (Promega) with pGEM® β-Gal 
(Promega) as the DNA template.  Error bars represent standard deviation. 
5.3.4 Discussion 
The lack of effect of BDM-I on cell-free protein synthesis seen here 
supports the observation of a lack of interaction (synergistic or antagonistic) with 
antibiotics affecting different stages of protein synthesis (Section 2.7). 
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Genes coding for proteins are transcribed by multi-unit DNA-dependent 
RNA polymerases.  Eukaryotes, have three distinct RNA polymerases (I, II and III), 
each responsible for the transcription of a different class of RNA.  In bacteria, 
transcription is accomplished by RNA polymerase (RNAP) with a conserved core 
linked to a sigma subunit that specifies binding to promoter elements and transcript 
regulators.  In E. coli, more than 100 additonal factors have been identified which 
modify the activity of RNAP (Iyer et al., 2004).  Unlike in Archea and Eukarya, 
bacterial RNAPs show considerable variation in RNAP domains across prokaryotic 
lineages (Murray et al., 2001; Pratt et al., 2004).  Extracted enzyme systems from one 
species, therefore, may not be as sensitive in detecting inhibition by an antimicrobial 
agent of the RNAP of another species.  Reports using assays based on extracted enzyme 
systems suggest variable responses to inhibitors by E. coli, S. aureus and Streptococcus 
pneumoniae (Tonks, 2006; Zhang, 2002).  This limits the extrapolation of data to other 
species.  While indicative, the failure of BDM-I to inhibit transcription or translation in 
E. coli should be prudently extended to other bacterial and eukaryotic pathogens. 
5.4 PROTEIN TYROSINE PHOSPHATASE ENZYME ASSAY 
5.4.1 Background 
The role of tyrosine phosphatases in eukaryotic and prokaryotic cells has 
been discussed briefly in Chapter 1 (Section 1.3.3).  Tyrosine phosphorylation in 
eukaryotes, controls many important cell functions: cell growth and differentiation, the 
cell cycle, cell-to-cell communication, cell migration, gene transcription, apoptosis and 
the immune response (Kennelly, 2002).  Tyrosine phosphorylation is less common in 
bacteria and less well investigated.  Conventional PTP, Dual specificity phosphatases 
(DSP) and low molecular weight phosphatases (LMW-PTP’s) have been identified in 
bacteria (Grangeasse et al., 2007).  They regulate particular functions in bacteria which 
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are different from those in eukaryotes.  These include stress responses and virulence 
mechanisms such as secretion of exopolysaccharides and proteins and production of 
secondary metabolites (Tonks, 2006). 
All PTP families share a common and highly conserved catalytic site which 
binds phosphate residues on tyrosine.  Conventional PTP’s contain a catalytic site of 
approximately 280 amino acids which contains an invariant signature motif ((H)CX5R) 
or “PTP loop” (Guan & Dixon, 1991).  Residues in this motif form a phosphate binding 
loop in which a cysteine and an arginine separated by any five amino acid residues.  The 
cysteine residue acts as a nucleophile and is essential for phosphate binding, the 
arginine residue is critical for substrate binding and stabilisation of the enzyme-
substrate intermediate and an aspartate residue acts as acid or base during catalysis 
(Guan & Dixon, 1991; Zhang et al., 1994a; Zhang et al., 1994b).  The thiol anion of the 
cysteine residue initiates the reaction through nucleophilic attack on phosphate to form 
the intermediate, coupled with protonation of tyrosine on the substrate by the adjacent 
aspartic acid residue.  Tonks (2002) and Zhang (Park & Pei, 2004) have reviewed the 
structure, function and substrate specificity of PTP’s. 
The species-specific effects noted for BDM-I on swarming motility in 
Proteus and on prodigiosin production in Serratia suggested that one MOA might be 
interference with aspects of QS involved in cell-to-cell communication and the export 
of cell products.  That insight led to a review of the literature on cell signalling and its 
regulation by phosphorylation in bacteria. 
Benzyl nitroalkenes related to BDM-I have been shown to be slow, 
reversible inhibitors of the tyrosine phosphatases PTP1B and Yop (2004).  They showed 
that benzyl-β-nitroethene acts as a tyrosine mimetic with the nitroethene chain 
pharmacophore forming a reversible, time-dependent covalent complex with cysteine at 
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the catalytic site.  Park & Pei (Park & Pei, 2004) also showed that the position of 
cysteine at its position in the catalytic loop was critical to inhibition by benzyl 
nitroethene and that a nucleophilic attack on the nitro group by the thiolate anion of 
cysteine formed a reversible covalent adduct.  They further showed that there was no 
nucleophilic addition at the alkene double bond as happens with the interaction with 
thiols (Section 2.4).  The double bond is not attacked by cysteine and appears necessary 
for phosphatase inhibition through the maintenance of a rigid planar geometry, critical 
for positioning the nitro group and/or for binding (Zhang, 2002). 
The conserved nature of PTP’s across prokaryotic and eukaryotic cells and 
the phylogenetic differences in structure and function makes them a plausible target for 
a compound with a broad spectrum of activity such as BDM-I.  The hypothesis that 
BDM-I, a tyrosine mimetic (Figure 5-4), acts as an inhibitor of bacterial PTP’s was 
proposed.  The ability of BDM-I to inhibit human and bacterial tyrosine phosphatases 
was therefore tested by enzymic assay.  The hypothesis was also reviewed for 
compatibility with the results of all investigations into the activity of BDM-I on 
bacterial and yeast cells undertaken to date. 
a) b)   
Figure 5-4.  Comparison of structures of a) BDM-I and b) Tyrosine 
 
Assayed phosphatases 
PTP1B, classified as a conventional PTP, is the most well-studied of the 
PTP’s as it was one of the first characterised in humans.  It plays a role in cellular 
signalling defects relating to cancer, diabetes and obesity.  PTP1B is a negative 
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regulator of the insulin-stimulated signal transduction pathway, binds to the epidermal 
growth factor receptor and is over-expressed in many cancers and is a target for 
inhibitor development (Taing et al., 1999).  It possesses the characteristic catalytic 
phosphate binding site and a second, adjacent, non-catalytic binding site, also for aryl 
phosphates (Pacitti et al., 1994).  The latter is not as highly conserved and is suggested 
as a target for selective PTP1B inhibitors.  PTP1B is an intracellular enzyme with high 
activity, making it especially useful for screening inhibitors of phosphorylation 
reactions, phosphorylation kinetics and substrate specificity. 
Human CD45 is a transmembrane dual-specificity phosphatase (DSP), also 
known as leukocyte common antigen (LAC) (Pacitti et al., 1994).  DSP’s can 
dephosphorylate a tyrosine and either a serine or threonine residue on the same protein. 
CD45, a glycoprotein expressed on immune cells, dephosphorylates both tyrosine and 
serine and plays a crucial role in regulating signal transduction leading to T-cell 
mediated immune responses (Kennelly, 2002; Zhang, 2002).  CD45 is routinely used for 
regulation and inhibition studies in the immunological field.  No ortholog of CD45 has 
been discovered in bacteria (Bliska et al., 1991; Viboud & Bliska, 2005). 
Yop is one of the first bacteria-derived PTP’s available in a purified form.  
Yop proteins have sequence and structural similarity to eukaryotic conventional PTP’s 
and are encoded in a virulence plasmid of pathogenic Yersinia species which also 
encodes a Type III secretion system (TTSS).  Yersinia export these toxic effector 
proteins (Yop’s) through TTSS into host cells where they promote virulence through 
host protein dephosphorylation and interference with host signal transduction involved 
in adhesion, phagocytosis and killing of bacteria (Yao et al., 1999).  It is an outer 
membrane protein of Yersinia spp. that is active in host cells, its phosphatase activity 
altering host cell function and immune responses to benefit the bacterium (2004). 
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An enzyme assay was used to investigate the ability of BDM-I to inhibit 
PTP1B, Yop and CD45.  A fluorescent assay was chosen for its sensitivity and 
compatibility with these enzymes. 
5.4.2 Materials and Methods 
Assay principle 
Phosphatase activity was investigated using the ProFluor™ Tyrosine 
Phosphatase Assay, V1281 (Promega).  The selected PTP’s are able to dephosphorylate 
a Rhodamine 110 substrate (bis-amide rhodamine 110 phosphopeptide).  In the bis-
amide form, R110 fluorescence is suppressed.  Dephosphorylation of this substrate 
enables cleavage by protease and release of highly fluorescent R110.  Therefore, the 
intensity of fluorescence is directly proportional to the activity of the phosphatase.  
Conversely, inhibition of phosphatase activity will result in the persistence of the 
phosphorylated substrate and greatly decreased fluorescence.  The positive control, 
vanadate, inhibits both PTP’s and DSPs.  A fluorogenic peptide, alanine-alanine-
phenylalanine linked to 7-amino-4-methyl-coumarin (AAF-AMC,) which cannot be 
phosphorylated or dephosphorylated but is degraded by proteases, is included in the 
assays to identify protease inhibitors that are not phosphatase inhibitors.  Liberation of 
free AMC is quantified at excitiation and emission wavelengths different from those 
used to detect R110 fluorescence.  If the protease is inhibited and cleavge of AAF-AMC 
is prevented, a decrease in AMC fluorescence will accompany the change in R110 
fluorescence.  AMC fluorescence should remain high while R110 fluorescence 
decreases in presence of phosphatase only inhibitors. 
Assays were carried out according to the manufacturer’s recommendations 
(Technical Bulletin 334, revised 01/04, Promega).  The phosphatases (PTP1B, 539735; 
Yop, 539734 and CD45, 217614) were sourced from Calbiochem (Merck, Darmstadt, 
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Germany).  The specific activity of each enzyme was 75 U/mg protein, 100,000 U/mg 
protein and 148,375 U/mg protein respectively.  Enzymes were aliquoted for individual 
experiments to avoid repetitive freezing and thawing. 
Enzyme titration 
Each enzyme was titrated with the Promega reagents to determine the 
amount required to achieve 80% of the maximum fluorescent signal which is considered 
optimal for screening assays.  Reagent master mixes were prepared in appropriate 
volumes according to the following schedule: 
 
Reagent Component µL component /mL 
solution 
Phosphatase dilution solution Promega 5× reaction buffer B 200 
 Sterile MilliQ water 800 
Peptide solution Promega 5× reaction buffer B 200 
 Promega R110 substrate 1 
 Promega AMC substrate 1 
 Sterile MilliQ water 798 
Protease solution Promega termination buffer C 200 
 Promega protease reagent 20 
 Sodium vanadate, 100 mM 2 
 Sterile MilliQ water 778 
Stabiliser solution Promega termination Buffer C 20 
 Promega stabiliser reagent 5 
 Sodium vanadate, 100 mM   2 
 Sterile MilliQ water 973 
MilliQ water is ultrapure water derived from a Millipore system 
All reagents were kept on ice until 10 min prior to addition to the plate when 
they were brought to room temperature.  Reaction wells were prepared in duplicate and 
the enzyme titration performed on two separate occasions.  Each well of a 96-well white 
luminescence microplate (Greiner, Lumitrac® 200, 655075), except column 12 
(negative enzyme control well), received 25 µL of Phosphatase dilution solution.  A 50 
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µL aliquot of each enzyme was added into each of two wells in separate rows.  
Enzymes were serially diluted 2-fold on the plate by removing 25 µL into the following 
11 wells. 
Peptide solution (25 µL) was then added to each well to initiate the reaction.  
The plate was spun to ensure all reagents were mixed before incubation at 24°C for 60 
minutes in the dark.  Plates were spun for 1 min at 200 ×g in a benchtop centrifuge 
(3K15, Sigma Laborzentrifugen).  Protease solution, 25 µL, was added to all wells.  The 
plate was spun and incubated for a further 30 minutes.  Fluorescence stabiliser solution 
(25 µL) was added to each well, the plate spun and the fluorescent signals read at two 
sets of wavelengths (FLUOstar Optima, BMG laboratories).  An excitation of 485 nm 
and emission of 520 nm was used to detect the signal indicative of enzyme activity on 
the R110 substrate.  An excitation of 355 nm and an emission of 460 nm were used to 
detect the signal indicative of non-specific inhibition (control AMC substrate).  
Standard curves were generated for each enzyme and enzyme concentrations producing 
80% of the maximum signal calculated as optimal for the screening assays. 
Screening assays 
For screening assays, 5 µL BDM-I (10× test concentration in 10% DMSO/ 
milliQ water) was added to appropriate wells in duplicate.  Sodium orthovanadate 
(Na3VO4, Calbiochem, Merck) was included on the plates (10× test concentration in 
10% DMSO/milliQ water) as a positive inhibitor control.  Final test concentrations of 
BDM-I and sodium orthovanadate ranged between 0.5 µM and 100 µM.  Control wells 
received the vehicle only.  Half the control wells (negative reaction controls) received 
20 µL control buffer.  All remaining assay wells, including the enzyme control wells, 
received 20 µL phosphatase enzyme preparations to give required enzyme 
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concentrations.  The reaction was initiated by the addition of peptide solution and 
continued as above. 
Duplicated fluorescence values were averaged and combined averages from 
2-4 individual assays were graphed.  Phosphatase activity (% maximum R110 
fluorescence) was plotted against log10 BDM-I concentrations (µM) ±standard deviation 
(SD) for each enzyme. 
Inhibition assay data was required to meet a number of arbitrary criteria in 
order to be deemed valid.  In each assay AMC fluorescence values had to be stable and 
vary ≤25% from the mean; the maximum R110 fluorescence had to be above 10,000 
units; the positive enzyme control well in each case had to read ≥70% maximum R110 
fluorescence.  Only assays that satisfied these criteria for both sodium orthovanadate 
and BDM-I were included.  
5.4.3 Results 
The optimal concentration of each enzyme for use in inhibition assays was 
determined empirically from standard curves (Figure 5-5 and Figure 5-7).  The 
concentration recommended by the manufacturer is that which produces 80% of the 
maximum fluorescence signal.  Optimal concentrations were estimated from log10 scale 
graphs as shown in Figure 5-5 and Figure 5-7 for each enzyme. 
The AMC fluorescent compound is provided as an internal control to test 
for agents that may inhibit the protease and therefore produce non-specific fluorescence 
at a different wavelength than the R110 substrate.  The AMC substrate was included in 
each reaction well and the results demonstrated no interference by sodium 
orthovanadate up to 100 µM.  BDM-I did cause a decrease in AMC fluorescence when 
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present at concentrations over 100 µM therefore these results for R110 fluorescence are 
not shown. 
BDM-I was a considerably less potent inhibitor of tyrosine phosphatases 
than vanadate and its activity was not as uniform.  Concentrations of sodium 
orthovanadate resulting in 50% inhibition were ≤40 nM for all enzymes.  BDM-I 
showed 50% inhibition at concentrations of 16 and 25 µM for PTP1B and Yop 
respectively (Figure 5-6a & b).  BDM-I was less effective against CD45 producing a 
maximum inhibition of 36% at 80 µM (Figure 5-8). 
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Figure 5-5.  Standard curve of PTP enzymes PTP1B and Yop. 
Optimum concentration for inhibition assays was estimated as the amount achieving 80% 
fluorescence.  Units of concentration for each enzyme on the x-axis are shown in brackets. 
Error bars represent standard deviation. 
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Figure 5-6.  Effect of BDM-I and sodium orthovanadate on fluorescence of R110 
substrate for PTP enzyme assays using PTP1B (a) and Yop (b). 
The amount of PTP1B and Yop enzymes used were 6 mU and 0.6 U respectively.  Error bars 
represent standard deviation. 
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Figure 5-7.  Standard curve of PTP enzyme CD45. 
Optimum concentration for inhibition assays was estimated as the amount achieving 80% 
fluorescence.  Units of concentration on the x-axis are shown in brackets. Error bars represent 
standard deviation. 
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Figure 5-8.  Effect of BDM-I and sodium orthovanadate on fluorescence of R110 
substrate for PTP enzyme assay using CD45. 
The amount of CD45 enzyme used was 5 U.  Error bars represent standard deviation. 
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5.4.4 Discussion 
Park & Pei (2004) have demonstrated that benzyl-β-nitroethene and some 
derivatives are competitive inhibitors of protein tyrosine phosphatases.  In the assays 
reported here, BDM-I showed similar level of inhibition of PTP1B (IC50 16 µM) to that 
reported by Park & Pei (Guo et al., 2002) for a related benzyl nitropropene (Compound 
6, 23 µg/mL).  The inhibiting concentration against Yop was 25 µM and BDM-I was 
much less active against CD45.  Inhibition of CD45 would have implications for host 
immunity.  CD45 positively regulates the response of functional lymphocytes to 
stimulation through antigen receptors.  The inhibitory effect of BDM-I would need to be 
investigated for a possible effect on T-cell function before therapeutic options could be 
discerned. 
Characterisation of signalling networks in cells is a very active field in 
biomedical research.  The catalytic site of PTP’s is highly conserved and it has been 
difficult to develop selective PTP inhibitors (Huyer et al., 1997).  Thiol-oxidising 
agents, such as vanadate, are potent general PTP inhibitors.  Vanadate, a phosphate 
analogue, is a reversible competitive inhibitor of PTP1B, oxidising the cysteine residue 
at the catalytic site (Combs et al., 2005; Desmarais et al., 1999; Taing et al., 1999; Xian 
et al., 2000; Zhang, 2002).  Many PTP inhibitors are composed of a tyrosine mimetic 
that reacts with the PTP active site and a component peptide or peptidomimetic or small 
molecules that interacts with key residues near the active site (Lydon & Druker, 2004). 
Protein tyrosine kinases have proven a successful target for anti-tumour 
agents such as imanitib (Zhang & Zhang, 2007).  PTP inhibitors may also be useful 
therapeutic candidates for the treatment of cancer, diabetes, obesity and immune 
disorders.  Several inhibitors of PTP1B are currently being investigated for therapeutic 
applications (Taing et al., 1999; Zhang, 2001).  BDM-I has potential as a lead 
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compound in the development of anti-infective agents based on PTP inhibition.  
Selectivity of action against bacteria is more likely given the differences between 
prokaryotic and eukaryotic PTP’s in regions outside the active site (2004). 
PTP inhibitors are useful compounds to investigate signal transduction 
pathways and the physiological functions of PTP’s.  There is a need for 
selective/specific, small molecule active site inhibitors that can enter cells.  Potent 
inhibitors, such as the non-hydrolisable phosphotyrosine mimetics, tend to be highly 
charged with consequent low bioavailability. BDM-I is a neutral tyrosine mimetic and 
penetrates cell membranes.  Peptide-containing analogues of BDM-I can be synthesised 
via a carboxyl substitution on the benzyl ring.  Park & Pei (2004) showed that the 
addition of a tripeptide to benzyl nitroethene resulted in increased activity against 
PTP’s. 
More work is needed on the kinetics to see where slow-binding inhibition 
observed by Park & Pei (Brazas & Hancock, 2005; Freiberg et al., 2004a) for related 
compounds against PTP’s is also applicable to BDM-I. 
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CHAPTER 6 THE EFFECT OF BDM-I ON GENE 
EXPRESSION 
6.1 INTRODUCTION 
Genetic mapping of resistant mutants can help identify the MOA of a 
compound.  Use of genetic analyses of resistant phenotypes to discover altered genes 
and proteins was not possible in this investigation since in repeated trials BDM-I failed 
to produce stable resistant phenotypes.  A whole genome transcription expression 
analysis was therefore used to investigate the global changes in gene expression in 
Bacillus subtilis on exposure to BDM-I. 
In living cells, environmental cues such as chemical stress, induce specific 
patterns of gene expression.  Transcriptional profiling using DNA microarray analysis is 
a recognised tool for evaluating changes in gene expression due to inhibitory agents and 
characterising or validating a MOA (Brazas & Hancock, 2005).  The bacterial gene 
expression profile responds very rapidly to environmental change with consequent 
changes in mRNA abundance (transcriptome).  Genomic responses of organisms to an 
inhibitor are very complex.  The gene expression profile will reflect changes that are a 
direct consequence of target inhibition, changes in genes that are indirectly affected by 
changes in the primary target and secondary changes resulting from the action of the 
compound.  There may also be organism or strain-specific responses, such as those 
related to virulence mechanisms and changes in genes of unknown function (Freiberg et 
al., 2004b; Hutter et al., 2004a; Hutter et al., 2004b; Ng et al., 2003). 
Transcriptional profiling of cells and conditional mutants treated with 
antibiotics has been used to identify characteristic profiles for well known classes of 
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antibacterial agents.  Each class of inhibitor induces changes in distinct sets of genes (a 
gene signature) in particular species, which reflect the primary targets for that class of 
compound.  Expression profiles induced by antibiotics with a known MOA in model 
organisms can be used to classify particular mechansims and to identify specific marker 
genes (2004b).  These studies have shown that well known agents can have many 
targets and different mechanisms of action.  Such reference compendia can be used to 
predict the MOA of novel compounds from comparison of their expression profiles with 
reference profiles.  Hutter et al. (2004a) have compiled database of transcriptional 
profiles of B. subtilis for 37 well-characterised antibiotics as a prediction tool for the 
MOA of uncharacterised compounds.  Hutter et al. (Freiberg et al., 2004a) have also 
identified promotor regions which are markers for antibiotic targets and constructed 
reporter strains of B. subtilis as indicators of specific MOA. 
B. subtilis is useful as a model organism for functional genomics-based drug 
research due to the abundance of physiological information available and its 
phylogenetic relationship to major pathogens such as staphylococci, enterococci and 
streptococci (Peterson et al., 2001). 
In this study Affymetrix Genechip® technology was used for a preliminary 
characterisation of the global expression responses of Bacillus subtilis treated with 
BDM-I focusing on concentration-dependent changes at one time point.  The analysis 
sought to identify genes whose transcription levels were significantly changed and 
subject those to a functional evaluation using an annotated gene database for B. subtilis 
and, if possible, relate them to biological observations of the effects of BDM-I. 
6.1.1 DNA Microarray analysis 
Measurement of the trancriptome (mRNA levels) is based on the 
hybridisation of sample cDNA with DNA probes spotted on microarray chips.  The 
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level of transcripts detected in a treated population is then compared to that of an 
untreated control.  Computational algorithms and statistical analyses identify genes with 
significant differential expression and online annotational databases allow the 
categorisation of genes based on related functions. 
Affymetrix GeneChip® 
Affymetrix GeneChip® microarrays are created by using lithography to coat 
quartz slides with small fragments of chemically synthesised DNA.  These fragments 
are termed probes and a probe set consists of one oligonucleotide with a perfect match 
and one with a single base mismatch.  The location of each probe set is known as a 
feature, with each array containing millions of features.  On antisense arrays the 
oligonucleotide sequence is the same as the coding sequence.  Nucleic acids can then be 
extracted from samples and cDNA generated, labelled and hybridised to the probes on 
the array.  Monitoring of the amount of label at each feature enables analyses of 
transcript levels indicative of expression and subsequent functional analyses. 
The Affymetrix GeneChip® B. subtilis Genome Array consists of 5039 
probe sets and enabling the relative monitoring of mRNA transcripts from 4,350 open 
reading frames and 600 intergenic regions from B. subtilis. The array contains 45 
control probe sets and probes that are complementary to the labelled first strand cDNA 
that is hybridised to the array.  Probe set data are available online through the NetAffx 
Feature on the Affymetrix website (www.affymetrix.com). 
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JCVI CMR Primary annotation database 
Differentially regulated genes identified in treated samples through 
statistical analyses were categorised by functional roles based on the JCVI CMR online 
database (2004b).  The J. Craig Venter Institute (formerly known as The Institute for 
Genomic Research, TIGR) Comprehensive Microbial Research (CMR) database 
(http://cmr.jcvi.org/tigr-scripts/CMR/GenomePage.cgi?org=ntbs01, June 2007) 
describes functional role categories for 2572 of the 4100 protein coding genes identified 
(Figure 6-1). 
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Figure 6-1.  Main functional categories of Bacillus subtilis protein coding genes 
identified in the primary annotation JCVI CMR database. 
Primary annotation of B. subtilis genome from the JCVI CMR database.  Pie chart percentages 
indicate the percentage of the total 4100 protein coding genes categorised to the nominated 
function.  Figures in parentheses indicate the total number of genes in functional categories. 
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6.2 MATERIALS AND METHODS 
6.2.1 Selection of treatment parameters 
There are as yet no strict guidelines for conducting and analysing 
microarray experiments.  A number of people interested in the use of microarrays in 
antimicrobial MOA studies have suggested parameters for such investigations using B. 
subtilis including Hutter et al. (2005) and Freiberg et al. (Brazas & Hancock, 2005; 
Freiberg et al., 2004a).  These parameters, based on time kill and optical density data, 
were considered in choosing treatments for this study and were similar to those used in 
Hong et al. (2003).  Treatment concentrations were determined as described below. 
A broth dilution assay to determine the MIC of B. subtilis ATCC 6633 in 
AOAC broth were performed as described in Section 2.2.2 and gave an MIC of 16 
µg/mL and an MMC of 32 µg/mL.  A time-kill assay was performed as described in 
Section 2.6.2 in AOAC broth with log2 concentrations of BDM-I from 2 to 32 µg/mL to 
determine treatment concentrations.  Cell densities, measured by viable counts using 
plate dilution and OD600nm, were recorded at 0, 0.5, 1, 2 and 4 h.  The time kill assay 
showed a similar rate of growth (70% of the control) for 2, 4, 8 and 16 µg/mL 
treatments to 30 min.  Viable cell counts and optical density data for 2 and 4 µg/mL 
were similar. 
The two treatment levels chosen for the microarray srudy were a 
subinhibitory concentration of 2 µg/mL and an inhibitory concentration of 16 µg/mL 
BDM-I to give a greater differential in treatment concentrations.  The time point of 30 
minutes was chosen as it is approximately half the generation time in AOAC broth.  The 
sub-inhibitory dose and analysis of an early time point was used to minimise expression 
of secondary targets and downstream effects.  Use of inhibitory concentrations allows 
detection of expression of genes outside the target pathway. (Affymetrix Inc., 2001).  
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Optical density data and viable counts were collected during treatment of samples to 
ensure close replication of sample treatments (Appendix B). 
6.2.2 Total RNA isolation 
B. subtilis was grown overnight in Synthetic broth AOAC (Difco 
Laboratories, USA) on a shaker (Ratek) at 160 rpm.  This culture was diluted 1:100 in 
fresh medium and returned to the shaker.  Bacterial growth was monitored by OD600nm 
using a spectrophotomter (Cary 50 UV-Vis, Varian) and by dilution plates (Appendix 
B).  At 3 h the culture was divided and BDM-I was added at 2 µg/mL or 16 µg/mL (1% 
DMSO).  The control culture received the same volume of DMSO vehicle.  Cell density 
was measured as above at 0 and 30 minutes.  After 30 minutes, RNA was isolated using 
the Qiagen RNAprotect bacteria kit, which includes a reagent that stabilises the RNA 
expression profile of the sample in vivo (Qiagen RNAprotect bacteria reagent 
handbook, 2005).  Protocol 5 was followed for enzymatic lysis, proteinase K digestion 
and mechanical disruption of the bacteria.  Protocol 7 was followed for purification of 
total RNA from bacterial lysate using the RNeasy Mini Kit with on column RNase 
digestion.  RNA was eluted in 2 × 30 µL of provided RNase free water.  Samples were 
designated a number based on the replicate group (3, 6, 7) and a letter to indicate the 
treatment (a, untreated; b, 2 µg/mL BDM-I; c, 16 µg/mL). 
Isolated total RNA was diluted in MilliQ water treated with 0.1% v/v 
diethylpyrocarbonate (DEPC) (Sigma-Aldrich) and autoclaved to remove RNase.  
Concentration was checked by spectrophotometry at 260/280 nm in quartz cuvettes with 
a path length of 1 cm (Cary 50 UV-Vis, Varian).  A 260/280 ratio of 1.8-2 was 
considered optimal for labelling and hybridisation to the array.  Concentrations were 
calculated and found to be 364-956 µg/mL with ratios 1.72-1.86 (Appendix B).  The 
quality of RNA was checked by electrophoresing samples on a 1.2% formaldehyde 
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agarose gel at 80V as described in the RNeasy handbook (Appendix A).  Ribosomal 
bands were visualised under UV light using a gel documentation system (Gel Doc, Bio-
Rad).  The total RNA was deemed acceptable for each of the 9 samples, as each 
produced clear bands and showed no degradation (Appendix B). 
6.2.3 Labelling and hybridisation 
Labelling of the 9 RNA samples from B. subtilis and hybridisation to 
GeneChips was carried out by the Australian Genome Research Facility (AGRF, 
Parkville, Vic, AUS) according to standard Affymetrix protocols.  Briefly, the quality of 
B. subtilis total RNA was confirmed on the Agilent Bioanalyser 2100 using the 
NanoChip protocol (Supplemantary data CD).  A total of 7 µg of each sample was used 
according to recommended GeneChip® E. coli Antisense Genome Array Expression 
Analysis Protocol (Affymetrix Inc., 2004). 
GeneChip® Eukaryotic poly-A RNA spikes (Millenium Science, Vic, AUS) 
were added to the reaction to indicate the labelling efficiency.  First strand cDNA was 
generated according to Affymetrix protocols and cleaned using the Affymetrix 
GeneChip® Sample Cleanup kit (Millenium Science).  The cDNA was then fragmented 
using DNase I.  A final quality check of the fragmented cDNA was performed on the 
Agilent Bioanalyser 2100 using the NanoChip protocol. 
The fragmented cDNA was end-labelled using terminal deoxynucleotidyl 
transferase enzyme and the Affymetrix GeneChip® DNA biotinylated labelling reagent 
(Millenium Science).  A total of 7 µg of labelled cDNA was then hybridised to the B. 
subtilis GeneChip® (Millenium Science) by preparing a probe cocktail (labelled cDNA, 
0.05 µg/µL) that includes 1× Hybridisation Buffer (100 mM MES, 1 mM NaCl, 20 mM 
EDTA, 0.01 % Tween-20), 0.1 mg/mL Herring Sperm DNA, 0.5 mg/mL bovine serum 
albumin and 7 % DMSO. 
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A total hybridisation volume of 300 µL was prepared for each sample and 
200 µL loaded onto each GeneChip®.  The chip was hybridised at 45ºC for 16 h in an 
oven with a rotating wheel at 60 rpm.  After hybridisation the chip was washed and 
stained with Streptavidin-Phycoerythrin (SAPE) using the appropriate fluidics script 
(ProkGE-WS2) in the automated Affymetrix Fluidics Station 450.  Upon completion of 
washing, the chips were scanned at 570 nm using the Affymetrix GeneChip® Scanner 
3000.  The scanner operating software, GCOS, converted signals on the chips into 
image files (*.DAT).  Image files were received from AGRF for analysis using GCOS 
software (Supplementary data). 
6.2.4 Analysis of data 
Image analysis (GCOS) 
The global method was used to generate a grid, anchored at each corner of 
the array and based on the feature size of 18 µm to determine the pixel coordinates for 
each feature.  Each raw image file (*.DAT) was inspected carefully for successful 
hybridisation of the B2 oligo border, correct alignment and for image artefacts.  All 
arrays were satisfactorily aligned as indicated by the alternating pattern.  Outlier cells 
(fluorescent intensity) detected by GCOS and cells affected by system artefacts detected 
visually were ‘masked’ and eliminated before cell intensity (*.CEL) files were 
generated.  Artefacts were only observed on one array out of nine (6a, untreated).  
System artefacts may be due to array manufacture itself, application of hybridisation 
cocktail or washing and staining procedures. 
Cell intensity image files were used to generate probe set data (*.CHP) and 
report files for each array to provide data for absolute analysis. 
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Absolute analysis (GCOS): Evaluation of data quality 
Scatter plots of signal values for treatment versus control data were 
generated from probe set data (*.CHP files) and examined for skewness and variability 
(Figure 6-2).  This single array analysis included examination of a number of factors 
across replicates including scale factor, background, noise and percentage of probe sets 
called ‘present’ (Table 6-3).  Values for control probe sets (spike controls, polyA tails, 
internal housekeeping genes) were also examined for each array. 
Comparison analysis (GCOS): Experiment versus baseline arrays 
for each replicate 
The data was filtered using criteria based on detection calls, change calls 
and signal log ratios generated using the GCOS program to provide an overview of 
changes between treated and untreated cells. 
Comparison analyses between control and treated samples within each 
replicate (*.CEL files), were performed in GCOS for first order analyses of expression 
differences.  For each biological replicate the untreated control was set as the baseline 
file for comparison to each BDM-I treatment in that replicate and .CHP file data 
generated including signal log ratios, change calls and change p-values. 
The detection algorithm in GCOS calculates a discrimination score (R) from 
probe pair intensities according to the formula: 
R = (PM-MM)/(PM-MM) 
where PM is the incidence of perfect match probe pairs and MM is the incidence of 
Mismatch probe pairs.  The discrimination score is compared to a user defined value, 
Tau (0.015) and the probe set assigned a detection call of “Present” if R>Tau or 
“Absent” if R<Tau.  The confidence of this calculation is reflected by a p-value which 
is generated by a One-sided Wilcoxon’s Signed Rank test and refines the detection call 
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based on the α1 (0.04) and α2 (0.06) parameters (Appendix C).  Probe sets are assigned 
a final detection call of ‘Present’ if p= <α1, marginal if p=α1>α2 and absent if p=>α2.  
Signal is then calculated by a One-step Tukey’s Biwight Estimate and represents 
relative expression levels (1995).  The program compares PM-MM intensities and 
assigns a change call as I (increase), D (decrease) or NC (no change) with an associated 
p-value.  The signal represents relative abundance of the transcript and the signal log 
ratio indicates the direction of the change call and its magnitude.  Significantly 
regulated genes identified from comparison analyses for each BDM-I treatment 
concentration were selected in GCOS by the criteria listed in Table 6-1. 
Table 6-1.  Criteria for selection of significantly regulated genes in GCOS in 
comparison analysis. 
Up-regulated genes Down-regulated genes 
Detection call of “Present” in treatment Detection call of “Present” in untreated 
(baseline) 
Change call of “Increase”  Change call of “Decrease”  
Signal log ratio ≥1 (i.e. ≥2-fold change) Signal log ratio <1 (i.e. <2-fold change) 
Signal Units >100 Signal Units >100 
Present calls are based the discrimination score generated from probe match intensities and 
compared to user definable parameters, Tau (0.015), α1 (0.04) and α2 (0.06). 
Change calls are based on probe match intensities and reflected by the signal log ratio.  Signal 
units reflect the relative abundance of the transcript. 
Statistical analysis of microarray data 
Analysis of microarray data was performed on data exported into an Excel 
spreadsheet (Microsoft, WA, USA, 2003).  Imported text files of probe set data were 
added as two datasets each consisting of three replicates of controls and either 2 µg/mL 
or 16 µg/mL treatments.  Altered transcript levels for probe sets for treatment samples 
compared to the untreated control in each replicate were identified by performing a 
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paired t-test at a confidence level of 95%.  Only those probe sets which were 
differentially regulated (P<0.05) in 2 of 3 biological replicates of treatments were 
selected for further analysis.  Probe sets with a mean signal of <100 in both untreated 
and treated samples were discarded.  Probe sets with a mean signal of <100 in the 
untreated samples were discarded.  Significantly changed probe sets were considered to 
have a fold change of ≥2.  Significantly changed probe sets were ranked according to 
ascending p-values and a Benjamini and Hochberg (Ko et al., 2004) false discovery rate 
(FDR) was applied to isolate the final list of probe sets of interest.  The application of 
this FDR is one of the least stringent statistical methods for evaluating false positives 
and negatives and tolerates more false positives with the advantage that it identifies less 
false negatives.  The method involved ranking p values in ascending order and the FDR 
was calculated according to the equation: p value × total number in list/rank with a cut-
off of 0.05. 
Functional analysis of differentially regulated genes 
The genes represented by these final probe set lists were then placed into 
functional categories based on data current in the online JCVI CMR database.  Primary 
Annotations were used to identify functional categories for B. subtilis genes and to 
describe differentially regulated genes in response to BDM-I exposure demonstrated by 
changes in trancripts levels. 
6.2.5 Validation of microarray results by quantitative 
PCR 
Validation of microarray data performed by qPCR on original samples 
provided experimental verification of gene-expression levels. 
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RNA samples used for the microarray were used to generate cDNA using 
Superscript II reverse transcriptase (Invitrogen Australia, Vic, AUS).  A total of 5 ng 
of total RNA was combined with 225 ng random primers (Invitrogen Aust.), 1 µL dNTP 
mix (10 mM each, Invitrogen Aust.) and nuclease free water (Promega) to 12 µL.  The 
mixture was heated to 65°C for 5 min using a thermocycler (PCR Express, Hybaid, 
MA, USA) and quickly chilled on ice.  The contents of each tube was collected by brief 
centrifugation and 5× first strand buffer (4 µL), 0.1 M DTT (2 µL) and 40 U/µL 
RNaseOUT (Invitrogen Aust.) (1 µL) added.  Tube contents were mixed briefly and 
incubated for 25°C for 2 min.  Superscript II RT (200 U) was added and mixed by 
pipetting and the tubes incubated at 25°C for 10 min and at 42°C for 60 min.  The 
reaction was inactivated by heating at 70°C for 15 min.  First strand cDNA was purified 
using Qiaquick spin columns (Qiagen, Vic, AUS) according to manufacturer’s 
instructions.  Final elution was in two volumes of 50 µL of buffer EB for a final 
concentration of 50 ng/µL. 
Changed probe sets common to both treatment levels were identified and are 
shown in Figure 6-5.  Three were selected for validation of microarray results using 
qPCR with sequence specific primers.  Target genes were clpC (a class III stress 
response-related ATPase), spoVG (required for stage V sporulation) and dnaE (DNA 
polymerase III subunit alpha).  One unchanged gene, mbl, was included as an internal 
housekeeping control.  It encodes an actin-like protein and has been used in other 
studies as a housekeeping control in B. cereus (Altschul et al., 1990). 
Sequence specific primers were designed based on probe set sequences from 
Affymetrix.  Primer design was carried out online using PrimerQuest from Integrated 
DNA technologies (http://www.idtdna.com/Scitools/Applications/Primerquest/).  Primer 
sequence specificity was checked using the basic local alignment search tool (blastn, 
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NCBI, (Pfaffl, 2001).  Primers were synthesised by Geneworks (SA, AUS).  Stocks 
were prepared at 10 µM from the lyophilised sequences in Nuclease free water 
(Promega) and stored in aliquots at -20°C.  A summary of the primers used is shown in 
Table 6-2. 
Quantitative PCR reactions were carried out using SYBR green supermix 
(Bio-Rad Laboratories) and the Miniopticon real-time PCR detection system in a 
thermal cycler (MJ Mini, Bio-Rad).  Validation of primer sets was performed using 2-
fold amounts of template equivalent to 12.5 ng up to 400 ng starting material for cDNA 
first-strand synthesis. Melt-curve analysis and agarose gel electrophoresis was used to 
confirm generation of distinct PCR products (data not shown). 
The following cycling protocol was used: denaturation (95°C, 10 min) 
amplification and quantification repeated 35 cycles (95°C, 15 s; 55°C, 20 s; 72°C, 20 s, 
single fluorescence measurement), 95°C, 1 min, cooling at 50°C, 1 min, melting curve 
program (50-99°C with heating rate of 1°C per 5 s and a continuous fluorescence 
measurement, cooling step to 4°C. 
Standard curves consisting of two-fold sample concentrations in duplicate 
were used to determine primer pair efficiencies for each gene.  Efficiencies were 
calculated from the Ct using the pearson correlation coefficient according to the 
equation E = 10(-1/slope) and are presented as percentages in Table 6-2. 
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Table 6-2.  Summary of primers used for validation of microarray results by 
qPCR. 
Probe Set ID Primer 
Name Sequence 5'  3' 
Target 
length Start Tm (ºC) 
E (%) 
BG10916/mbl_at mbl F CAAACGCGAGTACAAGCTGCTGAT 631 300 59.6 76 
 mbl R AAATTTCCTCGTGACGTGCGTCTG 631 397 59.5  
BG12583/dnaE_2_at dnaE_2 F TTATGTGCGGATTGCTGACAAGCG 1261 633 59.9 76 
 dnaE_2 R TGACTGCTGAGACGCCTACACTTT 1261 824 59.9  
BG10112/spoVG_at spoVG F GCATGAGAGCGATTGCATCCATCA 271 29 59.5 93 
 spoVG R CGTTTACTCGGCATCGCAACGAAA 271 134 59.9  
BG10148/clpC_at clpC F GAACTTGCACGAGCACTTGCTGAA 2173 1582 60.0 90 
 clpC R ACATAACCCGGAGGTGAACCAACA 2173 1706 60.1  
F = forward primers (same sequence as probe); R = Reverse primers (reverse complement of 
the probe); E = efficiency of primer pair according to Pearson’s correlation coefficient. 
The cycle threshold (Ct) is defined as the point at which the fluorescence 
rises appreciably above background fluorescence.  The cut-off threshold value for 
calculation of the Ct in experimental reactions was set manually at the same level at 
which maximum efficiency was achieved in the standard curve for each set of primers. 
Quantitative PCR was performed on three seaparate occasions.  Average 
relative fold changes for each treatment were calculated using the Pfaffl method with 
reference to the housekeeping gene (mbl) and the untreated control (Hong et al., 2003).  
The equation for calculating the Relative Expression Ratio is shown below:  
(Etarget) 
∆Ct target (Ctuntreated  Cttreated)
 
 
(Ehousekeeping) 
∆Cthousekeeping (Ctuntreated  Cttreated) 
 
where E is the expression of a gene calculated from Ct (cycle threshold) values of genes 
across samples. 
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6.3 RESULTS 
6.3.1 Absolute analysis:  Evaluation of data quality 
The scatter plots enable visualisation of comparisons between all biological 
replicates of arrays within treatments (Figure 6-2).  These graphs show that the data 
points are not skewed for either treatment level indicating that the data represents 
reliable biological replicates. 
The parameters used to assess the quality of the microarray data presented in 
Table 6-3 indicate acceptable replicate data was obtained from the samples on separate 
gene chips.  The scale factor for all arrays was well within the 3-fold acceptable range 
and ruled out the need to normalise signal intensities to the baseline before comparison 
analyses.  The mean average background signal range of 96.0 to 170.8 was outside the 
normal range of 80-130 which applies to the new scanning technology at the AGRF 
facility.  The discrepency was deemed to be caused by the mismatch of technology as 
the B. subtilis chip, is available only in an older platform version.  The background 
range obtained was deemed acceptable by AGRF.  Both the background and the RawQ 
values were acceptable, indicating that the image quality was satisfactory. 
The proportion of the probe sets with a detectioin call of ‘present’ in this 
analysis varied from 27% to 39% with a mean of 32.5%.  This is comparable to similar 
gene chip studies on E. coli (Kobayashi et al., 2003). 
 
 141 
 
 
Figure 6-2.  Scatter plots for B. subtilis treatment signals against control group signals. 
B. subtilis was treated with 2 µg/mL BDM-I (a) or 16 µg/mL BDM-I (b).  Lines represent 2-fold 
and 10-fold differences respectively. Each dot represents a probe set.  Colours represent 
detection calls between probe pairs.  Key: Red, both Present (PP); Blue, one Present (MP, PM, 
AP, PA); Yellow = None Present (MM, AM, MA, AA). 
Signal values of all untreated control arrays 
a) 
Si
gn
a
l v
a
lu
e
 
o
f a
ll 1
6 
µg
/m
L 
tre
at
m
e
n
ts
 
a
rr
a
ys
 
Si
gn
a
l v
a
lu
e
s 
o
f a
ll 2
 
µg
/m
L 
tre
at
m
e
n
ts
 
a
rr
a
ys
 
Signal value of all untreated control arrays 
b) 
 142 
The hybridisation efficiency controls, biotin labelled spike controls (BioB 
and Cre) increased in the expected order indicating that hybridisation efficiency was 
satisfactory.  However, the lysine spike control did not give expected signals on any of 
the arrays and only one Poly A tail labelling control was detected as present for all 
arrays.  This is due to the prokaryotic sample not possessing polyadenylated tails and is 
required predominantly on eukaryotic arrays as a hybridisation control.  The 3’/5’ ratio 
for housekeeping genes was <3 in all instances indicating good RNA integrity, efficient 
first strand cDNA synthesis and transcription of cRNA. 
Table 6-3.  Results of absolute analysis of data quality parameters for B. subtilis 
GeneChip® experiments. 
 Treatment 
Attribute Untreated cells Low concentration 
(2 µg/mL) 
High concentration 
(16 µg/mL) 
 
Replicate i.d. 3a 6a 7a 3b 6b 7b 3c 6c 7c Mean s.d. 
Raw Q noise1 3.3 2.5 2.5 3.2 3.0 2.9 3.1 3.0 2.3 2.9 ± 0.4 
Average Noise 17.2 9.9 10.5 15.8 12.7 13.7 14.3 13.4 8.3 12.9 ± 2.9 
Average 
Background2 
170.7 108.6 113.5 163.3 139.7 138.7 156.6 147.7 96.0 137.2 ± 25.9 
Scale factor3  
at TGT 1504 
1.4 2.1 1.4 1.9 1.6 1.6 0.8 1.1 1.8 1.5 ± 0.4 
% genes 
present5 
28.8 30.7 35.2 26.9 31.4 30.9 38.5 35.7 34.2 32.5 ± 3.7 
Average % 
present 
31.6 29.7 36.1   
1Raw Q noise and Average noise values measures the degree of pixel-to-pixel variation.  
Replicates should be within 5 RawQ noise units. 
2Mean average background expected range is 80-130 but may vary with Genechip® platform 
and scanner technology employed. 
3Scale factor indicates closeness of average array intensity to the target intensity, 1.0 indicating 
equal intensity and a 3-fold range being acceptable. 
4Target signal value = 150 is Affymetrix recommendation for the AGRF protocols and 
equipment. 
Percent genes called ‘present’ from 5039 probe sets. 
Appendix D 
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Variation coefficients for probe set signals for all biological replicates were 
calculated by dividing the standard deviation by the mean signal and presented as a 
percentage to demonstrate reproducibility across biological replicates (Figure 6-3).  In 
total, over 98% of genes called present for at least 2 of 3 treatment replicates had 
variation coefficients (VC) less than 50%. 
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Figure 6-3.  Reproducibility of Genechip® signal data across treatment groups. 
VC % of genes called present for at least 2 of 3 biological replicates for each treatment.  VC % 
= stdev/mean *100. 
6.3.2 Comparison analysis: Experiment versus baseline 
arrays for each replicate.  
Comparison analyses, using GCOS software (ver 1.0, Affymetrix Inc.) and 
applying the selection criteria in Table 6-1, between each treatment and the control 
(pairs) for each biological replicate identified probes sets showing  increased or 
decreased expression (Table 6-4).  The comparison analysis showed consistency of data 
across biological replicates. 
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Table 6-4.  Percentage of probe sets changed in B. subtilis treated with BDM-I 
compared to controls for each biological replicate performed in GCOS. 
 Low concentration (2 µg/mL) High concentration (16 µg/mL) 
Replicate i.d. 
(baseline & treatment) 
3a&3b 3a&3b 6a&6b mean 7a&7c 6a&6c 7a&7c mean 
Increases         
Number of probe sets ‘P’ 1351 1579 1554 1495 1936 1797 1721 1818 
Also with a Change call of ‘I’ 233 266 176 225 547 557 509 538 
Also with a Signal Log Ratio 
of ≥1 71 45 65 60 281 290 285 285 
Also with signal >100 69 44 64 59 266 276 263 268 
% Probe sets increased  5% 3% 4% 4% 14% 15% 15% 15% 
Decreases         
Number of probe sets ‘P’ in 
Baseline 
1450 1542 1773 1588 1450 1542 1773 1588 
Also with a Change call of ‘D’ 290 252 337 293 575 475 712 587 
Also with a Signal Log Ratio 
of ≤-1 79 63 45 62 507 222 449 393 
Also with signal >100 58 36 19 38 233 36 184 151 
% Probe sets decreased 4% 2% 1% 2% 16% 2% 10% 10% 
Present calls are based the discrimination score generated from probe match intensities and 
compared to user definable parameters, Tau (0.015), α1 (0.04) and α2 (0.06). 
Change calls are based on probe match intensities and reflected by the signal log ratio.  Signal 
units reflect the relative abundance of the transcript. 
Appendix D 
6.3.3 Statistical analysis of microarray data  
Data was exported from GCOS as text files and opened with Excel 
(Microsoft, 2003) in order to perform statistical analysis (Supplementary data).  A 
summary of the number of probe sets found changed by statistical analysis included 
application of a t-test and FDR and identified a number of probe sets significantly 
changed in response to BDM-I at 2 µg/mL and 16 µg/mL compared to the control 
(Table 6-5).  Approximately 1% and 8% of the 5039 probe sets were significantly 
changed (up or down-regulated) in response to BDM-I at 2 µg/mL and 16 µg/mL 
respectively. 
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Forty six genes were changed at the sub-inhibitory concentration (2 µg/mL), 
63% of these being up-regulated.  Eight-fold more genes (384) were changed at the 
inhibitory concentration of 16 µg/mL with 66% of these being down- regulated.  This 
suggests a strong adaptive stress response to BDM-I exposure. 
Table 6-5.  Probe sets identified as significantly changed in B. subtilis treated 
with BDMI at 2 or 16 µg/mL by sequential application of selection criteria based 
on statistical analysis of Genechip® data. 
Statistical criteria 2 µg/mL 
treatment 
16 µg/mL 
treatment 
Total probe sets 5039 5039 
Total probe sets differentially regulated by T-test (p<0.05) 582 1323 
Total probe sets differentially regulated in at least 2 of 3 biological 
replicates 
296 790 
Total probe sets differentially regulated at least 2 of 3 biological 
replicates and with a mean signal >100 for both treatment and control 
283 760 
Total probe sets differentially regulated at least 2 of 3 biological 
replicates and with a mean signal >100 for control 
273 743 
Total probe sets significantly differentially regulated (fold change >2) 54 476 
Total probe sets significantly differentially regulated after FDR applied 53 476 
Total probe sets significantly differentially regulated after FDR applied 
and with “Present” calls for treatment in at least 2 of 3 biological 
replicates 
46 384 
Significantly up-regulated probe sets 29 129 
Significantly down-regulated probe sets 17 255 
 
6.3.4 Functional analysis of differentially regulated genes 
The genes represented by the probe sets determined to be significantly up or 
down-regulated were identified in the JCVI CMR Primary annotation database (JCVI).  
Identified genes were grouped according to their functional categories for each 
treatment to present a holistic picture of transcriptional changes in response to exposure 
to BDM-I.  The relevant probe lists are annotated to molecular and biological processes.  
Pie charts are used to represent the frequency of the identified functional categories.  
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Significantly changed genes associated with good microbial targets were the focus of 
this analysis. 
Comparison of functional categories of genes 
A breakdown of all primary annotated genes in the B. subtilis genome is 
shown in Figure 6-1.  Functional categories are assigned to 2572 of the 4100 (63%) 
protein coding genes in the Primary annotation database.   
Genes identified in this study that were not assigned to any functional 
categories were excluded from the pie charts while some genes have been assigned 
more than one main functional role.  The percentages of differentially regulated genes 
identified as differentially regulated but not assigned functions (not found) in the JCVI 
CMR database were 16% (8 genes) and 27% (106 genes) for 2 μg/mL and 16 μg/mL 
BDM-I treatments respectively. 
There are notable changes in the expression of functional gene categories 
between treated samples compared to those in the annotated JCVI database (Figure 6-4).  
This suggests the changes are a response to treatment with BDM-I and also indicates the 
rapidity of the adaptive response at the genome level to chemical stress.  Compared to 
the annotated genome, for the sub-inhibitory (2 μg/mL) concentration, some categories 
are from 50% to ≥100% over-represented as a percentage of categorised genes.  ‘Energy 
metabolism’, ‘amino acid biosynthesis’ and ‘intermediary metabolism’ are ~50% over-
represented and ‘biosynthesis of cofactors, prosthetic groups and carriers’, ‘purines, 
pyrimidines, nucleosides and nucleotides’ and ‘protein fate’, more than 100 % over-
represented.  Two category functions are not represented at all in the differetially 
regulated subset: ‘protein synthesis’ and ‘mobile and extrachromosomal element 
functions’. 
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For the higher concentration (16 μg/mL) more gene categories were 
identified and the differences in percentage representation compared to the annotated 
database were not as great.  ‘Purines, pyrimidines, nucleosides and nucleotides’ and 
‘protein synthesis’ are 100% over-represented and ‘signal transductioon’ ~50% over-
represented. 
The changes in functional category representation observed between the 
sub-inhibitory and the inhibitory concentration of BDM-I (8-fold concentration range) 
were variable.  Most categories were under-represented at 16 μg/mL, but differential 
changes in ‘protein synthesis’, ‘cell envelope’ and transcription’ were at least 7-fold 
higher at 16 μg/mL. 
Comparison of differentially expressed genes 
Functional annotations of significantly changed genes (up-regulated and 
down-regulated combined) is shown in Figure 6-4a & b.   
Of the 46 genes changed at 2 μg/mL, 10 related to energy pathways and 5 
have unknown functions (2 being genes described as such in the JCVI database).  The 
remaining genes were distributed fairly evenly over 11 functional areas. 
Of the 384 genes changed at 16 µg/mL, 292 were spread among 15 of the 16 
functional categories with 52.7% of these in the five largest functional groups (Figure 
6-1).  ‘Energy metabolism’ and ‘Cellular processes’ accounted for 55 and 40 changed 
genes respectively.  Nine of the 292 genes are classified as ‘unknown’ function in JCVI. 
Thirty-four differentially regulated genes have been identified as being 
essential to the survival of B. subtilis (Kobayashi et al., 2003).  Thirty-two of these were  
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Figure 6-4.  Functional categories of differentially expressed genes in B. subtilis 
exposed to BDM-I at 2 µg/mL (a) and 16 µg/mL (b). 
Primary annotation of B. subtilis genome from the JCVI CMR database.  Data collected from a 
Genechip® microarray study described in Section 6.2.  Figures in parentheses indicate number 
of changed genes (up-regulated and down-regulated) for treated samples in main functional 
categories. 
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changed in response to 16 µg/mL BDM-I.  Of these, 9 are involved in protein synthesis 
(ribosomal proteins and tRNA synthases) and 5 are involved in energy metabolism.  
Twenty-three were down-regulated and 8 were up-regulated exclusively in response to 
16 µg/mL BDM-I. 
Genes differentially regulated at both treatment concentrations 
To identify possible genes involved in the MOA of BDM-I, significantly 
changed genes that were common to both 2 and 16 μg/mL treatments were selected for 
functional analysis.  BDM-I treatment at 2 μg/mL for 30 min reduced the cell numbers 
of B. subtilis by about 10%.  The expression profile 2 μg/mL, therefore, better reflects 
the early changes due to the effect of BDM-I rather than follow-on effects or secondary 
effects due to greater growth arrest at 16 μg/mL. 
Forty-six genes were differentially regulated at 2 μg/mL and 31 of these 
(67%) were also changed at 16 µg/mL.  The commonly regulated genes constitute 8% 
of those changed at 16 μg/mL.  Twenty up-regulated genes (≥2-fold change) common to 
both concentrations are shown in Table 6-6 and Figure 6-5a.  The function of the most 
up-regulated gene (28-fold), ycnE, unfortunately has not yet been identified.  Nine of 
these genes were in the top four represented categories in the normal B. subtilis genome 
and are involved in major cell activities (Figure 6-1).  Of the genes changed in both 
treatments, only two, clpP (protein degradation) and yugJ (energy & intermediary 
metabolism), failed to show a larger change at the higher concentration.  Three genes 
with lower representation in the reference genome, yraA (purines, pyrimidines, 
nucleosides & nucleotides), yvrD (fatty acid & phospholipid metabolism) and yqfY 
(biosynthesis of cofactors, prosthetic groups and carriers) have not been fully 
characterised and are listed as genes ‘similar to known or hypothetical proteins’.  One 
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gene, dnaE, which is involved in DNA metabolism and essential to B. subtilis survival 
was commonly up-regulated both both 2 and 16 µg/mL.  Two genes, trxA and trxB, 
were differentially regulated in response to 2 µg/mL and 16 µg/mL BDM-I.  Both are 
involved in energy metabolism and have been found to be essential to B. subtilis 
survival (Hutter et al., 2004a).  
Eleven genes are down-regulated at both concentrations (Table 6-7 and 
Figure 6-5).  The most down-regulated gene, spoVG, was decreased 7-fold and 17-fold 
in 2 and 16 µg/mL treatments respectively.  This gene is required for synthesis of the 
spore cortex.  Two additional genes involved in spore formation were differentially 
expressed, soj (transcription regulator of spore proteins) which was down-regulated 2-
fold at 16 μg/mL only and yrbC (spore coat protein) which was up-regulated 3-fold at 
16 μg/mL only.  Five down-regulated genes are involved in energy metabolism, one in 
regulatory functions, one in amino acid biosynthesis and three with 6-fold to 4-fold 
decreases, have no known function. 
No commonly regulated genes were found that were up-regulated in one 
concentration and down-regulated in another.   No commonly deregulated genes were 
involved in protein synthesis, cell envelope function and RNA transcription, all major 
targets of antibiotics.   Promotor regions have been identified from transcriptional data 
in B. subtilis treated with a range of antibiotics and incorporated in reported strains 
which can be used as indicators of antimicrobial MOA (2001).  None of these genes 
(fabHB, glpD, yrzI, expZ, ypbG, ytrA, ywoB, dinB, yneA, yorB, ydeK, yvgS) were found 
to be significantly changed by treatment of B. subtilis with BDM-I. 
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Table 6-6.  Genes commonly up-regulated at both 2 and 16 µg/mL treatment concentrations of BDM-I. 
Probe set ID 
Gene 
Symbol 
Fold 
change  
2 µg/mL 
Fold 
change  
16 µg/mL Main role Sub role Common Name 
BG12041/ycnE_at ycnE 28.6 28.2 not found not found not found 
BG10146/yacH_at yacH 5.4 10.1 Unknown function General similar to hypothetical proteins 
BG10148/clpC_at clpC 4.1 6.9 Protein fate 
Degradation of proteins, peptides & 
glycopeptides 
class III stress response-related ATPase 
BG10145/ctsR_at ctsR 4.5 6.2 Regulatory functions DNA interactions transcriptional regulator 
BG11187/yckK_at yckK 3.3 6.6 Transport and binding proteins Amino acids, peptides and amines 
similar to glutamine ABC transporter (glutamine-
binding protein) 
BG10147/yacI_at yacI 3.6 5.7 
Transport and binding proteins; 
Cellular processes 
Carbohydrates, organic alcohols and acids; 
Toxin production and resistance 
similar to creatine kinase 
BG11186/yckJ_at yckJ 2.1 6.7 Transport and binding proteins Amino acids, peptides and amines similar to glutamine ABC transporter (permease) 
BG12583/dnaE_3_at dnaE 2.7 5.5 DNA metabolism DNA replication, recombination & repair dna polymerase iii alpha subunit 
BG12583/dnaE_2_at dnaE 2.2 5.0 DNA metabolism DNA replication, recombination & repair dna polymerase iii alpha subunit 
BG19016/clpP_at clpP 4.3 3.3 Protein fate 
Degradation of proteins, peptides & 
glycopeptides 
ATP-dependent Clp protease, proteolytic subunit 
BG12398/trxB_at trxB 2.8 4.3 Energy metabolism Electron transport thioredoxin reductase 
BG13776/yraA_at yraA 2.7 3.8 
Purines, pyrimidines, 
nucleosides & nucleotides 
Pyrimidine ribonucleotide biosynthesis similar to hypothetical proteins 
BG14144/yvrD_at yvrD 2.8 3.4 
Fatty acid & phospholipid 
metabolism 
Biosynthesis similar to ketoacyl-carrier protein reductase 
BG13023/yhdQ_at yhdQ 2.5 3.7 Regulatory functions DNA interactions similar to transcriptional regulator (MerR family) 
BG13559/yojG_at yojG 2.7 3.0 not found not found not found 
BG12364/yugJ_at yugJ 3.2 2.4 
Energy metabolism; Central 
intermediary metabolism 
Electron transport;  Fermentation; 
Glycolysis/gluconeogenesis; TCA cycle; Other 
similar to NADH-dependent butanol dehydrogenase 
BG13434/ymzA_at ymzA 2.1 3.2 not found not found not found 
BG13022/yhdP_at yhdP 2.0 2.9 Cellular processes Other similar to hemolysin 
BG10348/trxA_at trxA 2.1 2.5 Energy metabolism Electron transport thioredoxin 
BG11671/yqfY_at yqfY 2.0 2.0 
Biosynthesis of cofactors, 
prosthetic groups and carriers 
Other similar to peptidoglycan acetylation 
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Table 6-7.  Genes commonly down-regulated at both 2 and 16 µg/mL treatment concentrations of BDM-I. 
Probe set ID 
Gene 
Symbol 
Fold 
change  
2 µg/mL 
Fold 
change  
16 µg/mL Main role Sub role Common Name 
BG10112/spoVG_at spoVG 6.9 17.4 Cellular processes Other required for spore cortex synthesis (stage V) 
BG13246/yknZ_at yknZ 2.2 6.3 not found not found not found 
BG10272/odhA_1_at odhA 2.1 6.2 Energy metabolism TCA cycle 2-oxoglutarate dehydrogenase (E1 subunit) 
BG11156/yxjG_at yxjG 2.2 5.8 not found not found not found 
BG12681/sucD_at sucD 3.2 3.7 Energy metabolism TCA cycle succinyl-CoA synthetase (alpha subunit) 
BG13416/ymaH_at ymaH 2.5 4.7 Regulatory functions Other similar to host factor-1 protein 
BG11570/ybbI_at ybbI 2.1 3.8 Unknown function General similar to hypothetical proteins 
BG10673/ilvA_at ilvA 2.2 3.5 Amino acid biosynthesis Other threonine dehydratase 
BG10722/rocD_at rocD 2.1 2.9 Energy metabolism Amino acids & amines acetylornithine aminotransferase 
BG10353/sdhB_at sdhB 2.3 2.7 Energy metabolism TCA cycle succinate dehydrogenase (iron-sulfur protein) 
BG10478/citB_1_at citB 2.2 2.5 Energy metabolism TCA cycle aconitate hydratase 
not found – not listed in the JCVI database
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Figure 6-5.  Scatter graph showing fold changes of genes commonly up-regulated (a) 
and down-regulated (b) between 2 and 16 µg/mL treatments of BDM-I. 
Circled genes exhibited fold changes ≥3 for both treatments 
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Genes differentially regulated at one treatment concentration only 
To highlight the differences in responses between the two concentrations of 
BDM-I, genes differentially regulated that were unique to one concentration of BDM-I were 
identified.  In total, 14 genes were identified as being uniquely changed in response to 2 
µg/mL BDM-I and 327 in response to 16 µg/mL BDM-I. (Table 6-8). 
Table 6-8.  Number of genes differentially regulated at either 2 µg/mL or 16 µg/mL 
BDM-I treatments only. 
Treatment 2 µg/mL 16 µg/mL 
 Up-regulated Down-
regulated 
Up-regulated Down-
regulated 
Number of unique genes 8 6 106 231 
No: main functions 
assigned  
9 6 111 238 
No: genes identified in 
primary annotations 
6 6 68 183 
A complete list of differentially regulated genes identified as being unique to one concentration of 
BDM-I and their main functional categories is in Appendix G. 
Treatment with 2 µg/mL BDM-I resulted in a 3.5-fold up-regulation of ribB, the 
riboflavin synthase α subunit in the main functional category of ‘Biosynthesis of cofactors, 
prosthetic groups and carriers’.  The remaining genes unique to 2 µg/mL were changed ≤2-
fold and are not listed here (Appendix H). 
BDM-I treatment with 16 µg/mL resulted in 104 genes being up-regulated ≥3 fold 
in response to this concentration alone, 37% of which were not found in the primary 
functional annotations.  The fourteen genes up-regulated ≥5 fold are listed in Table 6-9.  The 
most changed gene in response to 16 µg/mL was mrgA (18.5-fold) which has no assigned 
function.  In response to 16 µg/mL BDM-I, 233 probe sets were down-regulated ≥3 fold and 
41 of these were down-regulated ≥5 fold (Table 6-10).  Genes identified in the general stress 
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response of B. subtilis by Price et al. (Goh et al., 2002; Hong et al., 2003; Ng et al., 2003) 
which were changed by BDM-I 16 µg/mL were the up-regulated ynfC (6-fold, listed as not 
found in JCVI), the down-regulated yvyD (8-fold, protein synthesis) and yxjG (6-fold, not 
found). 
Most of the genes identified as unique in response to 16 µg/mL BDM-I were 
classified as ‘Cellular processes’, ‘Energy metabolism’ or ‘Protein synthesis’ which are the 
largest classes in B. subtilis and are not considered particularly indicative of mechanism (Data 
not shown).  This could be an indication of global stress adaptive responses to an inhibitory 
concentration which would fit with the treatment concentrations chosen.  It is also likely 
given that a number of genes have been classed as essential for B. subtilis survival.  The main 
roles that stand out as being highly represented beyond that expected are ‘Biosynthesis of 
cofactors, prosthetic groups and carriers’ or of ‘Purines, pyrimidines, nucleosides and 
nucleotides. 
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Table 6-9.  Up-regulated genes showing ≥5 fold change and unique to 16 µg/mL BDM-I 
Probe set ID 
Gene 
Symbol 
Fold 
change 
Main role Sub role Common Name 
BG10864/mrgA_at mrgA 18.5 not found not found not found 
BG12034/yclN_at yclN 12.3 Transport & binding proteins Other 
similar to ferrichrome ABC transporter 
(permease) 
BG12863/yetG_at yetG 9.6 not found not found not found 
BG14055/yuzF_at yuzF 9.2 not found not found not found 
BG12291/yrhB_at yrhB 7.9 Amino acid biosynthesis Other similar to cystathionine gamma-synthase 
BG14107/yvgY_at yvgY 7.8 Transport and binding proteins Other similar to mercuric transport protein 
BG14108/yvgZ_at yvgZ 6.5 not found not found not found 
BG11828/ynfC_at ynfC 6.4 not found not found not found 
BG14098/yvgP_at yvgP 6.3 Transport and binding proteins Cations and iron carrying compounds similar to hypothetical proteins 
BG12325/yshA_at yshA 5.5 not found not found not found 
BG12878/yfhC_at yfhC 5.1 not found not found not found 
BG10133/yacB_at yacB 5.1 not found not found not found 
BG10680/mecA_at mecA 5.0 Cellular processes DNA transformation negative regulator of genetic competence 
BG12612/lmrA_at lmrA 5.0 Regulatory functions DNA interactions transcriptional regulator 
not found – not listed in the JCVI database 
  
157
 
Table 6-10.  Down-regulated genes with ≥5 fold change and unique to 16 µg/mL BDM-I 
Probe set ID 
Gene 
Symbol 
Fold 
change 
Main role Sub role Common Name 
BG10240/fliF_at fliF 13.2 Cellular processes Chemotaxis & motility flagellar basal-body M-ring protein 
BG19003/lctE_at lctE 13.0 not found not found not found 
BG10706/purQ_at purQ 11.7 Purines, pyrimidines, nucleosides and nucleotides Purine ribonucleotide biosynthesis phosphoribosylformylglycinamidine synthetase I 
BG10704/yexA_at yexA 10.7 not found not found not found 
BG11062/pgk_at pgk 10.6 Energy metabolism Glycolysis/gluconeogenesis phosphoglycerate kinase 
BG14170/yxzG_at yxzG 10.2 not found not found not found 
BG12605/hisS_at hisS 10.0 Protein synthesis tRNA aminoacylation histidyl-tRNA synthetase 
BG12838/yerL_at yerL 9.7 not found not found not found 
BG12660/pycA_3_at pycA_ 8.4 Energy metabolism Glycolysis/gluconeogenesis pyruvate carboxylase 
BG10740/yvyD_at yvyD 7.9 Protein synthesis Translation factors alternate gene name: yviI similar to ribosomal 
BG11846/wprA_at wprA 7.9 Cell envelope Other 
cell wall-associated protein precursor (CWBP23, 
CWBP52) 
BG10276/hbs_at hbs 7.8 DNA metabolism 
DNA replication, recombination, & repair; 
Chromosome-associated proteins 
DNA-binding protein HB 
BG10707/purF_at purF 7.5 Purines, pyrimidines, nucleosides, & nucleotides Purine ribonucleotide biosynthesis amidophosphoribosyltransferase 
BG13785/yrbF_at yrbF 7.3 Protein fate Protein and peptide secretion and trafficking similar to hypothetical proteins 
BG11384/accC_at accC 7.1 Fatty acid & phospholipid metabolism Biosynthesis acetyl-CoA carboxylase, biotin carboxylase 
BG10897/tpi_at tpi 7.1 Energy metabolism Glycolysis/gluconeogenesis triose phosphate isomerase 
BG11023/yvcE_at yvcE 6.9 Cell envelope 
Biosynthesis & degradation of murein sacculus & 
peptidoglycan 
alternate gene name: yzkA; similar to cell wall-
binding protein 
BG11023/yvcE_at yvcE 6.9 not found not found not found 
BG11846/wprA_1_at wprA 6.9 Cell envelope Other cell wall-associated protease precursor 
BG10703/purC_at purC 6.6 Purines, pyrimidines, nucleosides, & nucleotides Purine ribonucleotide biosynthesis 
phosphoribosylaminoimidazole-
succinocarboxamide synthase 
BG12572/aspS_at aspS 6.6 Protein synthesis tRNA aminoacylation aspartyl-tRNA synthetase 
BG13245/yknY_at yknY 6.6 Transport & binding proteins Other similar to ABC transporter (ATP-binding protein) 
BG11247/tkt_at tkt 6.5 Energy metabolism Pentose phosphate pathway transketolase 
BG11135/yxiF_at yxiF 6.3 not found not found not found 
BG10705/purL_at purL 6.2 Purines, pyrimidines, nucleosides, & nucleotides Other phosphoribosylformylglycinamidine synthetase II 
BG11816/yktA_at yktA 6.2 not found not found not found 
BG11460/efp_at efp 6.1 Protein synthesis Translation factors translation elongation factor P 
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BG13236/ykgB_at ykgB 6.1 not found not found not found 
BG10815/atpB_at atpB 6.0 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit a) 
BG13395/yloU_at yloU 6.0 Cellular processes Adaptations to atypical conditions similar to alkaline-shock protein 
BG10816/atpE_at atpE 6.0 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit c) 
BG10622/rocA_at rocA 5.8 Energy metabolism Amino acids and amines pyrroline-5 carboxylate dehydrogenase 
BG11138/yxiI_at yxiI 5.6 not found not found not found 
BG10817/atpF_at atpF 5.5 Energy metabolism ATP-proton motive force interconversion ATP synthase F0, B subunit 
BG13392/yloQ_at yloQ 5.5 not found not found not found 
BG12839/yerM_at yerM 5.5 Protein synthesis tRNA aminoacylation alternate gene name: yedB similar to amidase 
BG11709/yqhY_at yqhY 5.5 not found not found not found 
BG13152/yjbW_at yjbW 5.3 Fatty acid & phospholipid metabolism Biosynthesis similar to enoyl- acyl-carrier protein reductase 
BG10241/fliG_at fliG 5.3 Cellular processes Chemotaxis & motility flagellar motor switch protein 
BG12366/pgi_at pgi 5.3 Energy metabolism Glycolysis/gluconeogenesis glucose-6-phosphate isomerase 
BG13934/ytwP_at ytwP 5.1 Energy metabolism Sugars unknown 
BG11708/yqhT_at yqhT 5.0 Protein fate 
Degradation of proteins, peptides, & 
glycopeptides 
similar to Xaa-Pro dipeptidase 
 
not found – not listed in the JCVI database 
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6.3.5 Validation of microarray data by quantitative PCR 
Relative transcript amounts for selected genes to verify transcriptional 
expression values were determined by qPCR of cDNA (Section 6.2.5).  Uniform 
expression was seen for mbl across untreated and BDM-I treated cells (Figure 6-6).  This 
unchanged mbl gene was included as an internal control.  The target genes exhibited 
differential expression under the two treatment conditions.  The class III stress-response 
ATPase, clpC, and the DNA polymerase III subunit α, dnaE, were up-regulated while 
spoVG, involved in spore cortex formation, was down-regulated compared to the control 
and relative to the housekeeping gene mbl. 
Results from qPCR assays mirrored microarray fold-changes in gene 
expression (Figure 6-6).  All qPCR results for gene expression were within two-fold of 
results from the microarray for B. subtilis treated with 2 µg/mL BDM-I.  For B. subtilis 
treated with 16 µg/mL BDM-I, changes detected by qPCR were 4, 5 and 12-fold greater 
for dnaE, clpC and spoVG respectively, than those calculated from the microarray data.  
These results highlight the greater sensitivity of the qPCR procedure over microarray 
transcription analysis for three out of the four genes used here. 
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Figure 6-6.  Relative fold changes in B. subtilis genes compared between Genechip® 
microarray and qPCR results. 
Error bars represent standard deviation.  Array fold changes shown in italics, qPCR fold changes in 
normal text.  mbl was used as the internal control and baseline comparison (no change).  Genes 
were chosen based on differential regulation in both 2 and 16 µg/mL treatment concentrations. 
6.4 DISCUSSION 
This preliminary analysis of the B. subtilis genome has illustrated the rapid and 
complex genomic response of bacteria to chemical stress.  Using one treatment time and 
two concentrations, this study has identified that the optimum treatment concentration for 
further analysis of transcripts in response to BDM-I is likely between 2 and 16 µg/mL.  An 
additional earlier time point, less than the 30 min exposure used here, might help identify 
time-related specific patterns of expression that could be linked to more directed studies of 
the genes affected by BDM-I.  The percentages of transcribed genes which were 
significantly changed at 30 min for 2 and 16 µg/mL treatments were 1% and 8%.  Similar 
levels of changed genes have been reported in studies of the transcriptional profiles of 
other bacteria subjected to antimicrobial agents (2002).  The significantly changed genes 
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covered many functional categories, particularly at the inhibitory concentration of 16 
µg/mL, illustrating the complexity of the bacterial response to chemical stress. 
The analysis identified genes that were changed at both sub-inhibitory and 
inhibitory concentrations, most showing a dose response in expression fold change with 
concentration.  Changed genes common to both treatment concentration may include genes 
specifically altered by BDM-I or genes changed as a consequence of these.  The commonly 
regulated genes (Table 6-6 & Table 6-7) included two greatly up-regulated genes, ycnE 
(28-fold) and yacH (10-fold), both of unknown function, which warrant further 
investigation.  Other genes with high fold changes of interest include those relating to 
‘DNA metabolism’, ‘purine, pyrimidine, nucleoside and nucleotide synthesis’, ‘fatty acid 
biosytnhesis and phospholipid metabolism’, which are target areas of antimicrobial 
compounds not yet investigated for BDM-I.  A gene involved in toxin production and toxin 
resistance (‘cellular processes’), yacI (6-fold) would also be of interest given the 
demonstrated inhibition by BDM-I of secreted secondary metabolites (Chapter 4).  A gene, 
fliF, in the function of ‘cellular processes’ and associated with chemotaxis and motility 
was down-regulated 13-fold in response to only 16 µg/mL BDM-I.  This warrants further 
investigation given its connection with cell signalling and possible links to BDM-I activity.  
Also of interest for further work is the 7-fold down-regulation of accC which is involved in 
fatty acid biosynthesis, a current antimicrobial target. 
A gene significant in endospore formation, spoVG was down-regulated 7-fold 
at 2 µg/mL and 17-fold at 16 µg/mL (Table 6-7).  Eymann et al., (2000) have identified 
spoVG as part of the stringent response to amino acid and carbon starvation in B. subtilis.  
SpoVG is a protein inhibitor of sporulation involved in spore cortex formation in the 
stationary phase of sporulation.  Two other genes involved in endospore formation were 
changed at16 µg/mL.  A transcriptional regulator of spore proteins, soj, was up-regulated 
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2-fold and yrbC (spore coat protein synthesis) was up-regulated 3-fold.  Quisel & 
Grossman (Quisel & Grossman, 2000) showed that Soj, a chromosome partitioning protein 
with putative ATPase activity, negatively regulates transcription of spoII genes and of 
spo0A which itself activates transcription of the spoII genes (2004a).  The down-regulation 
of spoVG and the up-regulation of soj in Bacillus spp. will require further investigation to 
reconcile observations in Chapter 3 of a decrease in endospore formation in B. cereus 
treated with BDM-I.  BDM-I may interfere with the complex of signals governing control 
of spore formation. 
Hutter et al. (Bandow et al., 2002) identified 12 functionally annotated marker 
genes suitable for identifying classes of compounds as listed below. 
Gene Mechanism and/or compound class Reference antibiotic 
fabHB, glpD Fatty acid synthesis Cerulenin 
yrzl, expZ Protein synthesis Clindamycin 
ypbG, ytrA, ywoB Cell wall synthesis (glycopeptides) Vancomycin 
dinB, yneA, yorB DNA replication (quinolones) Ciprofloxacin 
ydeK Cell wall synthesis Cycloserine 
yvgS Transcription Rifampicin 
 
None of these genes were differentially regulated by BDM-I in this analysis.  
This suggests that BDM-I does not act on these current major cellular targets for 
antibiotics.  This investigation failed to show an effect of BDM-I on protein or cell wall 
synthesis or DNA transcription.  This supports the liklihood that BDM-I is not acting on a 
cellular mechanism targeted by the above classes of compounds. 
Two genes differentially regulated by both concentrations and identified as 
essential, clpC and clpP (protein fate) are part of the σB-dependent general stress response 
(Table 6-6).  They have been identified as part of B. subtilis response to Rifampin, which 
inhibits DNA-dependent RNA polymerase and therefore RNA synthesis (2001).  A further 
2 genes involved in the general stress responses in B. subtilis , yxjG (σB ) and sucD (ComK 
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competence transcription factor) were among the most down-regulated genes.  The general 
stress response brings about widespread changes in metabolism in anticipation of stress 
and is governed by the σΒ transcription factor.  Price et al. (2002) identified 127 genes in 
B. subtilis as candidates for the σΒ regulon including yxjG (methionine synthase II, 
cobalamine independent).  Competence is a cellular state allowing exogenous DNA to be 
internalised.  The competence transcription factor, ComK, is a regulator of the competence 
response, activating transcription of genes encoding DNA transport proteins.  Berka et al. 
(Berka et al., 2002) identified 165 genes that were up-regulated by ComK, including 28 
annotated as regulators of transcription or translation (Bandow et al., 2002).  This 
investigation found no inhibition by BDM-I of transcription or translation using a cell-free 
protein synthesis assay (Chapter 5).  Com K is repressed by exposure to rifampin, a RNA 
polymerase inhibitor (2002).  Berka et al. (2001) further suggest that the ComK regulon 
defines an adaptation to stress distinct from sporulation which enables the cell to repair 
DNA damage, acquire exogenous genes by transformation and use novel substrates.  Other 
genes identified in the general stress response by Price et al. (Musumeci et al., 2005) 
which were changed by BDM-I 16 µg/mL were the down-regulated yvyD (8-fold) and the 
up-regulated ynfC (6-fold).  Inhibition by BDM-I of genes in the general stress response 
may act to reduce the resistance of B. subtilis to environmental stresses, including the 
acquisition of antibiotic resistance genes. 
B. subtilis stress resistance responses can be tied to phosphatases yfkJ and ywlE 
(Mijakovic et al., 2003; Mijakovic et al., 2005a; Musumeci et al., 2005).  The B. subtilis 
genome shows orthologs for many phosphatases including four identified LMWPTP’s – 
yfkJ, arsC (yqcM), ywqE, ywlE.  These are involved in protein degradation, detoxification, 
adaptations to atypical conditions and general stress responses (Bandow et al., 2003; 
Freiberg et al., 2004a; Gmuender et al., 2001; Goh et al., 2002).  Unfortunately, no 
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annotated phosphatase genes were identified as directly changed by BDM-I from this 
study. 
Not all cellular processes, however, are controlled at the level of gene 
transcription and detected by transcript levels.  Other regulatory mechanisms act at the 
level of mRNA translation.  Post-transcriptional and post-translational modifications such 
as phosphorylation of proteins, will not be detected by mRNA transcript levels.  Proteome-
based expression analysis can be used to detect such changes and will complement 
transcriptional analyses (Freiberg et al., 2004a).  Proteomic studies are notoriously labour 
intensive and focus on a limited set of cytoplasmic proteins with limited molecular weights 
and isoelectric points (2004a).  Proteomic analysis was not attempted in this investigation 
because of difficulties in detecting low abundance phosphorylated proteins and time 
consraints and delayed access to highly used laboratory resources.  Phosphoproteome 
searches using 32P and two-dimensional SDS-PAGE are a challenge in bacteria that 
contain low levels of total phosphotyrosine.  Use of ∆ptp2 (phosphatase deficient strains) 
can help sensitivity in these investigations.  Once a specific phosphatase target is 
suspected, proteomic studies utilising deficient strains would complement genomic studies 
and provide more leads for detailing the MOA of BDM-I. 
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CHAPTER 7 CONCLUSONS AND FUTURE DIRECTIONS 
A new mechanism of action 
The results of this research support the proposal that 3,4-methylenedioxy-β-
nitropropene (BDM-I) acts as a tyrosine mimetic to inhibit bacterial tyrosine phosphatases, 
the nitropropene side-chain being the pharmacophore.  This is a plausible explanation for 
its broad activity against bacteria, fungi and protozoa and for certain species-specific 
effects in bacteria.  The hypothesis is supported indirectly by the studies reported here. It 
has not yet been demonstrated that BDM-I directly inhibits any bacterial PTP’s in target 
microbial cells or that such inhibition is responsible for its antimicrobial effects.  
Protein tyrosine phosphatases as antimicrobial drug targets  
The catalytic site of PTP’s is highly conserved across prokaryotic and 
eukaryotic cells.  It is thus expected that the pharmacophore of a PTP inhibitor would act 
on all PTP’s to varying degrees.  Tyrosine phosphatases and dual specific phosphatases are 
promising drug targets for human therapeutics especially as anti-tumour drugs.  This work 
suggests they are also promising targets for anti-infective drugs.  Microorganisms, 
particularly prokaryotes, are evolutionarily removed from mammals and may have adapted 
phosphatases for different functions, providing selective targets for drug action.  A single 
molecule inhibiting phosphatases can inhibit a family of essential proteins that have 
multiple cellular functions.  Given the multiple mutations that would be required to 
produce a resistant phenotype, it is unlikely that resistance in pathogens will readily 
emerge.   
Evidence in support of the proposal 
BDM-I inhibits both a human and a bacterial PTP in an enzyme assay (Section 
5.4.4).  Park & Pei (2004) have shown how an unsubstituted benzyl nitroethene with a 
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similar pharmacophore interacts at the catalytic site (Section 5.4.1).  The highly conserved 
nature of the catalytic site strongly supports the likelihood that BDM-I would inhibit other 
microbial PTP’s in similar enzyme assays and in whole cells.  No evidence was found to 
support action of BDM-I on an already known bacterial target, although not all were 
investigated in this project. The biological effects of BDM-I, extended in these 
investigations and presented below, were examined for consistency with this hypothesis.   
The cell wall and cytoplasmic membrane of microorganisms are major targets 
for biocides and many therapeutic antimicrobial agents.  BDM-I has been shown by cell 
and enzyme assays and studies on ultramorphology not to degrade or damage the cell 
wall/envelope of bacteria or damage the plasma membrane (Chapter 3).  No ultra-structural 
changes in bacterial or yeast cells were observed by TEM.  The lipopolysaccharide outer 
leaflet of Gram negative bacteria is shown not to be a major contributor to the lack of 
activity against many enteric Gram negative rods (Section 2.3.4). 
The intracellular site of action of BDM-I and its ability to act on intracellular 
pathogens has been extended by demonstration of inhibition of the early stage of the 
replication cycle of Chlamydia trachomatis in mammalian cells.  It is proposed that BDM-
I inhibits binding or endocytosis of the elementary bodies and formation of vacuoles, but 
does not interfere with replication of reticulate bodies.  Host cell tyrosine phosphatases 
have been shown to be involved in chlamydial vacuole formation and a probable 
explanation of BDM-I activity could be inhibition of host PTP’s such as cortactin, a 
phosphotyrosine actin-binding protein associated with vacuole formation (Section 2.5.4). 
BDM-I has been shown to be variably and slowly bactericidal to different 
species.  The killing rate is not affected by the growth rate and is time-dependent rather 
than concentration-dependent.  This differentiates BDM-I from antibiotics targeting 
pathways important to cell replication, namely protein synthesis, cell wall synthesis and 
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DNA replication, which have their greatest effects on growing cells (Section 2.6.4).  BDM-
I also did not show synergistic or antagonistic interaction with antibiotics affecting the 
same pathways, which further supports the inference that the major action of BDM-I lies 
elsewhere (Section 2.7.4).  In a cell-free protein synthesis assay (E. coli), BDM-I inhibited 
neither transcription nor translation of exogenous DNA, supporting other observations that 
it does not affect ribosomal function (Section 5.3.4). 
In contrast, killing of C. albicans was rapid and dose-dependent.  The different 
effects in bacterial and yeast cells can be explained by a difference in the significance of 
PTP’s in bacteria and fungi.  In bacteria, PTP’s have heterogeneous distribution and varied 
functions which, to date, have not been shown to relate to cell growth or replication.  In 
eukaryotes, PTP’s are directly involved in cell growth and the cell cycle and a more 
uniform and direct effect on yeast replication would be expected (Section 2.6.4).  BDM-I 
shows high and uniformly fungicidal activity against all fungi tested to date. 
Thiol-containing compounds were shown to lower BDM-I activity against 
bacteria.  Thiols have been shown to reduce the double bond of the nitropropene side 
chain, the proposed pharmacophore of BDM-I, inactivating its inhibitory effect on PTP’s 
(Section 2.4.4). 
BDM-I is not known to induce or select for resistant phenotypes in vitro in 
species which have readily developed resistance to other agents.  It did produce small 
colony variants in S. aureus but these were not stable (Section 4.2.4).  The failure of BDM-
I to induce resistance is understandable if it acts on a basic and widespread cell signalling 
mechanism. 
Phosphatases in bacteria have been shown to be related to virulence and stress 
survival mechanisms.  Inhibition of virulence factors in addition to inhibition of growth is 
a desirable attribute in an anti-infective drug for inhibiting colonisation or entry and 
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limiting microbial pathology.  This study has shown that BDM-I inhibits the virulence 
mechanism of group swarming motility in Proteus (Section 4.4.4), though it does not 
affect individual cell flagellar motility.  The former has been shown to be affected by QS 
signalling.  Tyrosine phosphatases have not to date been shown to be involved in QS in 
bacterial motility. 
Protein tyrosine phosphatases have been implicated in the production of 
exopolysaccharides in bacteria which are virulence factors for many species.  A 
preliminary investigation of the effect of BDM-I on capsule production by Klebsiella 
showed no obvious reduction of capsule size (Section 4.5.4).  As a more direct measure of 
inhibition, BDM-I will be investigated for effect on colonic acid synthesis in E. coli in 
which PTP’s have been shown to be involved.  BDM-I also inhibited the production of 
prodigiosin, a pigmented antimicrobial secondary metabolite of Serratia (Section 4.3.4).  
Prodigiosins have been shown to inhibit PTP’s in Streptomyces.  Inhibition of a 
homologous PTP could explain the inhibitory effect in Serratia. 
Another stress response and survival mechanism, endospore production, was 
inhibited by BDM-I as noted in TEM ultrastructure studies of B. cereus (Section 3.4.4).  
Down regulation of spoVG and up regulation of soj, two genes involved in endospore 
formation in Bacillus spp. were noted in the DNA microarray analysis (Section 6.4).  
These observations will require further investigation. 
BDM-I appears not to interfere with energy metabolism.  It did not inhibit ATP 
production under conditions promoting oxidative energy metabolism which suggests it 
does not affect either ATP synthase or components of the electron transport system 
(Section 5.2.4).  This is consistent with earlier observations that BDM-I was equally 
effective against a wide range of facultatively anaerobic species under aerobic or anaerobic 
conditions. 
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The pilot whole genome DNA microanalysis has provided several genes of 
interest for further analysis.  No tyrosine phosphatase genes were differentially expressed.  
None of the marker genes identified by Hutter et al.  for identifying inhibitors of cell wall 
synthesis, fatty acid synthesis, protein synthesis or DNA replication, were differentially 
regulated, further supporting the claim that BDM-I has a novel MOA.  Two changed genes 
related to the stress response of endospore production are mentioned above.  A protein 
involved in the general stress response ComK was also implicated by differential 
regulation of sucD.  It has been proposed that this regulates DNA repair and acquisition of 
exogenous genes by transformation.  Inhibition of stress response genes may reduce 
resistance to environmental stresses, including the acquisition of resistance genes. 
Future work 
At present little is known of the role of PTP’s in bacteria.  Identification of 
more endogenous phosphorylated proteins and their functions will clarify the significance 
of tyrosine phosphorylation in bacteria and provide specific targets for direct investigation 
to confirm the action of BDM-I on bacterial PTP’s.  Further genetic and proteomic 
analyses to follow up on highly deregulated genes will be undertaken.  Some specific 
investigations are outlined in the chapter discussions.   
BDM-I as an anti-infective 
BDM-I is microbicidal to many significant bacterial, fungal and protozoal 
pathogens at concentrations sufficiently selectively toxic to be developed as a topical or 
mucosal anti-infective drug for human or animal use.  A phosphatase inhibitor is likely to 
have non-specific effects in eukaryotic, especially mammalian cells, because of overlaps 
with human targets.  However, many clinically successful antibiotics are active against 
targets that are highly conserved but nevertheless show sufficient diversity to be selective 
targets.   BDM-I has several desirable features to support therapeutic use.   
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There is a renewed need for broad spectrum agents.  As drug delivery methods 
improve, localised treatment of mucosal infections becomes a possibility.  This would 
permit the use of broad spectrum agents that may be too toxic when given systemically, 
reserving the use of less toxic drugs for the treatment of serious systemic infections.  Many 
gastro-intestinal and genitourinary infections are treatable at the mucosal surface.  Activity 
against major sexually transmitted pathogens suggests a possible use as a vaginal 
microbicide.  BDM-I is highly active against many bacterial and fungal skin pathogens, 
particularly the dermatophytic fungi, and might be suitable for topical application. 
No strains have developed resistance to BDM-I indicating that it will likely 
induce a low frequency of resistance in microbial populations.  The novel MOA would 
also preclude cross-resistance with currently available drugs.  BDM-I thus has the potential 
for treating pathogenic strains of bacteria, fungi and protozoa without adding to multi-drug 
resistance.  Its likely suppression of virulence mechanisms in pathogens is also a desirable 
attribute. 
BDM-I is amenable to structural modification to improve activity and reduce 
toxicity.  Many analogues have been synthesised and, directed by knowledge of the MOA, 
further analogues are being synthesised. 
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APPENDICES 
Appendix A.  Media and buffers. 
Brucella broth with Campylobacter Growth Supplement 
Suspended 28 g of Brucella broth (#211088, BBL, BD Biosciences, CA, 
USA) dehydrated powder in 1 L of distilled water and mixed thoroughly.  Sterilised by 
autoclaving at 121°C for 15 minutes.  To prepare medium for Campylobacter, added 
Campylobacter Growth Supplement (Oxoid) when cooled to 50°C.  Stored at 2-8°C. 
Difco Synthetic broth AOAC 
Suspended 17 g of Dehydrated powder (#235220, BD Biosciences) in 1 L of 
purified water and mixed thoroughly.  Powder dissolved completely by heating with 
frequent agitation and boiling for 1-2 minutes.  Dispensed into medicine bottles.  
Autoclaved at 121°C for 20 minutes.  Stored at 2-8°C.  Before inoculating, aseptically 
added sterile glucose solution (10%) to a final concentration of 1% . 
Horse blood agar 
Used Columbia agar base (#CM0331, Oxoid, Cambridge, UK).  Added 39 g to 
1 L distilled water.  Boiled to dissolve the medium completely. Sterilised by autoclaving at 
121°C for 15 minutes. Cooled to 50°C and added 5% sterile defibrinated horse blood 
(#SR0050, Oxoid).  Poored into sterile petri dishes and allowed to set.  Stored at 2-8°C. 
Nutrient agar 
Suspended 28 g of dehydrated powder (#CM0003, Oxoid) in 1 litre of distilled 
water. Solution brought to the boil to dissolve completely. Sterilised by autoclaving at 
121°C for 15 minutes. Stored at 2-8°C. 
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Mueller-Hinton broth 
Placed 21.0 g of dehydrated powder (#CM0405, Oxoid) in 1 litre of distilled 
water and mixed to dissolve completely. Sterilised by autoclaving at 121°C for 15 minutes. 
Stored at 2-8°C. 
Performance was monitored regularly using the standard QC organisms S. 
aureus and P. aeruginosa. If the broth did not yield the expected MIC values, the volumes 
of Mg++ and Ca++ solutions were modified until the MIC values approximated those in 
Table 3 in the NCCLS ‘Methods for Dilution Antimicrobial Susceptibility Tests for 
bacteria that grow Aerobically’ (Approved Standard M7-A5, 2000).  
Sabouraud liquid medium 
Dissolved 30 g of dehydrated powder (#CM0147, Oxoid) in 1 litre of distilled 
water. Mixed well and distribute into bottles for sterilisation by autoclaving at 121°C for 
15 minutes. Stored at 2-8°C. 
Yeast nitrogen broth 
Prepared Difco Yeast nitrogen base without amino acids (#291940, BD 
Biosciences)  by dissolving 6.7 g of base, 5 g of glucose and 5-10 mg of the desired amino 
acid in 100 mL of purified water (with warming to dissolve).  Mixed well and filter 
sterilised (0.2 µM).  Stored at 2-8°C. 
YNB (no population growth):  6.7 g of base only in 100 mL prified water. 
YNB (suboptimal growth):  6.7 g YNB base, 10 mg glucose and 1.7 mg Casamino acids 
(#223050, Difco, BD Biosciences, CA, USA). 
YNB (optimal growth):  6.7 g YNB base, 0.5 g glucose and 1.7 g Casamino acids. 
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Luria broth agar (1.5%) 
Combined 10 g/L tryptone (#LP0042, Oxoid), 5 g/L yeast extract (#LP0021, 
Oxoid), 10 g/L NaCl (#LP0005, Oxoid), 1 g/L Glucose (#LP0071, Oxoid), 1 g/L 
MgCl2⋅6H2O (105833, BDH Chemicals) and 15 g/L Agar (#LP0011, Oxoid).  Sterilised by 
autoclaving at 121°C for 15 minutes. 
BDM-I was prepared at 100× test concentrations in 100% DMSO and added at 
a ratio of 1:100 with measured aliquots of molten agar at 50°C.  All plates were poured in a 
laminar flow cabinet and stored at 4°C for no more than 2 weeks before use. 
Immunofluorescence washing buffer 
PBS/Tween (20x) pH 7.4:  Added to 1 L distilled water: 160 g NaCl, 4 g 
KH2PO4, 23 g NaH2PO4⋅2H2O, 4 g KCl and 10 mL Tween 20. 
Maintencence media  
Minimum essential medium with Earle’s balanced salts without glutamine, 500 
mL (11-050-0500v, Trace Scientific, Victoria, AUS); foetal calf serum 10 mL (CSL 
Limited Australia); non-essential amino acids, 100×, 5 mL (21-145-0100v, Trace 
Scientific); L-glutamine, 200 mM (21-125-0100v, Trace Scientific), 5 mL; 40 µg/mL 
vancomycin (Sigma-Aldrich); 50 µg/mL gentamycin (Sigma-Aldrich); 0.5 µg/mL 
cyclohexamide (C7698, Sigma-Aldrich) and 4.5 g/L glucose (#8769, Sigma-Aldrich) 5 
mL. 
Mounting medium 
Combined 5 g potassium iodide, 5 g Iodine, 50 mL distilled water and 50 mL 
glycerol.  Filter through qualitative paper.  Stored away from light and store for up to 3 
months at room temperature. 
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Phosphate Buffered Saline (PBS) 
Dissolved the following in 800 ml MilliQ H2O: 8 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4, 0.24 g KH2PO4.  Adjusted pH to 7.4.  Added MilliQ H2O to 1L.  Sterilized to 
autoclave.  Stored at room temperature. 
Formaldehyde Agarose (FA) gel electrophoresis of total RNA 
FA Gel:  Weighed 1.2 g Agarose (Amresco, Solon, Ohio, USA) and made up to 10 mL 
with 10× FA gel buffer (below).  Added 100 mL of DEPC treated water then heated the 
mixture in a microwave. After cooling to 50°C, add 1.8 mL of 37% formaldehyde.  Mixed 
by swirling before casting on the gel.   
10× FA gel buffer:  200 mM 3-[N-Morpholino]propanesulfonic acid (MOPS) (free acid), 
50 mM sodium acetate, 10 mM EDTA (pH 7.0). 
RNA sample preparation for FA gel electrophoresis:  Add 1 volume of 5× loading 
buffer (below) to 4 volumes of RNA sample (for example 10 µl of loading buffer and 40 µl 
of RNA) and mix.  Incubate for 3–5 min at 65°C, chill on ice and load onto the 
equilibrated FA gel. 
5× RNA loading buffer: 16 µl saturated aqueous bromophenol blue solution, 80 µl 500 
mM EDTA (pH 8.0), 720 µl 37% (12.3 M) formaldehyde, 2 ml 100% glycerol, 3.084 ml 
formamide, 4 ml 10 x FA gel buffer, RNase-free water to 10 mL.  Store approximately 3 
months at 4°C.  
Run at 5-7 V/cm in 1×FA gel running buffer (below).  
1× FA gel running buffer: 100 ml 10× FA gel buffer, 20 ml 37% (12.3 M) formaldehyde, 
880 ml RNase-free water. 
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Transmission electron microscopy 
Stock 0.1 M Cacodylate buffer pH7.4.  (a) 0.2 M Na(CH3)2AsO2.3H2O (42.8 g/L); (b) 
0.2 M HCl (i.e. conc. HCl 36-38% = 10 mL + 603 mL dH2O); 25 mL of A plus 1.4 mL B 
= pH 7.4. 
NaAsO buffer 0.2 M (ProSciTech).  4.3 g / 100 mL ddH2O, pH with 0.2 M HCl.  Mix 1:1 
with water, 2× glutaraldehyde or 2× OsO4.  Add 5 mM CaCl2 to preserve DNA and 
membrane.  Store cacodylate buffer in clearly labelled airtight container in the fume hood 
at all times.  Do not let dry onto glassware. 
Gluteraldehyde. 1% (25% aqueous ampoules, ProSciTech).  Dilute in buffer in 
fumehood.  Store at 4°C 
Osmium tetroxide (2% aqueous, ProSciTech).  Dilute in buffer in fumehood.  Store in 
glass only in an airtight container at 4°C. 
ONE-STEP PROCURE  812 RESIN - medium hardness 
  Volume 1 Volume 2 Volume 3 
PROCURE 812 5 mL 10 mL 20 mL 
DDSA 4 mL 8 mL 16 mL 
NMA 2 mL 4 mL 8 mL 
BDMA 0.3 mL 0.6 mL 1.2 mL 
Total 11.3 mL 22.6 mL 45.2 mL 
 
Uranyl acetate staining.  Make up saturated solution of Uranyl acetate in 50% methanol 
(% mL MeOH + 5 mL DW) (~ 1 small spatula / 20 mL).  Filter before use (discarding first 
few drops).  Recommended to make and filter at least 10 mL, discarding the first 5 mL.  
Place drops on dental wax in petri dish and place 1 grid per drop section side down on top 
of each.  Note: Include in petri dish filter paper saturated in Uranyl acetate to avoid 
precipitation.  Leave (5) – 20 mins at RT.  Rinse by immersing grids through meniscus of 
DW (10× each solution) at least three times.  Blot and allow to air dry before staining with 
lead citrate. 
  
190 
Lead Citrate staining.  Prepare CO2 free water by autoclaving and sealing tightly 
immediately on removal from autoclave.  Make 10 M NaOH in CO2 free water.  Add 1 
small spatula (0.02 g) Lead citrate to 10 mL. CO2-free water.  Add 0.1 mL of 10 M NaOH 
in CO2-free water and seal.  Shake vigorously to dissolve.  Filter before use.  Will keep 
several days. 
CO2-free staining chamber.  Dip filter paper in 0.1 M NaOH and place on wax.  Add few 
NaOH pellets and replace lid.  Quickly place drops of stain on dental wax and immediately 
replace lid.  Add grids, section side down to top of drops and cover quickly.  Stain 30 sec-
10 min.  Rinse in CO2-free water.  Blot & air dry. 
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Appendix B.  Data from samples used for RNA extractions. 
Table B1.  OD and viable count data obtained from treated B. subtilis cultures used 
for Microarray experiments. 
  Time (min) 
  0 30 0.00 30.00 
Treatment sample i.d. CFU/mL OD600nm 
untreated 3a 7.0E+07 2.1E+08 0.305 not determined 
2 µg/mL 3b not determined   not determined 
16 µg/mL 3c not determined   not determined 
untreated 6a 1.4E+08 4.6E+08 0.332 0.294 
2 µg/mL 6b not determined 2.4E+08 0.310 0.305 
16 µg/mL 6c not determined 1.9E+08 0.313 0.227 
untreated 7a 1.6E+07 7.0E+07 0.302 0.525 
2 µg/mL 7b not determined 6.0E+07 0.329 0.523 
16 µg/mL 7c not determined 3.0E+07 0.305 0.351 
Table B2.  Quality data for B. subtilis RNA used for Microarray experiments. 
Treatment sample i.d. OD260nm OD280nm Ratio 
Estimated 
Concentration 
(µg/mL) 
Est. 
Yield 
µg/50uL 
untreated A 0.239 0.139 1.72 956 48 
2 µg/mL B 0.166 0.096 1.73 663 33 
16 µg/mL C 0.202 0.117 1.72 807 40 
untreated A 0.129 0.071 1.82 514 26 
2 µg/mL B 0.228 0.125 1.82 914 46 
16 µg/mL C 0.184 0.099 1.86 736 37 
untreated A 0.135 0.073 1.82 542 27 
2 µg/mL B 0.153 0.084 1.83 610 31 
16 µg/mL C 0.091 0.050 1.81 364 18 
Refer to Supplementary data for accurate Bioanalyser results. 
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Figure B1.  Quality of total RNA isolated from B. subtilis ATCC 6633. 
Each sample (2 µL) was denatured at 65°C for 5 min and run on a formaldehyde agarose gel.  RNA 
from three replicate experiments is shown.  Lanes: i, iv, vii, untreated B. subtilis; ii, v, viii BDM-I 2 
µg/mL; iii, vi, ix, BDM-I 2 µg/mL. 
 i ii iii iv v vi vii viii ix 
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Appendix C.  GCOS settings. 
GCOS 1.0 Expression anlaysis default settings 
Default Parameter Value 
Alpha1 0.04 
Alpha2 0.06 
Tau 0.015 
Gamma1L 0.0025 
Gamma1H 0.0025 
Gamma2L 0.003 
Gamma2H 0.003 
Perturbation 1.1 
Applicable to Genechips with 20 probe pairs/probe set and 28 µm feature size. 
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Appendix D.  GCOS Expression Reports. 
Attribute Value Value Value Value Value Value Value Value Value
Barcode@51102600640053040307401988826295@511 2600640053040307401988826331@511 2600640053040 07401988826310@511 26006400510403 7401988826238@511 2600640051040 07401988826239@511 2600640051040 07401988826243@511 2600640053040307401988826304@511 2600640053040307401988826327@511 2600640053040307401988826301
User Created s9806505 s9806505 s9806505 s9806505 s9806505 s9806505 s9806505 s9806505 s9806505
User Edited s9806505 s9806505 s9806505 s9806505 s9806505 s9806505 s9806505 s9806505 s9806505
Date Created May 04 2007 03:54PM May 04 2007 04:01PMMay 04 2007 04:01PMMay 04 2007 04:02PMMay 04 2007 04:02PMMay 04 2007 04:03PMMay 04 2007 03:55PMMay 04 2007 04:04PMMay 04 2007 04:04PM
Date Edited May 04 2007 03:54PM May 04 2007 04:01PMMay 04 2007 04:01PMMay 04 2007 04:02PMMay 04 2007 04:02PMMay 04 2007 04:03PMMay 04 2007 04:04PMMay 04 2007 04:04PMMay 04 2007 04:04PM
Archived NO NO NO NO NO NO NO NO NO
Chip Type Bsubtilis Bsubtilis Bsubtilis Bsubtilis Bsubtilis Bsubtilis Bsubtilis Bsubtilis Bsubtilis
Assay Type Expression Expression Expression Expression Expression Expression Expression Expression Expression
NormFactor 1 1 1 1 1 1 1 1 1
TGT 150 150 150 150 150 150 150 150 150
ScaleFactor 1.438123 1.845551 0.77579 2.088942 1.643646 1.13954 1.386816 1.640094 1.770404
Alpha1 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04
Alpha2 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06
Tau 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015 0.015
Gamma1H 0.0025 0.0025 0.0025 0.0025 0.0025 0.0025 0.0025 0.0025 0.0025
Gamma1L 0.0025 0.0025 0.0025 0.0025 0.0025 0.0025 0.0025 0.0025 0.0025
Gamma2H 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003
Gamma2L 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003
Perturbation 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1
Algorithm Name ExpressionStat ExpressionStat ExpressionStat ExpressionStat ExpressionStat ExpressionStat ExpressionStat ExpressionStat ExpressionStat
Baseline File
Scale Mask File
Norm Mask File
Probe Mask File
NormMethod User Defined User Defined User Defined User Defined User Defined User Defined User Defined User Defined User Defined
SFMethod All Probe Sets All Probe Sets All Probe Sets All Probe Sets All Probe Sets All Probe Sets All Probe Sets All Probe Sets All Probe Sets
UsersetUsed s9806505_BN_Bsubtilis_def s9806505_BN_Bsubtilis_defs9806505_BN_Bsubtilis_defs9806505_BN_Bsubtilis_defs9806505_BN_Bsubtilis_defs9806505_BN_Bsubtilis_defs9806505_BN_Bsubtilis_defs9806505_BN_Bsubtilis_defs9806505_BN_Bsubtilis_def
Background Avg:170.77,Stdev:4.11,Max:180.1,Min:159.0 
Avg:163.35,Std
ev:4.44,Max:17
4.8,Min:150.6 
Avg:156.60,Std
ev:3.34,Max:16
6.6,Min:147.8 
Avg:108.63,Std
ev:1.98,Max:11
3.1,Min:102.9 
Avg:139.72,Std
ev:5.52,Max:15
4.3,Min:129.5 
Avg:147.73,Std
ev:3.92,Max:15
7.9,Min:138.9 
Avg:113.52,Std
ev:2.27,Max:11
8.2,Min:107.3 
Avg:138.75,Std
ev:3.44,Max:14
6.9,Min:128.6 
Avg:95.95,Stde
v:2.82,Max:103
.2,Min:87.6 
Noise Avg:17.16,Stdev:0.71,Max:19.1,Min:15.2 
Avg:15.81,Stde
v:0.83,Max:19.
8,Min:14.2 
Avg:14.32,Stde
v:0.77,Max:16.
4,Min:12.6 
Avg:9.86,Stdev
:0.39,Max:11.0,
Min:8.6 
Avg:12.67,Stde
v:0.67,Max:15.
0,Min:11.1 
Avg:13.43,Stde
v:0.67,Max:15.
9,Min:11.9 
Avg:10.48,Stde
v:0.49,Max:11.
8,Min:9.4 
Avg:13.68,Stde
v:0.55,Max:15.
0,Min:12.1 
Avg:8.32,Stdev
:0.45,Max:9.5,
Min:6.9 
RawQ 3.31 3.21 3.09 2.52 2.95 2.99 2.51 2.92 2.27
Corner+ Avg:443,Count:32 Avg:408,Count:32
Avg:364,Count:
32
Avg:257,Count:
32
Avg:364,Count:
32
Avg:327,Count:
32
Avg:297,Count:
32
Avg:364,Count:
32
Avg:223,Count:
32
Corner- Avg:15939,Count:32 Avg:16260,Cou
nt:32
Avg:15822,Cou
nt:32
Avg:16400,Cou
nt:32
Avg:15670,Cou
nt:32
Avg:15936,Cou
nt:32
Avg:16937,Cou
nt:32
Avg:15382,Cou
nt:32
Avg:17165,Cou
nt:32
Central- Avg:13853,Count:9 Avg:14085,Cou
nt:9
Avg:14039,Cou
nt:9
Avg:15395,Cou
nt:9
Avg:14649,Cou
nt:9
Avg:14635,Cou
nt:9
Avg:14771,Cou
nt:9
Avg:14317,Cou
nt:9
Avg:15232,Cou
nt:9
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Report Type: Expression Report
Date:          04:05PM 05/04/2007
______________________________________________________________________
Filename: Bs3a.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 3.31
Scale Factor (SF): 1.438
TGT Value: 150
Norm Factor (NF): 1
______________________________________________________________________
Background:
Avg: 170.77Std: 4.11 Min: 159.00Max: 180.10
Noise:
Avg: 17.16 Std: 0.71 Min: 15.20 Max: 19.10
Corner+
Avg: 443 Count: 32
Corner-
Avg: 15939 Count: 32
Central-
Avg: 13853 Count: 9
______________________________________________________________________
The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1450 28.80%
Number Absent: 3459 68.80%
Number Marginal: 121 2.40%
Average Signal (P): 1033.2
Average Signal (A): 33.2
Average Signal (M): 117.8
Average Signal (All): 323.5
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 1137.8 P 1515 P 1373.4 P 1342.05 1.21
AFFX-BIOC 2791.1 P   2167.9 P 2479.5 0.78
AFFX-BIOD 5709.3 P   9224.9 P 7467.09 1.62
AFFX-CRE 19637 P   21663.2 P 20650.12 1.1
AFFX-DAP 163.7 P 562.6 P 263.3 P 329.89 1.61
AFFX-LYS 88.2 A 25.7 A 13.7 A 42.53 0.15
AFFX-PHE 506.8 P 114.4 M 94 A 238.39 0.19
AFFX-THR 123.8 P 136.6 P 113.1 A 124.49 0.91
AFFX-TRP 48 A 74.4 A 15.3 A 45.9 0.32
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Report Type: Expression Report
Date:          04:08PM 05/04/2007
______________________________________________________________________
Filename: Bs3b.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 3.21
Scale Factor (SF): 1.846
TGT Value: 150
Norm Factor (NF): 1
______________________________________________________________________
Background:
Avg: 163.35Std: 4.44 Min: 150.60Max: 174.80
Noise:
Avg: 15.81 Std: 0.83 Min: 14.20 Max: 19.80
Corner+
Avg: 408 Count: 32
Corner-
Avg: 16260 Count: 32
Central-
Avg: 14085 Count: 9
______________________________________________________________________
The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1351 26.90%
Number Absent: 3536 70.30%
Number Marginal: 143 2.80%
Average Signal (P): 1041.5
Average Signal (A): 40.4
Average Signal (M): 140
Average Signal (All): 312.1
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 1320.6 P 1714.9 P 1633.3 P 1556.27 1.24
AFFX-BIOC 3231.3 P   2267.3 P 2749.32 0.7
AFFX-BIOD 6266.8 P   11120.5 P 8693.63 1.77
AFFX-CRE 22780.5 P   26580 P 24680.27 1.17
AFFX-DAP 155.3 P 697.2 P 204.1 P 352.19 1.31
AFFX-LYS 39.7 A 13.6 A 13.4 A 22.24 0.34
AFFX-PHE 420.5 P 69.6 A 57.6 A 182.55 0.14
AFFX-THR 51.1 A 19.7 A 51 A 40.64 1
AFFX-TRP 14.8 A 24 A 10.6 A 16.46 0.72
  
202 
Report Type: Expression Report
Date:          04:08PM 05/04/2007
______________________________________________________________________
Filename: Bs3c.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 3.09
Scale Factor (SF): 0.776
TGT Value: 150
Norm Factor (NF): 1
______________________________________________________________________
Background:
Avg: 156.60Std: 3.34 Min: 147.80Max: 166.60
Noise:
Avg: 14.32 Std: 0.77 Min: 12.60 Max: 16.40
Corner+
Avg: 364 Count: 32
Corner-
Avg: 15822 Count: 32
Central-
Avg: 14039 Count: 9
______________________________________________________________________
The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1936 38.50%
Number Absent: 2944 58.50%
Number Marginal: 150 3.00%
Average Signal (P): 717
Average Signal (A): 16.8
Average Signal (M): 54.3
Average Signal (All): 287.4
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 537.4 P 853.5 P 673.8 P 688.23 1.25
AFFX-BIOC 1391.3 P   1059.2 P 1225.24 0.76
AFFX-BIOD 2584.9 P   4207.7 P 3396.26 1.63
AFFX-CRE 9681.7 P   10827 P 10254.34 1.12
AFFX-DAP 92.8 P 149.8 P 85 P 109.22 0.92
AFFX-LYS 60.1 P 33 P 43.5 A 45.55 0.72
AFFX-PHE 244.6 P 23.3 A 19.6 A 95.86 0.08
AFFX-THR 93.4 P 80.7 P 69.1 A 81.09 0.74
AFFX-TRP 9.6 A 30.3 A 3.8 A 14.59 0.4
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Report Type: Expression Report
Date:          04:08PM 05/04/2007
______________________________________________________________________
Filename: Bs6a.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.52
Scale Factor (SF): 2.089
TGT Value: 150
Norm Factor (NF): 1
______________________________________________________________________
Background:
Avg: 108.63Std: 1.98 Min: 102.90Max: 113.10
Noise:
Avg: 9.86 Std: 0.39 Min: 8.60 Max: 11.00
Corner+
Avg: 257 Count: 32
Corner-
Avg: 16400 Count: 32
Central-
Avg: 15395 Count: 9
______________________________________________________________________
The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1542 30.70%
Number Absent: 3326 66.10%
Number Marginal: 162 3.20%
Average Signal (P): 1002.4
Average Signal (A): 30.9
Average Signal (M): 100.8
Average Signal (All): 331
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 1341.3 P 1655.8 P 1787.9 P 1595 1.33
AFFX-BIOC 3341.4 P   2617.6 P 2979.5 0.78
AFFX-BIOD 7564.1 P   12312.8 P 9938.44 1.63
AFFX-CRE 26828.2 P   29288.9 P 28058.53 1.09
AFFX-DAP 251.6 P 613.9 P 248.2 P 371.25 0.99
AFFX-LYS 41.9 A 41.5 A 13.6 A 32.3 0.32
AFFX-PHE 466 P 87.4 P 88 A 213.78 0.19
AFFX-THR 141.3 P 117.1 P 158.3 A 138.91 1.12
AFFX-TRP 26.3 A 140.6 A 13.7 A 60.21 0.52
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Report Type: Expression Report
Date:          04:08PM 05/04/2007
______________________________________________________________________
Filename: Bs6b.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.95
Scale Factor (SF): 1.644
TGT Value: 150
Norm Factor (NF): 1
______________________________________________________________________
Background:
Avg: 139.72Std: 5.52 Min: 129.50Max: 154.30
Noise:
Avg: 12.67 Std: 0.67 Min: 11.10 Max: 15.00
Corner+
Avg: 364 Count: 32
Corner-
Avg: 15670 Count: 32
Central-
Avg: 14649 Count: 9
______________________________________________________________________
The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1579 31.40%
Number Absent: 3305 65.70%
Number Marginal: 146 2.90%
Average Signal (P): 968.4
Average Signal (A): 28.4
Average Signal (M): 105.4
Average Signal (All): 325.7
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 973.4 P 1366.7 P 1268.4 P 1202.86 1.3
AFFX-BIOC 2497.2 P   1944.2 P 2220.71 0.78
AFFX-BIOD 5425.3 P   9410.9 P 7418.12 1.73
AFFX-CRE 19676.3 P   23286 P 21481.15 1.18
AFFX-DAP 206.7 P 890.4 P 260.5 P 452.55 1.26
AFFX-LYS 66.1 A 52.7 A 29.7 A 49.52 0.45
AFFX-PHE 427.8 P 95.5 P 80.6 A 201.32 0.19
AFFX-THR 86 M 40.9 A 89 A 71.97 1.04
AFFX-TRP 10.3 A 21.4 A 14.4 A 15.35 1.4
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Report Type: Expression Report
Date:          04:09PM 05/04/2007
______________________________________________________________________
Filename: Bs6c.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.99
Scale Factor (SF): 1.14
TGT Value: 150
Norm Factor (NF): 1
______________________________________________________________________
Background:
Avg: 147.73Std: 3.92 Min: 138.90Max: 157.90
Noise:
Avg: 13.43 Std: 0.67 Min: 11.90 Max: 15.90
Corner+
Avg: 327 Count: 32
Corner-
Avg: 15936 Count: 32
Central-
Avg: 14635 Count: 9
______________________________________________________________________
The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1797 35.70%
Number Absent: 3095 61.50%
Number Marginal: 138 2.70%
Average Signal (P): 839.1
Average Signal (A): 21
Average Signal (M): 68.9
Average Signal (All): 314.6
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 572.2 P 926.9 P 950.2 P 816.44 1.66
AFFX-BIOC 1796.4 P   1413.3 P 1604.87 0.79
AFFX-BIOD 3620.2 P   6565.5 P 5092.84 1.81
AFFX-CRE 13393.2 P   16176.4 P 14784.78 1.21
AFFX-DAP 107.8 P 174.3 P 78.4 P 120.17 0.73
AFFX-LYS 37.6 A 35.2 A 20.6 A 31.11 0.55
AFFX-PHE 247.1 P 24.1 A 14 A 95.07 0.06
AFFX-THR 45 A 56.7 P 101.2 A 67.64 2.25
AFFX-TRP 10 A 21.2 A 5.6 A 12.28 0.55
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Report Type: Expression Report
Date:          04:09PM 05/04/2007
______________________________________________________________________
Filename: Bs7a.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.51
Scale Factor (SF): 1.387
TGT Value: 150
Norm Factor (NF): 1
______________________________________________________________________
Background:
Avg: 113.52Std: 2.27 Min: 107.30Max: 118.20
Noise:
Avg: 10.48 Std: 0.49 Min: 9.40 Max: 11.80
Corner+
Avg: 297 Count: 32
Corner-
Avg: 16937 Count: 32
Central-
Avg: 14771 Count: 9
______________________________________________________________________
The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1773 35.20%
Number Absent: 3109 61.80%
Number Marginal: 148 2.90%
Average Signal (P): 857.9
Average Signal (A): 23
Average Signal (M): 74.4
Average Signal (All): 318.8
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 922.5 P 1295.3 P 1180.2 P 1132.68 1.28
AFFX-BIOC 2350.4 P   1842.9 P 2096.68 0.78
AFFX-BIOD 4818.9 P   7815.1 P 6317.02 1.62
AFFX-CRE 17937.9 P   19053 P 18495.43 1.06
AFFX-DAP 218.1 P 620.5 P 277.1 P 371.93 1.27
AFFX-LYS 58 A 30.2 A 23 A 37.06 0.4
AFFX-PHE 507.9 P 87.1 P 85.6 A 226.88 0.17
AFFX-THR 132.8 P 113.5 P 139.3 A 128.54 1.05
AFFX-TRP 53.6 A 155 M 25.6 A 78.09 0.48
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Report Type: Expression Report
Date:          04:09PM 05/04/2007
______________________________________________________________________
Filename: Bs7b.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.92
Scale Factor (SF): 1.64
TGT Value: 150
Norm Factor (NF): 1
______________________________________________________________________
Background:
Avg: 138.75Std: 3.44 Min: 128.60Max: 146.90
Noise:
Avg: 13.68 Std: 0.55 Min: 12.10 Max: 15.00
Corner+
Avg: 364 Count: 32
Corner-
Avg: 15382 Count: 32
Central-
Avg: 14317 Count: 9
______________________________________________________________________
The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1554 30.90%
Number Absent: 3345 66.50%
Number Marginal: 131 2.60%
Average Signal (P): 1037.1
Average Signal (A): 27
Average Signal (M): 97.3
Average Signal (All): 340.9
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 975.6 P 1472.7 P 1570.5 P 1339.61 1.61
AFFX-BIOC 3128.2 P   2139.8 P 2633.99 0.68
AFFX-BIOD 5671.2 P   10303.7 P 7987.44 1.82
AFFX-CRE 21475.5 P   23685.6 P 22580.56 1.1
AFFX-DAP 235.3 P 806.7 P 261.1 P 434.38 1.11
AFFX-LYS 67.3 A 29.6 A 30 A 42.29 0.45
AFFX-PHE 428.8 P 87.2 P 78 A 198.02 0.18
AFFX-THR 78.1 P 71.8 P 83.4 A 77.77 1.07
AFFX-TRP 9.7 A 16.5 A 13.7 A 13.33 1.41
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Report Type: Expression Report
Date:          04:10PM 05/04/2007
______________________________________________________________________
Filename: Bs7c.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.27
Scale Factor (SF): 1.77
TGT Value: 150
Norm Factor (NF): 1
______________________________________________________________________
Background:
Avg: 95.95 Std: 2.82 Min: 87.60 Max: 103.20
Noise:
Avg: 8.32 Std: 0.45 Min: 6.90 Max: 9.50
Corner+
Avg: 223 Count: 32
Corner-
Avg: 17165 Count: 32
Central-
Avg: 15232 Count: 9
______________________________________________________________________
The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1721 34.20%
Number Absent: 3170 63.00%
Number Marginal: 139 2.80%
Average Signal (P): 973.5
Average Signal (A): 22.4
Average Signal (M): 68.7
Average Signal (All): 349.1
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 794.1 P 1455 P 1422.6 P 1223.89 1.79
AFFX-BIOC 2680.1 P   1842.9 P 2261.47 0.69
AFFX-BIOD 4503.5 P   8424.6 P 6464.05 1.87
AFFX-CRE 17314 P   19968.4 P 18641.17 1.15
AFFX-DAP 95.8 P 143.6 P 81.1 P 106.84 0.85
AFFX-LYS 35.9 A 46.7 A 41 A 41.2 1.14
AFFX-PHE 280.6 P 11 A 16.1 A 102.56 0.06
AFFX-THR 39.5 A 33 A 79.2 A 50.57 2.01
AFFX-TRP 4.8 A 17.4 A 6.2 A 9.45 1.28
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Appendix E.  GCOS Comparison Reports. 
Report Type: Comparison Report
Date:          04:37PM 05/04/2007
______________________________________________________________________
Filename: 3a&3b.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 3.21
Scale Factor (SF): 1.846
TGT Value: 150
Norm Factor (NF): 1
Baseline filename: Bs3a.CHP
Gamma1H: 0.0025
Gamma1L: 0.0025
Gamma2H: 0.003
Gamma2L: 0.003
Perturbation: 1.1
Baseline Noise (RawQ): 3.31
Baseline Scale Factor (SF): 1.438123
______________________________________________________________________
mean stdev min max
Background: 163.35 4.44 150.6 174.8
Noise: 15.81 0.83 14.2 19.8
count
Corner+ 408 32
Corner- 16260 32
Central- 14085 9
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The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1351 26.90%
Number Absent: 3536 70.30%
Number Marginal: 143 2.80%
Average Signal (P): 1041.5
Average Signal (A): 40.4
Average Signal (M): 140
Average Signal (All): 312.1
Number Increase: 297 5.90%
Number Decrease: 317 6.30%
Number MIncrease: 11 0.20%
Number MDecrease: 6 0.10%
Number No Change: 4399 87.50%
Number (A/M->P, MI/I) 42 0.80%
Number (P->A/M, MD/D) 55 1.10%
Number (P->P, MI/I) 196 3.90%
Number (P->P, MD/D) 238 4.70%
Number (A/M->A/M, MI/I) 69 1.40%
Number (A/M->A/M, MD/D) 30 0.60%
Number (P->P, NC) 811 16.10%
Number (A/M->A/M, NC) 3375 67.10%
Number Increase:
(0<=SLR<1): 212
(SLR>=1): 96
(SLR>=2): 19
(SLR>=3): 3
(SLR>=4): 1
Number Decrease:
(0>=SLR>-1): 228
(SLR<=-1): 95
(SLR<=-2): 16
(SLR<=-3): 2
(SLR<=-4): 0
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 1320.6 P 1714.9 P 1633.3 P 1556.27 1.24
AFFX-BIOC 3231.3 P   2267.3 P 2749.32 0.7
AFFX-BIOD 6266.8 P   11120.5 P 8693.63 1.77
AFFX-CRE 22780.5 P   26580 P 24680.27 1.17
AFFX-DAP 155.3 P 697.2 P 204.1 P 352.19 1.31
AFFX-LYS 39.7 A 13.6 A 13.4 A 22.24 0.34
AFFX-PHE 420.5 P 69.6 A 57.6 A 182.55 0.14
AFFX-THR 51.1 A 19.7 A 51 A 40.64 1
AFFX-TRP 14.8 A 24 A 10.6 A 16.46 0.72
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Report Type: Comparison Report
Date:          04:43PM 05/04/2007
______________________________________________________________________
Filename: 6a&6b.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.95
Scale Factor (SF): 1.644
TGT Value: 150
Norm Factor (NF): 1
Baseline filename: Bs6a.CHP
Gamma1H: 0.0025
Gamma1L: 0.0025
Gamma2H: 0.003
Gamma2L: 0.003
Perturbation: 1.1
Baseline Noise (RawQ): 2.52
Baseline Scale Factor (SF): 2.088942
______________________________________________________________________
mean stdev min max
Background: 139.72 5.52 129.5 154.3
Noise: 12.67 0.67 11.1 15
count
Corner+ 364 32
Corner- 15670 32
Central- 14649 9
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The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1579 31.40%
Number Absent: 3305 65.70%
Number Marginal: 146 2.90%
Average Signal (P): 968.4
Average Signal (A): 28.4
Average Signal (M): 105.4
Average Signal (All): 325.7
Number Increase: 308 6.10%
Number Decrease: 279 5.50%
Number MIncrease: 8 0.20%
Number MDecrease: 6 0.10%
Number No Change: 4429 88.10%
Number (A/M->P, MI/I) 43 0.90%
Number (P->A/M, MD/D) 40 0.80%
Number (P->P, MI/I) 228 4.50%
Number (P->P, MD/D) 217 4.30%
Number (A/M->A/M, MI/I) 45 0.90%
Number (A/M->A/M, MD/D) 28 0.60%
Number (P->P, NC) 964 19.20%
Number (A/M->A/M, NC) 3245 64.50%
Number Increase:
(0<=SLR<1): 258
(SLR>=1): 57
(SLR>=2): 9
(SLR>=3): 3
(SLR>=4): 1
Number Decrease:
(0>=SLR>-1): 210
(SLR<=-1): 75
(SLR<=-2): 13
(SLR<=-3): 3
(SLR<=-4): 0
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 973.4 P 1366.7 P 1268.4 P 1202.86 1.3
AFFX-BIOC 2497.2 P   1944.2 P 2220.71 0.78
AFFX-BIOD 5425.3 P   9410.9 P 7418.12 1.73
AFFX-CRE 19676.3 P   23286 P 21481.15 1.18
AFFX-DAP 206.7 P 890.4 P 260.5 P 452.55 1.26
AFFX-LYS 66.1 A 52.7 A 29.7 A 49.52 0.45
AFFX-PHE 427.8 P 95.5 P 80.6 A 201.32 0.19
AFFX-THR 86 M 40.9 A 89 A 71.97 1.04
AFFX-TRP 10.3 A 21.4 A 14.4 A 15.35 1.4
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Report Type: Comparison Report
Date:          04:43PM 05/04/2007
______________________________________________________________________
Filename: 7a&7b.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.92
Scale Factor (SF): 1.64
TGT Value: 150
Norm Factor (NF): 1
Baseline filename: Bs7a.CHP
Gamma1H: 0.0025
Gamma1L: 0.0025
Gamma2H: 0.003
Gamma2L: 0.003
Perturbation: 1.1
Baseline Noise (RawQ): 2.51
Baseline Scale Factor (SF): 1.386816
______________________________________________________________________
mean stdev min max
Background: 138.75 3.44 128.6 146.9
Noise: 13.68 0.55 12.1 15
count
Corner+ 364 32
Corner- 15382 32
Central- 14317 9
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The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1554 30.90%
Number Absent: 3345 66.50%
Number Marginal: 131 2.60%
Average Signal (P): 1037.1
Average Signal (A): 27
Average Signal (M): 97.3
Average Signal (All): 340.9
Number Increase: 274 5.40%
Number Decrease: 353 7.00%
Number MIncrease: 19 0.40%
Number MDecrease: 9 0.20%
Number No Change: 4375 87.00%
Number (A/M->P, MI/I) 31 0.60%
Number (P->A/M, MD/D) 56 1.10%
Number (P->P, MI/I) 153 3.00%
Number (P->P, MD/D) 288 5.70%
Number (A/M->A/M, MI/I) 108 2.10%
Number (A/M->A/M, MD/D) 18 0.40%
Number (P->P, NC) 1040 20.70%
Number (A/M->A/M, NC) 3058 60.80%
Number Increase:
(0<=SLR<1): 197
(SLR>=1): 96
(SLR>=2): 10
(SLR>=3): 3
(SLR>=4): 1
Number Decrease:
(0>=SLR>-1): 305
(SLR<=-1): 54
(SLR<=-2): 11
(SLR<=-3): 2
(SLR<=-4): 0
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 975.6 P 1472.7 P 1570.5 P 1339.61 1.61
AFFX-BIOC 3128.2 P   2139.8 P 2633.99 0.68
AFFX-BIOD 5671.2 P   10303.7 P 7987.44 1.82
AFFX-CRE 21475.5 P   23685.6 P 22580.56 1.1
AFFX-DAP 235.3 P 806.7 P 261.1 P 434.38 1.11
AFFX-LYS 67.3 A 29.6 A 30 A 42.29 0.45
AFFX-PHE 428.8 P 87.2 P 78 A 198.02 0.18
AFFX-THR 78.1 P 71.8 P 83.4 A 77.77 1.07
AFFX-TRP 9.7 A 16.5 A 13.7 A 13.33 1.41
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Report Type: Comparison Report
Date:          04:42PM 05/04/2007
______________________________________________________________________
Filename: 3a&3c.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 3.09
Scale Factor (SF): 0.776
TGT Value: 150
Norm Factor (NF): 1
Baseline filename: Bs3a.CHP
Gamma1H: 0.0025
Gamma1L: 0.0025
Gamma2H: 0.003
Gamma2L: 0.003
Perturbation: 1.1
Baseline Noise (RawQ): 3.31
Baseline Scale Factor (SF): 1.438123
______________________________________________________________________
mean stdev min max
Background: 156.6 3.34 147.8 166.6
Noise: 14.32 0.77 12.6 16.4
count
Corner+ 364 32
Corner- 15822 32
Central- 14039 9
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The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1936 38.50%
Number Absent: 2944 58.50%
Number Marginal: 150 3.00%
Average Signal (P): 717
Average Signal (A): 16.8
Average Signal (M): 54.3
Average Signal (All): 287.4
Number Increase: 561 11.20%
Number Decrease: 1171 23.30%
Number MIncrease: 11 0.20%
Number MDecrease: 41 0.80%
Number No Change: 3246 64.50%
Number (A/M->P, MI/I) 184 3.70%
Number (P->A/M, MD/D) 117 2.30%
Number (P->P, MI/I) 372 7.40%
Number (P->P, MD/D) 460 9.10%
Number (A/M->A/M, MI/I) 16 0.30%
Number (A/M->A/M, MD/D) 604 12.00%
Number (P->P, NC) 499 9.90%
Number (A/M->A/M, NC) 2355 46.80%
Number Increase:
(0<=SLR<1): 288
(SLR>=1): 282
(SLR>=2): 108
(SLR>=3): 30
(SLR>=4): 9
Number Decrease:
(0>=SLR>-1): 235
(SLR<=-1): 972
(SLR<=-2): 284
(SLR<=-3): 67
(SLR<=-4): 8
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 537.4 P 853.5 P 673.8 P 688.23 1.25
AFFX-BIOC 1391.3 P   1059.2 P 1225.24 0.76
AFFX-BIOD 2584.9 P   4207.7 P 3396.26 1.63
AFFX-CRE 9681.7 P   10827 P 10254.34 1.12
AFFX-DAP 92.8 P 149.8 P 85 P 109.22 0.92
AFFX-LYS 60.1 P 33 P 43.5 A 45.55 0.72
AFFX-PHE 244.6 P 23.3 A 19.6 A 95.86 0.08
AFFX-THR 93.4 P 80.7 P 69.1 A 81.09 0.74
AFFX-TRP 9.6 A 30.3 A 3.8 A 14.59 0.4
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Report Type: Comparison Report
Date:          04:43PM 05/04/2007
______________________________________________________________________
Filename: 6a&6c.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.99
Scale Factor (SF): 1.14
TGT Value: 150
Norm Factor (NF): 1
Baseline filename: Bs6a.CHP
Gamma1H: 0.0025
Gamma1L: 0.0025
Gamma2H: 0.003
Gamma2L: 0.003
Perturbation: 1.1
Baseline Noise (RawQ): 2.52
Baseline Scale Factor (SF): 2.088942
______________________________________________________________________
mean stdev min max
Background: 147.73 3.92 138.9 157.9
Noise: 13.43 0.67 11.9 15.9
count
Corner+ 327 32
Corner- 15936 32
Central- 14635 9
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The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1797 35.70%
Number Absent: 3095 61.50%
Number Marginal: 138 2.70%
Average Signal (P): 839.1
Average Signal (A): 21
Average Signal (M): 68.9
Average Signal (All): 314.6
Number Increase: 586 11.70%
Number Decrease: 882 17.50%
Number MIncrease: 10 0.20%
Number MDecrease: 18 0.40%
Number No Change: 3534 70.30%
Number (A/M->P, MI/I) 171 3.40%
Number (P->A/M, MD/D) 172 3.40%
Number (P->P, MI/I) 392 7.80%
Number (P->P, MD/D) 457 9.10%
Number (A/M->A/M, MI/I) 33 0.70%
Number (A/M->A/M, MD/D) 268 5.30%
Number (P->P, NC) 493 9.80%
Number (A/M->A/M, NC) 2732 54.30%
Number Increase:
(0<=SLR<1): 296
(SLR>=1): 295
(SLR>=2): 102
(SLR>=3): 29
(SLR>=4): 11
Number Decrease:
(0>=SLR>-1): 258
(SLR<=-1): 640
(SLR<=-2): 227
(SLR<=-3): 48
(SLR<=-4): 4
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 572.2 P 926.9 P 950.2 P 816.44 1.66
AFFX-BIOC 1796.4 P   1413.3 P 1604.87 0.79
AFFX-BIOD 3620.2 P   6565.5 P 5092.84 1.81
AFFX-CRE 13393.2 P   16176.4 P 14784.78 1.21
AFFX-DAP 107.8 P 174.3 P 78.4 P 120.17 0.73
AFFX-LYS 37.6 A 35.2 A 20.6 A 31.11 0.55
AFFX-PHE 247.1 P 24.1 A 14 A 95.07 0.06
AFFX-THR 45 A 56.7 P 101.2 A 67.64 2.25
AFFX-TRP 10 A 21.2 A 5.6 A 12.28 0.55
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Report Type: Comparison Report
Date:          04:43PM 05/04/2007
______________________________________________________________________
Filename: 7a&7c.CHP
Probe Array Type: Bsubtilis
Algorithm: Statistical
Probe Pair Thr: 8
Controls: Antisense
______________________________________________________________________
Alpha1: 0.04
Alpha2: 0.06
Tau: 0.015
Noise (RawQ): 2.27
Scale Factor (SF): 1.77
TGT Value: 150
Norm Factor (NF): 1
Baseline filename: Bs7a.CHP
Gamma1H: 0.0025
Gamma1L: 0.0025
Gamma2H: 0.003
Gamma2L: 0.003
Perturbation: 1.1
Baseline Noise (RawQ): 2.51
Baseline Scale Factor (SF): 1.38681579
______________________________________________________________________
mean stdev min max
Background: 95.95 2.82 87.6 103.2
Noise: 8.32 0.45 6.9 9.5
count
Corner+ 223 32
Corner- 17165 32
Central- 15232 9
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The following data represents probe sets that exceed the probe pair threshold 
and are not called "No Call".
Total Probe Sets: 5030
Number Present: 1721 34.20%
Number Absent: 3170 63.00%
Number Marginal: 139 2.80%
Average Signal (P): 973.5
Average Signal (A): 22.4
Average Signal (M): 68.7
Average Signal (All): 349.1
Number Increase: 538 10.70%
Number Decrease: 924 18.40%
Number MIncrease: 7 0.10%
Number MDecrease: 24 0.50%
Number No Change: 3537 70.30%
Number (A/M->P, MI/I) 117 2.30%
Number (P->A/M, MD/D) 240 4.80%
Number (P->P, MI/I) 398 7.90%
Number (P->P, MD/D) 484 9.60%
Number (A/M->A/M, MI/I) 30 0.60%
Number (A/M->A/M, MD/D) 224 4.50%
Number (P->P, NC) 573 11.40%
Number (A/M->A/M, NC) 2737 54.40%
Number Increase:
(0<=SLR<1): 249
(SLR>=1): 295
(SLR>=2): 103
(SLR>=3): 37
(SLR>=4): 11
Number Decrease:
(0>=SLR>-1): 382
(SLR<=-1): 559
(SLR<=-2): 186
(SLR<=-3): 35
(SLR<=-4): 2
______________________________________________________________________
Spike Controls:
Probe Set Sig(5') Det(5') Sig(M') Det(M') Sig(3') Det(3') Sig(all) Sig(3'/5')
AFFX-BIOB 794.1 P 1455 P 1422.6 P 1223.89 1.79
AFFX-BIOC 2680.1 P   1842.9 P 2261.47 0.69
AFFX-BIOD 4503.5 P   8424.6 P 6464.05 1.87
AFFX-CRE 17314 P   19968.4 P 18641.17 1.15
AFFX-DAP 95.8 P 143.6 P 81.1 P 106.84 0.85
AFFX-LYS 35.9 A 46.7 A 41 A 41.2 1.14
AFFX-PHE 280.6 P 11 A 16.1 A 102.56 0.06
AFFX-THR 39.5 A 33 A 79.2 A 50.57 2.01
AFFX-TRP 4.8 A 17.4 A 6.2 A 9.45 1.28
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Appendix F.  Pie charts of differentially regulated genes common to both 
treatment concentrations. 
a)
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Figure F1.  Functional categories for all differentially regulated genes common to 
both treatment concentrations.  Up-regulated (a) and down-regulated (b). 
Primary annotation of B. subtilis genome from the JCVI CMR database.  Data collected from a 
Genechip® microarray study described in Section 6.2.  Figures in parentheses indicate number of 
changed genes for treated samples in main functional categories. 
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Appendix G.  Pie charts of differentially regulated genes in only one treatment 
concentration. 
34%
22%11%
11%
22% Biosynthesis of cofactors, prosthetic groups and carriers (3)
Protein fate (2)
Amino acid biosynthesis (1)
Purines, pyrimidines, nucleosides and nucleotides (1)
Not found (2)
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Cell envelope (1)
Central intermediary metabolism (1)
Purines, pyrimidines, nucleosides and nucleotides (1)
 
Figure G1.  Differentially regulated genes identified in only 2 µg/mL BDM-I 
treatment.  Up-regulated (a) and Down-regulated (b). 
Primary annotation of B. subtilis genome from the JCVI CMR database.  Data collected from a 
Genechip® microarray study described in Section 6.2.  Figures in parentheses indicate number of 
changed genes for treated samples in main functional categories. 
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Figure G2.  Differentially regulated genes identified in only 16 µg/mL BDM-I 
treatment.  Up-regulated (a) and Down-regulated (b). 
Primary annotation of B. subtilis genome from the JCVI CMR database.  Data collected from a 
Genechip® microarray study described in Section 6.2.  Figures in parentheses indicate number of 
changed genes for treated samples in main functional categories. 
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Appendix H:  Supplementary Tables - Selected differentially regulated genes and their functional categories as described in JCVI 
CMR. 
Table H1.  Genes differentially up-regulated in both treatment concentrations of BDM-I. 
Probe set ID 
Gene 
Symbol 
Fold 
change  
2 µg/mL 
Fold 
change  
16 µg/mL Main role Sub role Common Name 
BG12041/ycnE_at ycnE 28.6 28.2 not found not found not found 
BG10146/yacH_at yacH 5.4 10.1 Unknown function General similar to hypothetical proteins 
BG10148/clpC_at clpC 4.1 6.9 Protein fate Degradation of proteins, & glycopeptides class III stress response-related ATPase 
BG10145/ctsR_at ctsR 4.5 6.2 Regulatory functions DNA interactions transcriptional regulator 
BG11187/yckK_at yckK 3.3 6.6 Transport and binding proteins Amino acids, peptides and amines 
similar to glutamine ABC transporter 
(glutamine-binding protein) 
BG10147/yacI_at yacI 3.6 5.7 
Transport and binding proteins; Cellular 
processes 
Carbohydrates, organic alcohols and acids; 
Toxin production and resistance 
similar to creatine kinase 
BG11186/yckJ_at yckJ 2.1 6.7 Transport and binding proteins Amino acids, peptides and amines similar to glutamine ABC transporter 
BG12583/dnaE_3_at dnaE 2.7 5.5 DNA metabolism DNA replication, recombination & repair dna polymerase iii alpha subunit 
BG12583/dnaE_2_at dnaE 2.2 5.0 DNA metabolism DNA replication, recombination & repair dna polymerase iii alpha subunit 
BG19016/clpP_at clpP 4.3 3.3 Protein fate Degradation of proteins, & glycopeptides ATP-dependent Clp protease, subunit 
BG12398/trxB_at trxB 2.8 4.3 Energy metabolism Electron transport thioredoxin reductase 
BG13776/yraA_at yraA 2.7 3.8 Purines, pyrimidines, nucleosides & nucleotides Pyrimidine ribonucleotide biosynthesis similar to hypothetical proteins 
BG14144/yvrD_at yvrD 2.8 3.4 Fatty acid & phospholipid metabolism Biosynthesis similar to ketoacyl-carrier protein reductase 
BG13023/yhdQ_at yhdQ 2.5 3.7 Regulatory functions DNA interactions similar to transcriptional regulator (MerR) 
BG13559/yojG_at yojG 2.7 3.0 not found not found not found 
BG12364/yugJ_at yugJ 3.2 2.4 
Energy metabolism; Central intermediary 
metabolism 
Electron transport;  Fermentation; 
Glycolysis/gluconeogenesis; TCA cycle 
similar to NADH-dependent butanol 
dehydrogenase 
BG13434/ymzA_at ymzA 2.1 3.2 not found not found not found 
BG13022/yhdP_at yhdP 2.0 2.9 Cellular processes Other similar to hemolysin 
BG10348/trxA_at trxA 2.1 2.5 Energy metabolism Electron transport thioredoxin 
BG11671/yqfY_at yqfY 2.0 2.0 Biosynthesis of cofactors, prosthetic groups,  Other similar to peptidoglycan acetylation 
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Table H2.  Genes differentially down-regulated in both treatment concentrations of BDM-I. 
Probe set ID Gene Symbol 
Fold change  
2 µg/mL 
Fold change  
16 µg/mL Main role Sub role Common Name 
BG10112/spoVG_at spoVG 6.9 17.4 Cellular processes Other required for spore cortex synthesis (stage V) 
BG13246/yknZ_at yknZ 2.2 6.3 not found not found not found 
BG10272/odhA_1_at odhA 2.1 6.2 Energy metabolism TCA cycle 2-oxoglutarate dehydrogenase (E1 subunit) 
BG11156/yxjG_at yxjG 2.2 5.8 not found not found not found 
BG12681/sucD_at sucD 3.2 3.7 Energy metabolism TCA cycle succinyl-CoA synthetase (alpha subunit) 
BG13416/ymaH_at ymaH 2.5 4.7 Regulatory functions Other similar to host factor-1 protein 
BG11570/ybbI_at ybbI 2.1 3.8 Unknown function General similar to hypothetical proteins 
BG10673/ilvA_at ilvA 2.2 3.5 Amino acid biosynthesis Other threonine dehydratase 
BG10722/rocD_at rocD 2.1 2.9 Energy metabolism Amino acids & amines acetylornithine aminotransferase 
BG10353/sdhB_at sdhB 2.3 2.7 Energy metabolism TCA cycle succinate dehydrogenase (iron-sulfur protein) 
BG10478/citB_1_at citB 2.2 2.5 Energy metabolism TCA cycle aconitate hydratase 
not found, Not found in the JCVI Primary annotation database 
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Table H3.  Genes differentially up-regulated by 2 µg/mL BDM-I only. 
Probe set ID 
Gene 
Symbol 
Fold 
change  
2 µg/mL 
Fold change  
16 µg/mL Main role Sub role 
BG10520/ribA_at ribA 2.5 Amino acid biosynthesis Histidine family GTP cyclohydrolase II and 3,4-dihydroxy-2-butanone 4-
phosphate synthase 
BG10520/ribA_at ribA 2.5 Biosynthesis of cofactors, prosthetic groups and carriers Folic acid; Riboflavin, FMN and FAD; 
Molybdopterin 
GTP cyclohydrolase II and 3,4-dihydroxy-2-butanone 4-
phosphate synthase 
BG10519/ribB_at ribB 3.4 Biosynthesis of cofactors, prosthetic groups and carriers Riboflavin, FMN and FAD riboflavin synthase (alpha subunit) 
BG10521/ribH_at ribH 2.3 Biosynthesis of cofactors, prosthetic groups and carriers Riboflavin, FMN and FAD riboflavin synthase (beta subunit) 
BG10522/ribT_at ribT 2.1 not found not found not found 
BG10517/ypuE_i_at ypuE 2.3 not found not found not found 
BG10664/dnaK_at dnaK 2.2 Protein fate Protein folding and stabilization class I heat-shock protein (chaperonin) 
BG10663/grpE_at grpE 2.2 Protein fate Protein folding and stabilization heat-shock protein 
BG11426/ymaA_at ymaA 2.0 Purines, pyrimidines, nucleosides and nucleotides 2'-Deoxyribonucleotide metabolism similar to ribonucleoprotein 
not found, Not found in the JCVI Primary annotation database 
 
Table H4.  Genes differentially down-regulated by 2 µg/mL BDM-I only. 
Probe set ID 
Gene 
Symbol 
Fold 
change  
2 µg/mL  
Fold change  
16 µg/mL Main role Sub role 
BG10460/hom_at hom 2.1 Amino acid biosynthesis Other homoserine dehydrogenase 
BG10797/wapA_3_at wapA 2.1 Cell envelope Other cell wall-associated protein precursor (CWBP200, 105, 62) 
BG13379/ylnC_at ylnC 2.8 Central intermediary metabolism Sulfur metabolism similar to adenylylsulfate kinase 
BG10822/atpC_at atpC 2.1 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit epsilon) 
BG12001/lctP_at lctP 2.2 Energy metabolism Glycolysis/gluconeogenesis L-lactate permease 
BG10718/pyrD_at pyrD 2.4 Purines, pyrimidines, nucleosides and nucleotides Pyrimidine ribonucleotide biosynthesis dihydroorotate dehydrogenase 
not found, Not found in the JCVI Primary annotation database 
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Table H5.  Genes differentially up-regulated by 16 µg/mL BDM-I only. 
Probe set ID 
Gene 
Symbol 
Fold 
change  
2 µg/mL  
Fold change  
16 µg/mL Main role Sub role 
BG10864/mrgA_at mrgA 18.5 not found not found not found 
BG12034/yclN_at yclN 12.3 Transport and binding proteins Other similar to ferrichrome ABC transporter (permease) 
BG12863/yetG_at yetG 9.6 not found not found not found 
BG14055/yuzF_at yuzF 9.2 not found not found not found 
BG12291/yrhB_at yrhB 7.9 Amino acid biosynthesis Other similar to cystathionine gamma-synthase 
BG14107/yvgY_at yvgY 7.8 Transport and binding proteins Other similar to mercuric transport protein 
BG14108/yvgZ_at yvgZ 6.5 not found not found not found 
BG11828/ynfC_at ynfC 6.4 not found not found not found 
BG14098/yvgP_at yvgP 6.3 Transport and binding proteins Cations and iron carrying compounds similar to hypothetical proteins 
BG12325/yshA_at yshA 5.5 not found not found not found 
BG12878/yfhC_at yfhC 5.1 not found not found not found 
BG10133/yacB_at yacB 5.1 not found not found not found 
BG10680/mecA_at mecA 5.0 Cellular processes DNA transformation negative regulator of competence 
BG12612/lmrA_at lmrA 5.0 Regulatory functions DNA interactions transcriptional regulator 
BG13800/yrrU_at yrrU 4.9 Purines, pyrimidines, nucleosides 
and nucleotides; Unknown function 
Salvage of nucleosides and nucleotides, Other, 
General 
similar to purine nucleoside phosphorylase 
BG13816/yrzF_at yrzF 4.9 not found not found not found 
BG10829/ylxM_at ylxM 4.7 not found not found not found 
BG12495/ywoH_at ywoH 4.6 Regulatory functions DNA interactions similar to transcriptional regulator (MarR family) 
BG11067/ybxA_at ybxA 4.1 Transport and binding proteins Other alternate gene name: ybaD similar to ABC 
BG13138/yjbI_at yjbI 4.1 not found not found not found 
BG12223/ygaC_at ygaC 4.1 not found not found not found 
BG12370/yugP_at yugP 4.0 not found not found not found 
BG13832/ytcF_at ytcF 3.9 Central intermediary metabolism Polyamine biosynthesis unknown 
BG10830/ffh_at ffh 3.7 Protein fate Protein and peptide secretion and trafficking signal recognition particle 
BG13314/ykvL_at ykvL 3.7 Biosynthesis of cofactors, prosthetic 
groups and carriers 
Other similar to coenzyme PQQ synthesis 
BG13379/ylnC_at ylnC 3.6 Central intermediary metabolism Sulfur metabolism similar to adenylylsulfate kinase 
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BG13312/ykvJ_at ykvJ 3.6 Unknown function General similar to hypothetical proteins 
BG11971/rplT_at rplT 3.6 Protein synthesis Ribosomal proteins: synthesis and modification ribosomal protein L20 
BG11638/yqeJ_at yqeJ 3.6 Biosynthesis of cofactors, prosthetic 
groups and carriers 
Pyridine nucleotides similar to hypothetical proteins 
BG10060/thdF_at thdF 3.5 Protein synthesis tRNA and rRNA base modification thiophen and furan oxidation 
BG10662/hrcA_at hrcA 3.5 Regulatory functions DNA interactions transcriptional regulator 
BG13787/yrrA_at yrrA 3.4 Protein synthesis tRNA and rRNA base modification similar to hypothetical proteins 
BG12535/ywtD_at ywtD 3.4 Cell envelope Biosynthesis and degradation of murein 
sacculus and peptidoglycan 
similar to murein hydrolase 
BG14160/yvzD_at yvzD 3.4 not found not found not found 
BG14111/yvjD_at yvjD 3.3 not found not found not found 
BG10134/yacC_at yacC 3.3 Protein fate Protein folding and stabilization similar to hypothetical proteins 
BG12399/yvcI_at yvcI 3.3 DNA metabolism DNA replication, recombination and repair similar to mutator MutT protein 
BG13137/yjbH_at yjbH 3.2 not found not found not found 
BG13767/ypzE_at ypzE 3.2 not found not found not found 
BG10399/flgM_at flgM 3.2 Cellular processes Chemotaxis and motility anti-sigma factor repressor of sigma-D-dependent transcription 
BG10399/flgM_at flgM 3.2 Regulatory functions DNA interactions anti-sigma factor repressor of sigma-D-dependent transcription 
BG10501/csbA_at csbA 3.2 Cellular processes Other putative membrane protein 
BG11637/yqeI_at yqeI 3.1 not found not found not found 
BG11989/ybaE_at ybaE 3.1 Transport and binding proteins Other similar to ABC transporter (ATP-binding protein) 
BG13866/ytjB_at ytjB 3.1 Cellular processes Other unknown 
BG13783/yrbC_at yrbC 3.1 not found not found not found 
BG11992/truA_at truA 3.0 Protein synthesis tRNA and rRNA base modification pseudouridylate synthase I 
BG10786/sspA_at sspA 3.0 Cellular processes Adaptations to atypical conditions small acid-soluble spore protein (alpha-type SASP) 
BG11573/sigW_at sigW 3.0 DNA metabolism DNA replication, recombination and repair RNA polymerase ECF-type sigma factor (sigma-W) 
BG11573/sigW_at sigW 3.0 Transcription DNA-dependent RNA polymerase, Other RNA polymerase ECF-type sigma factor (sigma-W) 
BG10861/mcpA_at mcpA 2.9 Cellular processes Chemotaxis and motility methyl-accepting chemotaxis protein 
BG11202/ykyB_at ykyB 2.9 not found not found not found 
BG10103/yabE_at yabE 2.9 not found not found not found 
BG12083/ydbP_at ydbP 2.9 Energy metabolism ATP-proton motive force interconversion similar to thioredoxin 
BG11574/ybbM_at ybbM 2.8 not found not found not found 
BG10150/yacK_at yacK 2.8 not found not found not found 
BG12656/polA_at polA 2.8 DNA metabolism DNA replication, recombination and repair DNA polymerase I 
BG10589/ywcG_at ywcG 2.8 not found not found not found 
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BG11220/rplJ_at rplJ 2.8 Protein synthesis Ribosomal proteins: synthesis and modification ribosomal protein L10 (BL5) 
BG12632/nifZ_at nifZ 2.8 Cellular processes Other NifS protein homolog 
BG12957/yfmF_at yfmF 2.7 Transport and binding proteins Other similar to ferrichrome ABC transporter (ATP-binding protein) 
BG13467/ynzD_at ynzD 2.6 not found not found not found 
BG11635/yqeG_at yqeG 2.6 not found not found not found 
BG11012/pssA_at pssA 2.6 Fatty acid and phospholipid 
metabolism 
Biosynthesis phosphatidylserine synthase 
BG10130/yacA_at yacA 2.6 Cellular processes Cell division similar to cell-cycle protein 
BG10151/yacL_at yacL 2.6 not found not found not found 
BG11562/ybaR_at ybaR 2.6 Protein fate Degradation of proteins, peptides and 
glycopeptides 
similar to hypothetical proteins 
BG11562/ybaR_at ybaR 2.6 Transport and binding proteins Cations and iron carrying compounds similar to hypothetical proteins 
BG11337/phoH_at phoH 2.6 not found not found not found 
BG11766/yqkL_at yqkL 2.6 Regulatory functions Other similar to transcriptional regulator (Fur family) 
BG11522/aroD_at aroD 2.6 Amino acid biosynthesis Aromatic amino acid family shikimate 5-dehydrogenase 
BG10942/ywlF_at ywlF 2.5 Energy metabolism Pentose phosphate pathway alternate gene name: ipc-32d similar to ribose 
BG10654/csrA_at csrA 2.5 Energy metabolism Glycolysis/gluconeogenesis carbon storage regulator 
BG10654/csrA_at csrA 2.5 Regulatory functions RNA interactions; Other carbon storage regulator 
BG11434/ypbH_at ypbH 2.5 Cellular processes DNA transformation similar to negative regulation of competence MecA 
BG10699/degR_at degR 2.5 Regulatory functions Other activation of degradative enzymes (aprE, nprE, sacB) 
BG12842/yerP_2_at yerP 2.5 Cellular processes Detoxification similar to acriflavin resistance protein 
BG10097/yabA_at yabA 2.5 not found not found not found 
BG12205/ydiH_at ydiH 2.5 DNA metabolism DNA replication, recombination and repair unknown 
BG10149/sms_at sms 2.5 DNA metabolism DNA replication, recombination and repair DNA repair protein homolog 
BG11447/yppF_at yppF 2.5 not found not found not found 
BG12332/ysmB_at ysmB 2.4 Regulatory functions DNA interactions similar to transcriptional regulator (MarR family) 
BG14045/yutI_at yutI 2.4 Cellular processes Other similar to NifU protein homolog 
BG12451/yviF_at yviF 2.4 Cell envelope Other similar to hypothetical proteins from B. subtilis 
BG10678/lexA_at lexA 2.4 DNA metabolism DNA replication, recombination and repair transcriptional regulator 
BG10678/lexA_at lexA 2.4 Regulatory functions DNA interactions transcriptional regulator 
BG12745/ybfQ_at ybfQ 2.3 not found not found not found 
BG13377/ylnA_at ylnA 2.3 Transport and binding proteins Amino acids, peptides and amines similar to anion permease 
BG12666/rnh_at rnh 2.3 Transcription Degradation of RNA ribonuclease H 
BG10059/gidA_at gidA 2.3 Unknown function General glucose-inhibited division protein 
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BG12656/polA_1_at polA 2.3 DNA metabolism DNA replication, recombination and repair DNA polymerase I 
BG12204/ydiG_at ydiG 2.3 Biosynthesis of cofactors, prosthetic 
groups and carriers 
Molybdopterin similar to molybdopterin precursor biosynthesis 
BG10096/yaaT_at yaaT 2.3 Protein fate Degradation of proteins, peptides and 
glycopeptides 
similar to signal peptidase II 
BG10688/motA_at motA 2.2 Cellular processes Chemotaxis and motility motility protein A 
BG10104/yabF_at yabF 2.2 Unknown function General similar to hypothetical proteins 
BG12403/crh_at crh 2.2 Energy metabolism Other catabolite repression HPr-like protein 
BG12227/ygaG_at ygaG 2.2 Energy metabolism Sugars similar to transcriptional regulator (Fur family) 
BG10334/ysxB_at ysxB 2.2 not found not found not found 
BG11022/ypmR_at ypmR 2.2 not found not found not found 
BG11970/rplM_at rplM 2.2 Protein synthesis Ribosomal proteins: synthesis and modification ribosomal protein L13 
BG10372/rpsD_at rpsD 2.2 Protein synthesis Ribosomal proteins: synthesis and modification ribosomal protein S4 (BS4) 
BG11645/yqeU_at yqeU 2.1 not found not found not found 
BG12969/yfmR_at yfmR 2.1 Transport and binding proteins Other similar to ABC transporter (ATP-binding protein) 
BG13929/ytvB_at ytvB 2.1 not found not found not found 
BG11371/opuAB_at opuAB 2.1 Transport and binding proteins Amino acids, peptides and amines; Cations and 
iron carrying compounds; Unknown substrate 
glycine betaine ABC transporter (permease) 
BG11716/yqiG_at yqiG 2.1 Energy metabolism Aerobic; Electron transport similar to NADH-dependent flavin oxidoreductase 
BG13827/ytbJ_at ytbJ 2.1 Biosynthesis of cofactors, prosthetic 
groups and carriers 
Thiamine similar to hypothetical proteins 
BG10951/ygxA_at ygxA 2.1 not found not found not found 
BG12656/polA_2_at polA 2.1 DNA metabolism DNA replication, recombination and repair DNA polymerase I 
BG11641/yqeM_at yqeM 2.0 not found not found not found 
BG12920/yfkC_at yfkC 2.0 not found not found not found 
not found, Not found in the JCVI Primary annotation database 
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Table H6.  Genes differentially down-regulated by 16 µg/mL BDM-I only. 
Probe set ID 
Gene 
Symbol 
Fold 
change  
2 µg/mL  
Fold change  
16 µg/mL Main role Sub role 
BG10240/fliF_at fliF 13.2 Cellular processes Chemotaxis and motility flagellar basal-body M-ring protein 
BG19003/lctE_at lctE 13.0 Energy metabolism Aerobic, Glycolysis/gluconeogenesis L-lactate dehydrogenase 
BG10706/purQ_at purQ 11.7 Purines, pyrimidines, 
nucleosides and nucleotides 
Purine ribonucleotide biosynthesis phosphoribosylformylglycinamidine synthetase I 
BG10704/yexA_at yexA 10.7 not found not found not found 
BG11062/pgk_at pgk 10.6 Energy metabolism Glycolysis/gluconeogenesis phosphoglycerate kinase 
BG14170/yxzG_at yxzG 10.2 not found not found not found 
BG12605/hisS_at hisS 10.0 Protein synthesis tRNA aminoacylation histidyl-tRNA synthetase 
BG12838/yerL_at yerL 9.7 Protein synthesis tRNA aminoacylation alternate gene name: yedA similar to hypothetical 
BG12660/pycA_3_at pycA 8.4 Energy metabolism Glycolysis/gluconeogenesis pyruvate carboxylase 
BG10740/yvyD_at yvyD 7.9 Protein synthesis Translation factors alternate gene name: yviI similar to ribosomal 
BG11846/wprA_at wprA 7.9 Cell envelope Other cell wall-associated protein precursor (CWBP23, CWBP52) 
BG10276/hbs_at hbs 7.8 DNA metabolism DNA replication, recombination and repair; 
Chromosome-associated proteins 
non-specific DNA-binding protein HBsu 
BG10707/purF_at purF 7.5 Purines, pyrimidines, 
nucleosides and nucleotides 
Purine ribonucleotide biosynthesis phosphoribosylpyrophosphate amidotransferase 
BG13785/yrbF_at yrbF 7.3 Protein fate Protein and peptide secretion and trafficking similar to hypothetical proteins 
BG11384/accC_at accC 7.1 Fatty acid and phospholipid 
metabolism 
Biosynthesis acetyl-CoA carboxylase subunit (biotin carboxylase subunit) 
BG10897/tpi_at tpi 7.1 Energy metabolism Glycolysis/gluconeogenesis triose phosphate isomerase 
BG11023/yvcE_at yvcE 6.9 Cell envelope Biosynthesis and degradation of murein 
sacculus and peptidoglycan 
alternate gene name: yzkA similar to cell 
BG11846/wprA_1_at wprA 6.9 Cell envelope Other cell wall-associated protein precursor (CWBP23, CWBP52) 
BG10703/purC_at purC 6.6 Purines, pyrimidines, 
nucleosides and nucleotides 
Purine ribonucleotide biosynthesis phosphoribosylaminoimidazole succinocarboxamide synthetase 
BG12572/aspS_at aspS 6.6 Protein synthesis tRNA aminoacylation aspartyl-tRNA synthetase 
BG13245/yknY_at yknY 6.6 Transport and binding 
proteins 
Other similar to ABC transporter (ATP-binding protein) 
BG11247/tkt_at tkt 6.5 Energy metabolism Pentose phosphate pathway transketolase 
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BG11135/yxiF_at yxiF 6.3 not found not found not found 
BG10705/purL_at purL 6.2 Purines, pyrimidines, 
nucleosides and nucleotides 
Other phosphoribosylformylglycinamidine synthetase II 
BG11816/yktA_at yktA 6.2 not found not found not found 
BG11460/efp_at efp 6.1 Protein synthesis Translation factors elongation factor P 
BG13236/ykgB_at ykgB 6.1 not found not found not found 
BG10815/atpB_at atpB 6.0 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit a) 
BG13395/yloU_at yloU 6.0 Cellular processes Adaptations to atypical conditions similar to alkaline-shock protein 
BG10816/atpE_at atpE 6.0 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit c) 
BG10622/rocA_at rocA 5.8 Energy metabolism Amino acids and amines pyrroline-5 carboxylate dehydrogenase 
BG11138/yxiI_at yxiI 5.6 not found not found not found 
BG10817/atpF_at atpF 5.5 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit b) 
BG13392/yloQ_at yloQ 5.5 not found not found not found 
BG12839/yerM_at yerM 5.5 Protein synthesis tRNA aminoacylation alternate gene name: yedB similar to amidase 
BG11709/yqhY_at yqhY 5.5 not found not found not found 
BG13152/yjbW_at yjbW 5.3 Fatty acid and phospholipid 
metabolism 
Biosynthesis similar to enoyl- acyl-carrier protein reductase 
BG10241/fliG_at fliG 5.3 Cellular processes Chemotaxis and motility flagellar motor switch protein 
BG12366/pgi_at pgi 5.3 Energy metabolism Glycolysis/gluconeogenesis glucose-6-phosphate isomerase 
BG13934/ytwP_at ytwP 5.1 Energy metabolism Sugars unknown 
BG11708/yqhT_at yqhT 5.0 Protein fate Degradation of proteins, peptides and 
glycopeptides 
similar to Xaa-Pro dipeptidase 
BG11080/pbuX_at pbuX 4.8 not found not found not found 
BG14161/ywiB_at ywiB 4.8 not found not found not found 
BG10231/ftsA_at ftsA 4.8 Cellular processes Cell division cell-division protein 
BG10402/gtaB_at gtaB 4.6 Cell envelope Biosynthesis and degradation of surface 
polysaccharides and lipopolysaccharides 
UTP-glucose-1-phosphate uridylyltransferase 
BG11707/yqhS_at yqhS 4.6 Amino acid biosynthesis Aromatic amino acid family similar to 3-dehydroquinate dehydratase 
BG10702/purB_at purB 4.6 Purines, pyrimidines, 
nucleosides and nucleotides 
Purine ribonucleotide biosynthesis adenylosuccinate lyase 
BG11738/yqjI_at yqjI 4.5 Energy metabolism Pentose phosphate pathway similar to 6-phosphogluconate dehydrogenase (pentose phosphate) 
BG10711/purD_at purD 4.5 Purines, pyrimidines, 
nucleosides and nucleotides 
Purine ribonucleotide biosynthesis phosphoribosylglycinamide synthetase 
BG11005/ypfD_at ypfD 4.5 Protein synthesis Ribosomal proteins: synthesis and 
modification 
alternate gene name: jofD similar to ribosomal 
  
233
 
BG11502/ypmB_at ypmB 4.4 not found not found not found 
BG13403/ylqD_at ylqD 4.3 not found not found not found 
BG10989/kinC_at kinC 4.3 Regulatory functions Protein interactions two-component sensor histidine kinase 
BG12584/dps_at dps 4.3 Cellular processes Adaptations to atypical conditions alternate gene name: ytkB stress- and starvation-induced 
BG10898/pgm_at pgm 4.2 Energy metabolism Glycolysis/gluconeogenesis phosphoglycerate mutase 
BG10797/wapA_2_at wapA 4.2 Cell envelope Other cell wall-associated protein precursor (CWBP200, 105, 62) 
BG10281/gerCC_at gerCC 4.1 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Other heptaprenyl diphosphate synthase component II 
BG10856/citC_at citC 4.1 Energy metabolism TCA cycle isocitrate dehydrogenase 
BG10818/atpH_at atpH 4.1 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit delta) 
BG10282/ndk_at ndk 4.0 Purines, pyrimidines, 
nucleosides and nucleotides 
Other nucleoside diphosphate kinase 
BG10230/sbp_at sbp 3.9 not found not found not found 
BG10437/bglC_at bglC 3.9 Energy metabolism Other endo-1,4-beta-glucanase 
BG11141/yxiL_at yxiL 3.9 not found not found not found 
BG13801/yrvB_at yrvB 3.9 not found not found not found 
BG11137/yxiH_at yxiH 3.9 not found not found not found 
BG13215/yjoA_at yjoA 3.9 not found not found not found 
BG10948/glmS_at glmS 3.9 Central intermediary 
metabolism 
Amino sugars L-glutamine-D-fructose-6-phosphate amidotransferase 
BG10797/wapA_1_at wapA 3.9 Cell envelope Other cell wall-associated protein precursor (CWBP200, 105, 62) 
BG10239/fliE_at fliE 3.8 Cellular processes Chemotaxis and motility flagellar hook-basal body protein 
BG11739/yqjJ_at yqjJ 3.8 Energy metabolism Pentose phosphate pathway similar to glucose-6-phosphate 1-dehydrogenase (pentose 
phosphate) 
BG10874/pheS_at pheS 3.8 Protein synthesis tRNA aminoacylation phenylalanyl-tRNA synthetase (alpha subunit) 
BG10255/cheB_at cheB 3.8 Regulatory functions DNA interactions methyl-accepting chemotaxis proteins (MCP)-glutamate 
methylesterase and two-component 
BG10990/ykqA_at ykqA 3.7 not found not found not found 
BG14150/yvrM_at yvrM 3.7 not found not found not found 
BG13054/yhfI_at yhfI 3.6 Unknown function Enzymes of unknown specificity similar to hypothetical proteins 
BG10797/wapA_4_at wapA 3.6 Cell envelope Other cell wall-associated protein precursor (CWBP200, 105, 62) 
BG10468/ald_at ald 3.6 Energy metabolism Amino acids and amines L-alanine dehydrogenase 
BG10469/yuxI_at yuxI 3.5 Transcription Transcription factors alternate gene name: yukI 
BG11386/citH_at citH 3.5 Transport and binding 
proteins 
Other malate dehydrogenase 
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BG10797/wapA_at wapA 3.5 Cell envelope Other cell wall-associated protein precursor (CWBP200, 105, 62) 
BG10402/gtaB_g_at gtaB 3.5 Cell envelope Biosynthesis and degradation of surface 
polysaccharides and lipopolysaccharides 
UTP-glucose-1-phosphate uridylyltransferase 
BG10819/atpA_at atpA 3.4 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit alpha) 
BG13970/yuiE_at yuiE 3.4 Protein fate Degradation of proteins, peptides and 
glycopeptides 
similar to leucyl aminopeptidase 
BG14152/yvrP_at yvrP 3.4 Transport and binding 
proteins 
Other similar to hypothetical proteins from B. subtilis 
BG13244/yknX_at yknX 3.4 not found not found not found 
BG19025/tsf_at tsf 3.4 Protein synthesis Translation factors elongation factor Ts 
BG10325/ysxA_at ysxA 3.4 Cell envelope Surface structures; Other similar to DNA repair protein 
BG12460/ywhF_at ywhF 3.4 Central intermediary 
metabolism 
Polyamine biosynthesis similar to spermidine synthase 
BG10509/serA_at serA 3.3 Amino acid biosynthesis Serine family phosphoglycerate dehydrogenase 
BG10686/menB_at menB 3.3 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Menaquinone and ubiquinone dihydroxynapthoic acid synthetase 
BG11733/yqjD_at yqjD 3.3 Fatty acid and phospholipid 
metabolism 
Degradation; Other similar to propionyl-CoA carboxylase 
BG11657/glyQ_at glyQ 3.3 Protein synthesis tRNA aminoacylation glycyl-tRNA synthetase (alpha subunit) 
BG13349/ylaL_at ylaL 3.3 Protein synthesis tRNA aminoacylation unknown 
BG11856/ylmH_at ylmH 3.3 Cellular processes Cell division similar to cell-division protein 
BG11474/yydA_at yydA 3.3 not found not found not found 
BG10422/groES_at groES 3.3 Protein fate Protein folding and stabilization class I heat-shock protein (molecular chaperonin) 
BG10899/eno_at eno 3.2 Energy metabolism Glycolysis/gluconeogenesis enolase 
BG13814/yrzD_at yrzD 3.2 not found not found not found 
BG10920/yvyC_at yvyC 3.2 Cellular processes Chemotaxis and motility alternate gene name: yviH similar to flagellar 
BG12946/yflK_at yflK 3.2 not found not found not found 
BG11536/acpA_at acpA 3.2 Fatty acid and phospholipid 
metabolism 
Biosynthesis acyl carrier protein 
BG13432/ymfL_at ymfL 3.2 Unknown function General unknown 
BG11331/drm_at drm 3.2 Purines, pyrimidines, 
nucleosides and nucleotides 
Salvage of nucleosides and nucleotides phosphodeoxyribomutase 
BG13966/yueK_at yueK 3.2 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Pyridine nucleotides similar to nicotinate phosphoribosyltransferase 
BG11034/yfjL_at yfjL 3.1 Transcription Transcription factors alternate gene name: yztA 
BG13390/yloO_at yloO 3.1 Protein fate Protein modification and repair similar to hypothetical proteins 
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BG11211/ypjF_at ypjF 3.1 Energy metabolism Other alternate gene name: jojF similar to hypothetical 
BG12079/ydbL_at ydbL 3.1 not found not found not found 
BG12378/yukE_at yukE 3.1 not found not found not found 
BG14127/yvoE_at yvoE 3.1 Energy metabolism Sugars similar to phosphoglycolate phosphatase 
BG12060/ydaM_at ydaM 3.0 Energy metabolism Other similar to cellulose synthase 
BG10701/purK_at purK 3.0 Purines, pyrimidines, 
nucleosides and nucleotides 
Purine ribonucleotide biosynthesis phosphoribosylaminoimidazole carboxylase II 
BG12201/ydiD_at ydiD 3.0 Protein synthesis Ribosomal proteins: synthesis and 
modification 
similar to ribosomal-protein-alanine N-acetyltransferase 
BG10708/purM_at purM 2.9 Purines, pyrimidines, 
nucleosides and nucleotides 
Purine ribonucleotide biosynthesis phosphoribosylaminoimidazole synthetase 
BG10425/glnA_at glnA 2.9 Amino acid biosynthesis Glutamate family glutamine synthetase 
BG10797/wapA_5_at wapA 2.9 Cell envelope Other cell wall-associated protein precursor (CWBP200, 105, 62) 
BG13391/yloP_at yloP 2.9 Cell envelope Surface structures; Other similar to protein kinase 
BG12623/moeA_at moeA 2.9 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Other molybdopterin biosynthesis protein 
BG10352/sdhA_at sdhA 2.9 Energy metabolism TCA cycle succinate dehydrogenase (flavoprotein subunit) 
BG10351/sdhC_at sdhC 2.8 Energy metabolism Electron transport; TCA cycle succinate dehydrogenase (cytochrome b558 subunit) 
BG10054/spo0J_at spo0J 2.8 Cellular processes Adaptations to atypical conditions antagonist of Soj 
BG12800/ydjI_at ydjI 2.8 not found not found not found 
BG10237/flgB_at flgB 2.8 Cellular processes Chemotaxis and motility flagellar basal-body rod protein 
BG13160/yjcG_at yjcG 2.8 not found not found not found 
BG11494/ybaL_at ybaL 2.8 not found not found not found 
BG10945/upp_at upp 2.8 Purines, pyrimidines, 
nucleosides and nucleotides 
Salvage of nucleosides and nucleotides uracil phosphoribosyltransferase 
BG14143/yvrC_at yvrC 2.8 Transport and binding 
proteins 
Other similar to iron-binding protein 
BG11792/ileS_1_at ileS 2.8 Protein synthesis tRNA aminoacylation isoleucyl-tRNA synthetase 
BG13203/yjlD_at yjlD 2.8 Energy metabolism ATP-proton motive force interconversion similar to NADH dehydrogenase 
BG10814/atpI_at atpI 2.8 not found not found not found 
BG14128/yvoF_at yvoF 2.7 Energy metabolism Other similar to O-acetyltransferase 
BG10412/fbaA_at fbaA 2.7 Energy metabolism Glycolysis/gluconeogenesis fructose-1,6-bisphosphate aldolase 
BG10243/fliI_at fliI 2.7 Cellular processes Chemotaxis and motility flagellar-specific ATP synthase 
BG13361/ylbI_at ylbI 2.7 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Pantothenate and coenzyme A similar to lipopolysaccharide core biosynthesis 
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BG10238/flgC_at flgC 2.7 Cellular processes Chemotaxis and motility flagellar basal-body rod protein 
BG10963/proB_at proB 2.7 Amino acid biosynthesis Glutamate family gamma-glutamyl kinase 
BG11341/argS_at argS 2.7 Protein synthesis tRNA aminoacylation arginyl-tRNA synthetase 
BG10219/ylxA_at ylxA 2.7 Unknown function Enzymes of unknown specificity alternate gene name: yllC similar to hypothetical 
BG10413/ywjH_at ywjH 2.7 Energy metabolism Pentose phosphate pathway similar to transaldolase (pentose phosphate) 
BG10394/yviA_at yviA 2.7 not found not found not found 
BG10224/mraY_at mraY 2.7 Cell envelope Biosynthesis and degradation of murein 
sacculus and peptidoglycan 
phospho-N-acetylmuramoyl-pentapeptide transferase 
BG11491/pnpA_at pnpA 2.7 Purines, pyrimidines, 
nucleosides and nucleotides 
Other polynucleotide phosphorylase (PNPase) 
BG14146/yvrG_at yvrG 2.6 Regulatory functions Protein interactions similar to two-component sensor histidine kinase [YvrH] 
BG12640/opuCD_at opuCD 2.6 Transport and binding 
proteins 
Amino acids, peptides and amines glycine betaine/carnitine/choline ABC transporter (membrane 
protein) 
BG10837/feuC_at feuC 2.6 Cell envelope Other integral membrane protein 
BG10837/feuC_at feuC 2.6 Transport and binding 
proteins 
Cations and iron carrying compounds integral membrane protein 
BG11539/ftsY_at ftsY 2.6 Protein fate Protein and peptide secretion and trafficking signal recognition particle (docking protein) 
BG11527/bioF_at bioF 2.6 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Biotin 8-amino-7-oxononanoate synthase 
BG11425/yllB_at yllB 2.6 not found not found not found 
BG10294/aroE_at aroE 2.6 Amino acid biosynthesis Aromatic amino acid family 5-enolpyruvoylshikimate-3-phosphate synthase 
BG11207/dapB_at dapB 2.6 Amino acid biosynthesis Aspartate family dihydrodipicolinate reductase 
BG10262/fliR_at fliR 2.5 Cellular processes Chemotaxis and motility flagellar protein 
BG10542/flhA_at flhA 2.5 Cellular processes Chemotaxis and motility flagella-associated protein 
BG11711/folD_at folD 2.5 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Folic acid methylenetetrahydrofolate dehydrogenase 
BG10362/thrS_at thrS 2.5 Protein synthesis tRNA aminoacylation threonyl-tRNA synthetase 
BG11792/ileS_at ileS 2.5 Protein synthesis tRNA aminoacylation isoleucyl-tRNA synthetase 
BG11834/csbB_at csbB 2.5 Cell envelope Biosynthesis and degradation of surface 
polysaccharides and lipopolysaccharides 
stress response protein 
BG12644/pfk_at pfk 2.5 Energy metabolism Glycolysis/gluconeogenesis 6-phosphofructokinase 
BG11533/mcpC_at mcpC 2.5 Cellular processes Chemotaxis and motility methyl-accepting chemotaxis protein 
BG10261/fliQ_at fliQ 2.5 Cellular processes Chemotaxis and motility flagellar protein 
BG10259/fliZ_at fliZ 2.5 Cellular processes Chemotaxis and motility flagellar protein 
BG13939/ytzE_at ytzE 2.4 Regulatory functions DNA interactions similar to transcriptional regulator (DeoR family) 
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BG10198/ptsG_at ptsG 2.4 Signal transduction PTS phosphotransferase system (PTS) glucose-specific enzyme IIABC 
component 
BG10198/ptsG_at ptsG 2.4 Transport and binding 
proteins 
Carbohydrates, organic alcohols and acids phosphotransferase system (PTS) glucose-specific enzyme IIABC 
component 
BG10973/murC_at murC 2.4 Cell envelope Biosynthesis and degradation of murein 
sacculus and peptidoglycan 
UDP-N-acetyl muramate-alanine ligase 
BG10321/valS_2_at valS 2.4 Protein synthesis tRNA aminoacylation valyl-tRNA synthetase 
BG13951/yubB_at yubB 2.4 Cellular processes Toxin production and resistance similar to bacitracin resistance protein (undecaprenol kinase) 
BG12840/yerN_at yerN 2.4 Protein synthesis tRNA aminoacylation similar to pet112-like protein 
BG13202/yjlC_at yjlC 2.4 not found not found not found 
BG10242/fliH_at fliH 2.4 Cellular processes Chemotaxis and motility flagellar assembly protein 
BG12012/ycgN_at ycgN 2.4 Energy metabolism Amino acids and amines similar to 1-pyrroline-5-carboxylate dehydrogenase 
BG11206/birA_at birA 2.4 Regulatory functions Other transcriptional regulator and biotin acetyl-CoA-carboxylase 
synthetase 
BG13301/ykuQ_at ykuQ 2.4 Amino acid biosynthesis Other similar to tetrahydrodipicolinate succinylase 
BG10775/oppF_at oppF 2.4 Transport and binding 
proteins 
Other oligopeptide ABC transporter (ATP-binding protein) 
BG10273/odhB_at odhB 2.4 Energy metabolism TCA cycle 2-oxoglutarate dehydrogenase complex (dihydrolipoamide 
transsuccinylase, E2 subunit) 
BG10076/yaaE_at yaaE 2.4 Protein synthesis tRNA aminoacylation similar to hypothetical proteins 
BG11818/yktC_at yktC 2.4 not found not found not found 
BG10260/fliP_at fliP 2.3 Cellular processes Chemotaxis and motility flagellar protein 
BG10827/gap_at gap 2.3 Energy metabolism Glycolysis/gluconeogenesis glyceraldehyde-3-phosphate dehydrogenase 
BG10373/ytxJ_at ytxJ 2.3 Transcription Transcription factors alternate gene name: csb40 similar to general 
BG19023/tig_at tig 2.3 Protein fate Protein and peptide secretion and 
trafficking; Protein folding and stabilization 
trigger factor (prolyl isomerase) 
BG13980/yunF_at yunF 2.3 not found not found not found 
BG11873/yvfE_at yvfE 2.3 Cellular processes Adaptations to atypical conditions similar to spore coat polysaccharide biosynthesis 
BG13897/ytoI_at ytoI 2.3 not found not found not found 
BG10663/grpE_at grpE 2.3 Protein fate Protein folding and stabilization heat-shock protein 
BG11501/ypmA_at ypmA 2.3 not found not found not found 
BG10700/purE_at purE 2.3 Purines, pyrimidines, 
nucleosides and nucleotides 
Purine ribonucleotide biosynthesis phosphoribosylaminoimidazole carboxylase I 
BG10820/atpG_at atpG 2.3 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit gamma) 
BG10326/mreB_at mreB 2.3 Cell envelope Biosynthesis and degradation of murein 
sacculus and peptidoglycan 
cell-shape determining protein 
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BG10714/pyrC_at pyrC 2.3 Purines, pyrimidines, 
nucleosides and nucleotides 
Pyrimidine ribonucleotide biosynthesis dihydroorotase 
BG13965/yueJ_at yueJ 2.3 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Other similar to pyrazinamidase/nicotinamidase 
BG11607/ypdP_at ypdP 2.3 not found not found not found 
BG10201/ptsI_at ptsI 2.3 Transport and binding 
proteins 
Carbohydrates, organic alcohols and acids phosphotransferase system (PTS) enzyme I 
BG11330/pnp_at pnp 2.3 Purines, pyrimidines, 
nucleosides and nucleotides 
Salvage of nucleosides and nucleotides purine nucleoside phosphorylase 
BG11701/yqhM_at yqhM 2.2 not found not found not found 
BG13117/yitL_at yitL 2.2 not found not found not found 
BG10075/yaaD_at yaaD 2.2 Cellular processes Detoxification similar to hypothetical proteins 
BG11079/xpt_at xpt 2.2 Purines, pyrimidines, 
nucleosides and nucleotides 
Salvage of nucleosides and nucleotides xanthine phosphoribosyltransferase 
BG11515/dinG_1_at dinG 2.2 DNA metabolism DNA replication, recombination and repair ATP-dependent helicase 
BG13854/ytgD_at ytgD 2.2 not found not found not found 
BG10101/metS_at metS 2.2 Protein synthesis tRNA aminoacylation methionyl-tRNA synthetase 
BG13433/ymfM_at ymfM 2.2 not found not found not found 
BG10280/gerCB_at gerCB 2.2 Amino acid biosynthesis Serine family methyltransferase 
BG10280/gerCB_at gerCB 2.2 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Heme, porphyrin and cobalamin methyltransferase 
BG10280/gerCB_at gerCB 2.2 Central intermediary 
metabolism 
Other methyltransferase 
BG10280/gerCB_at gerCB 2.2 DNA metabolism Restriction/modification; DNA replication, 
recombination and repair 
methyltransferase 
BG10280/gerCB_at gerCB 2.2 Protein synthesis tRNA and rRNA base modification methyltransferase 
BG12202/ydiE_at ydiE 2.2 Protein fate Degradation of proteins, peptides and 
glycopeptides 
similar to glycoprotein endopeptidase 
BG12461/ywhG_at ywhG 2.2 Central intermediary 
metabolism 
Polyamine biosynthesis similar to agmatinase 
BG12771/yceG_at yceG 2.2 not found not found not found 
BG10055/soj_at soj 2.1 Cellular processes Other centromere-like function with Spo0J involved in forespore 
BG13950/yubA_at yubA 2.1 not found not found not found 
BG13046/yheN_at yheN 2.1 Energy metabolism Other similar to endo-1,4-beta-xylanase 
BG10783/asd_at asd 2.1 Amino acid biosynthesis Aspartate family aspartate-semialdehyde dehydrogenase 
BG12071/ydbD_at ydbD 2.1 Protein fate Protein and peptide secretion and trafficking similar to manganese-containing catalase 
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BG13901/ytpB_at ytpB 2.1 not found not found not found 
BG10100/abrB_at abrB 2.1 Energy metabolism ATP-proton motive force interconversion transcriptional regulator 
BG10100/abrB_at abrB 2.1 Regulatory functions Other transcriptional regulator 
BG13852/ytgB_at ytgB 2.1 Transport and binding 
proteins 
Amino acids, peptides and amines; 
Unknown substrate 
similar to ABC transporter (ATP-binding protein) 
BG11489/ylxX_at ylxX 2.1 not found not found not found 
BG10821/atpD_at atpD 2.1 Energy metabolism ATP-proton motive force interconversion ATP synthase (subunit beta) 
BG12473/ywmB_at ywmB 2.1 not found not found not found 
BG13476/yoaE_at yoaE 2.1 Energy metabolism ATP-proton motive force interconversion similar to formate dehydrogenase 
BG10279/gerCA_at gerCA 2.1 Biosynthesis of cofactors, 
prosthetic groups and carriers 
Other heptaprenyl diphosphate synthase component I 
BG12796/ydjE_at ydjE 2.1 not found not found not found 
BG12864/yetH_at yetH 2.0 Unknown function General similar to hypothetical proteins 
BG10392/degS_at degS 2.0 Regulatory functions Other two-component sensor histidine kinase 
BG10258/cheY_at cheY 2.0 Regulatory functions DNA interactions two-component response regulator 
BG10246/ylxF_at ylxF 2.0 Cell envelope Biosynthesis and degradation of surface 
polysaccharides and lipopolysaccharides 
unknown 
BG13232/ykfB_at ykfB 2.0 Energy metabolism Other similar to chloromuconate cycloisomerase 
BG14065/yvaJ_at yvaJ 2.0 Transcription RNA processing; Degradation of RNA similar to hypothetical proteins 
BG11016/penP_at penP 2.0 Cellular processes Toxin production and resistance beta-lactamase precursor 
BG10414/murZ_at murZ 2.0 Cell envelope Biosynthesis and degradation of murein 
sacculus and peptidoglycan 
UDP-N-acetylglucosamine 1-carboxyvinyltransferase 
BG11210/ypjD_at ypjD 2.0 Transcription Transcription factors alternate gene name: jojD 
BG14021/yusI_at yusI 2.0 Energy metabolism Aerobic; Electron transport similar to arsenate reductase 
BG12597/hisA_at hisA 2.0 Amino acid biosynthesis Histidine family phosphoribosylformimino-5-aminoimidazole carboxamide ribotide 
isomerase 
BG11817/yktB_at yktB 2.0 not found not found not found 
BG12772/yceH_at yceH 2.0 Cellular processes Detoxification similar to toxic anion resistance protein 
not found, Not found in the JCVI Primary annotation database 
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Appendix I.  Calculation sheet for qPCR. 
Rep 1  Rep 2  Rep 3     
Gene C(t) Gene C(t) Gene C(t)  Average sd 
mbl A 20.37 mbl A 22.46 mbl A 18.58 mbl A 20.2 1.6 
mbl A 20.33 mbl A 21.17 mbl A 18.26 mbl B 19.8 1.8 
mbl B 22.08 mbl B 18.94 mbl B 18.15 mbl C 19.1 1.1 
mbl B 22.21 mbl B 19.32 mbl B 18.33    
mbl C 20.27 mbl C 18.2 mbl C 18.47    
mbl C 20.62 mbl C 18.32 mbl C 18.74    
mbl N/A mbl 21.69 mbl N/A    
         
Gene C(t) Gene C(t) Gene C(t)  Average sd 
clpC A 20.54 clpC A 19.92 clpC A 19.13 clpC A 19.8 0.7 
clpC A 20.52 clpC A 19.46 clpC A 19.06 clpC B 16.8 2.6 
clpC B 20.14 clpC B 15.8 clpC B 14.74 clpC C 15.1 1.6 
clpC B 20.05 clpC B 15.72 clpC B 14.43    
clpC C 15.99 clpC C 14.49 clpC C 13.66    
clpC C 17.79 clpC C 14.49 clpC C 13.89    
clpC N/A clpC 18.62 clpC N/A    
         
Gene C(t) Gene C(t) Gene C(t)  Average sd 
spoVG A 20.06 spoVG A 20.7 spoVG A 17.29 spoVG A 19.2 1.7 
spoVG A 19.92 spoVG A 20.6 spoVG A 16.8 spoVG B 20.3 2.2 
spoVG B 22.67 spoVG B 20.07 spoVG B 17.68 spoVG C 21.0 1.6 
spoVG B 22.9 spoVG B 20.34 spoVG B 18.11    
spoVG C 22.48 spoVG C 21.26 spoVG C 19.03    
spoVG C 22.65 spoVG C 21.36 spoVG C 19.14    
spoVG 32.01 spoVG N/A spoVG 26.5    
         
Gene C(t) Gene C(t) Gene C(t)  Average sd 
dnaE2 A 19.14 dnaE2 A 15.56 dnaE2 A 13.52 dnaE2 A 17.0 2.3 
dnaE2 A 19.55 dnaE2 A 18.18 dnaE2 A 16.33 dnaE2 B 15.8 2.4 
dnaE2 B 18.65 dnaE2 B 15.12 dnaE2 B 13.17 dnaE2 C 13.5 1.8 
dnaE2 B 18.77 dnaE2 B 15.58 dnaE2 B 13.48    
dnaE2 C 15.6 dnaE2 C 14.28 dnaE2 C 12.78    
dnaE2 C 15.05 dnaE2 C 11.95 dnaE2 C 11.26    
dnaE2 28.24 dnaE2 29.42 dnaE2 25.53    
 
mbl standard mbl standard mbl standard 
2 µg/mL 16 µg/mL 2 µg/mL 16 µg/mL 2 µg/mL 16 µg/mL 
dCt fold dCt fold dCt fold dCt fold dCt fold dCt fold 
1.7 3.3 -0.1 0.9 -3.5 0.1 -0.4 0.8 -0.4 0.7 -0.1 0.9 
1.8 3.6 0.3 1.2 -3.1 0.1 -4.1 0.1 -0.3 0.8 0.2 1.1 
1.8 3.4 -0.1 1.0 -2.2 0.2 -3.0 0.1 -0.1 0.9 0.2 1.2 
1.9 3.7 0.3 1.2 -1.9 0.3 -2.9 0.1 0.1 1.0 0.5 1.4 
1.8 
Av 
dCt 0.1   -2.7 -2.6   -0.2 
Av 
dCt 0.2   
3.5 
Av. 
Fold 1.1   0.2 
Av. 
Fold 0.2   0.9 
Av. 
Fold 1.1   
 
